UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~June 30, 2021


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-38710

Corteva, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

82-4979096

(State or other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)

974 Centre Road,

Wilmington,

Delaware

19805

(302)

485-3000

(Address of Principal Executive Offices) (Zip Code)

(Registrant’s Telephone Number, including area code)

Commission File Number 1-815

E. I. du Pont de Nemours and Company

(Exact Name of Registrant as Specified in Its Charter)

Delaware

51-0014090

(State or other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)

974 Centre Road,

Wilmington,

Delaware

19805

(302)

485-3000

(Address of Principal Executive Offices) (Zip Code)

(Registrant’s Telephone Number, including area code)

Securities registered pursuant to Section 12(b) of the Act for Corteva, Inc.:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	CTVA	New York Stock Exchange

Securities registered pursuant to Section 12(b) of the Act for E. I. du Pont de Nemours and Company:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
$3.50 Series Preferred Stock	CTAPrA	New York Stock Exchange
$4.50 Series Preferred Stock	CTAPrB	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Corteva, Inc. �� Yes x No o

E. I. du Pont de Nemours and Company Yes x No o

Table of Contents

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)

Corteva, Inc. Yes x No o

E. I. du Pont de Nemours and Company Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Corteva, Inc.

Large Accelerated Filer

Accelerated Filer o

Non-Accelerated Filer

Smaller reporting company o

Emerging growth company o

E. I. du Pont de Nemours and Company

Large Accelerated Filer

Accelerated Filer o

Non-Accelerated Filer

Smaller reporting company o

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Corteva, Inc. ☐

E. I. du Pont de Nemours and Company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Corteva, Inc. Yes ☐ No x

E. I. du Pont de Nemours and Company Yes ☐ No x

Corteva, Inc. had ~~737,101,000~~734,185,000 shares of common stock, par value $0.01 per share, outstanding at ~~April~~July 30, 2021.

E. I. du Pont de Nemours and Company had 200 shares of common stock, par value $0.30 per share, outstanding at ~~April~~July 30, 2021, all of which are held by Corteva, Inc.

E. I. du Pont de Nemours and Company meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q (as modified by a grant of no-action relief dated February 12, 2018) and is therefore filing this form with reduced disclosure format.

Table of Contents

CORTEVA, INC.

E. I. DU PONT DE NEMOURS AND COMPANY

Table of Contents


		Page
Explanatory Note
Part I	Financial Information

Item 1.	Consolidated Financial Statements (Unaudited)
	Consolidated Statements of Operations	3
	Consolidated Statements of Comprehensive ~~(Loss)~~ Income	4
	~~Condensed~~ Consolidated Balance Sheets	5
	Consolidated Statements of Cash Flows	6
	Consolidated Statements of Equity	7
	Notes to the Interim Consolidated Financial Statements (Unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3842
	Cautionary Statements About Forward-Looking Statements	3842
	Recent Developments	3943
	Overview	3944
	Selected Financial Data	4146
	Results of Operations	4247

	Recent Accounting Pronouncements	4451
	Segment Reviews	4452
	Non-GAAP Financial Measures	4756
	Liquidity & Capital Resources	5058

	Contractual Obligations	5260

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5260
Item 4.	Controls and Procedures	5361

Part II	Other Information

Item 1.	Legal Proceedings	5462
Item 1A.	Risk Factors	5665
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	5766
Item 5.	Other Information	5867
Item 6.	Exhibits	5968
Exhibit Index		5968
Signature		6069
Consolidated Financial Statements of E.I. du Pont de Nemours and Company (Unaudited)		6170

Table of Contents

Explanatory Note

Corteva owns 100% of the outstanding common stock of EID (defined below), and EID owns, directly or indirectly, 100% of DAS (defined below). EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Securities Exchange Act of 1934, as amended.

Unless otherwise indicated or the context otherwise requires, references in this Quarterly Report on Form 10-Q to:

• "Corteva" or "the company" refers to Corteva, Inc. and its consolidated subsidiaries (including EID);

• "EID" refers to E. I. du Pont de Nemours and Company and its consolidated subsidiaries or E. I. du Pont de Nemours and Company excluding its consolidated subsidiaries, as the context may indicate;

• "DowDuPont" refers to DowDuPont Inc., and its subsidiaries prior to the Separation of Corteva (defined below);

• "Historical Dow" refers to ~~the~~The Dow Chemical Company and its consolidated subsidiaries prior to the Internal Reorganization (defined below);

• "Historical DuPont" refers to EID prior to the Internal Reorganization (defined below);

• "Internal Reorganizations" refers to the series of internal reorganization and realignment steps undertaken by Historical DuPont and Historical Dow to realign its business into three groups: agriculture, materials science and specialty products. These steps include:

1.the April 1, 2019 transfer of the assets and liabilities aligned with EID’s material science businesses including EID’s ethylene and ethylene copolymers business, excluding its ethylene acrylic elastomers business, (“EID ECP”) to DowDuPont, which were ultimately conveyed by DowDuPont to Dow;

2.the May 1, 2019 distribution of EID legal entities containing the assets and liabilities of EID’s specialty products business (the “EID Specialty Products Entities”) to DowDuPont;

3.the May 2, 2019 conveyance of Historical Dow's agriculture business ("Dow Ag Entities") to EID; and

4.the May 31, 2019 contribution of EID to Corteva, Inc. Refer to the company’s Annual Report on Form 10-K for the year ended December 31, 2020 for further information.

• "Dow Distribution" refers to the separation of DowDuPont's materials science business into a separate and independent public company, effective as of 5:00 pm ET on April 1, 2019, by way of a distribution of Dow Inc. through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock, par value $0.01 per share, to holders of DowDuPont's common stock, as of the close of business on March 21, 2019;

~~• "Distributions" refers to the Dow Distribution and the Corteva Distribution;~~

• "Merger” refers to the all-stock merger of equals strategic combination between Historical Dow and Historical DuPont;

• "Merger Effectiveness Time” refers to August 31, 2017 at 11:59 pm ET;

• "Dow" refers to Dow Inc. after the Dow Distribution;

• "DuPont" refers to DuPont de Nemours, Inc. after the Separation of Corteva (on June 1, 2019, DowDuPont Inc. changed its registered name to DuPont de Nemours, Inc.);

• "DAS" refers to the agriculture business of Historical Dow AgroSciences; ~~and~~

• "Separation" or "Separation of Corteva" refers to June 1, 2019, when Corteva, Inc. became an independent, publicly
traded ~~company.~~company;

• "Corteva Distribution" refers to the pro rata distribution of all of the then-issued and outstanding shares of Corteva, Inc.'s common stock, par value $0.01 per share, on June 1, 2019, which was then a wholly-owned subsidiary of DowDuPont, to holders of DowDuPont's common stock as of the close of business on May 24, 2019;

• "Distributions" refers to the Dow Distribution and the Corteva Distribution; and

• “Letter Agreement” refers to the Letter Agreement executed by DuPont and Corteva on June 1, 2019, which sets forth certain additional terms and conditions related to the Separation, including certain limitations on each party’s ability to transfer certain businesses and assets to third parties without assigning certain of such party’s indemnification obligations under the Corteva Separation Agreement to the other party to the transferee of such businesses and assets or meeting certain other alternative conditions.

This Quarterly Report on Form 10-Q is a combined report being filed separately by Corteva, Inc. and EID. The information in this Quarterly Report on Form 10-Q is equally applicable to Corteva, Inc. and EID, except where otherwise indicated.

The separate EID financial statements and footnotes for areas that differ from Corteva, are included within this Quarterly Report on Form 10-Q and begin on page ~~61.~~70. Footnotes of EID that are identical to that of Corteva are cross-referenced accordingly.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1.CONSOLIDATED FINANCIAL STATEMENTS

Corteva, Inc.

Consolidated Statements of Operations (Unaudited)


(In millions, except per share amounts)	(In millions, except per share amounts)	Three Months Ended March 31,				(In millions, except per share amounts)	Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020					2021		2020		2021		2020
Net sales	Net sales	$	4,178	$	3,956			Net sales	$	5,627	$	5,191	$	9,805	$	9,147
Cost of goods sold	Cost of goods sold	2,420		2,269				Cost of goods sold	3,010		2,829		5,430		5,098
Research and development expense	Research and development expense	281		280				Research and development expense	293		273		574		553
Selling, general and administrative expenses	Selling, general and administrative expenses	733		757				Selling, general and administrative expenses	998		965		1,731		1,722
Amortization of intangibles	Amortization of intangibles	183		163				Amortization of intangibles	180		176		363		339
Restructuring and asset related charges - net	Restructuring and asset related charges - net	100		70				Restructuring and asset related charges - net	135		179		235		249
Other income - net	Other income - net	337		1				Other income - net	298		89		635		90
Interest expense	Interest expense	7		10				Interest expense	7		14		14		24
Income from continuing operations before income taxes	Income from continuing operations before income taxes	791		408				Income from continuing operations before income taxes	1,302		844		2,093		1,252
Provision for income taxes on continuing operations	Provision for income taxes on continuing operations	178		127				Provision for income taxes on continuing operations	284		78		462		205
Income from continuing operations after income taxes	Income from continuing operations after income taxes	613		281				Income from continuing operations after income taxes	1,018		766		1,631		1,047
(Loss) income from discontinued operations after income taxes	(Loss) income from discontinued operations after income taxes	(10)		1				(Loss) income from discontinued operations after income taxes	(45)		0		(55)		1
Net income	Net income	603		282				Net income	973		766		1,576		1,048
Net income attributable to noncontrolling interests	Net income attributable to noncontrolling interests	3		10				Net income attributable to noncontrolling interests	3		6		6		16
Net income attributable to Corteva	Net income attributable to Corteva	$	600	$	272			Net income attributable to Corteva	$	970	$	760	$	1,570	$	1,032
Basic earnings per share of common stock:	Basic earnings per share of common stock:							Basic earnings per share of common stock:
Basic earnings per share of common stock from continuing operations	Basic earnings per share of common stock from continuing operations	$	0.82	$	0.36			Basic earnings per share of common stock from continuing operations	$	1.37	$	1.01	$	2.19	$	1.37
Basic loss per share of common stock from discontinued operations	Basic loss per share of common stock from discontinued operations	(0.01)		0				Basic loss per share of common stock from discontinued operations	(0.06)		0		(0.07)		0
Basic earnings per share of common stock	Basic earnings per share of common stock	$	0.81	$	0.36			Basic earnings per share of common stock	$	1.31	$	1.01	$	2.12	$	1.37
Diluted earnings per share of common stock:	Diluted earnings per share of common stock:							Diluted earnings per share of common stock:
Diluted earnings per share of common stock from continuing operations	Diluted earnings per share of common stock from continuing operations	$	0.81	$	0.36			Diluted earnings per share of common stock from continuing operations	$	1.37	$	1.01	$	2.18	$	1.37
Diluted loss per share of common stock from discontinued operations	Diluted loss per share of common stock from discontinued operations	(0.01)		0				Diluted loss per share of common stock from discontinued operations	(0.06)		0		(0.07)		0
Diluted earnings per share of common stock	Diluted earnings per share of common stock	$	0.80	$	0.36			Diluted earnings per share of common stock	$	1.31	$	1.01	$	2.11	$	1.37

See Notes to the ~~interim~~Interim Consolidated Financial Statements beginning on page 8.

Table of Contents

Corteva, Inc.

Consolidated Statements of Comprehensive ~~(Loss)~~ Income (Unaudited)


(In millions)	(In millions)	Three Months Ended March 31,				(In millions)	Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020					2021		2020		2021		2020
Net income	Net income	$	603	$	282			Net income	$	973	$	766	$	1,576	$	1,048
Other comprehensive income (loss) - net of tax:	Other comprehensive income (loss) - net of tax:							Other comprehensive income (loss) - net of tax:
Cumulative translation adjustments	Cumulative translation adjustments	(403)		(672)				Cumulative translation adjustments	243		97		(160)		(575)
Adjustments to pension benefit plans	Adjustments to pension benefit plans	8		0				Adjustments to pension benefit plans	8		(6)		16		(6)
Adjustments to other benefit plans	Adjustments to other benefit plans	(157)		3				Adjustments to other benefit plans	(160)		(1)		(317)		2
Unrealized gain on investments	Unrealized gain on investments	10		0				Unrealized gain on investments	0		0		10		0
Derivative instruments	Derivative instruments	65		6				Derivative instruments	31		(2)		96		4
Total other comprehensive loss		(477)		(663)
Comprehensive income (loss)		126		(381)
Total other comprehensive income (loss)								Total other comprehensive income (loss)	122		88		(355)		(575)
Comprehensive income								Comprehensive income	1,095		854		1,221		473
Comprehensive income attributable to noncontrolling interests - net of tax	Comprehensive income attributable to noncontrolling interests - net of tax	3		10				Comprehensive income attributable to noncontrolling interests - net of tax	3		6		6		16
Comprehensive income (loss) attributable to Corteva		$	123	$	(391)
Comprehensive income attributable to Corteva								Comprehensive income attributable to Corteva	$	1,092	$	848	$	1,215	$	457

See Notes to the ~~interim~~Interim Consolidated Financial Statements beginning on page 8.

Table of Contents

Corteva, Inc.

~~Condensed~~ Consolidated Balance Sheets (Unaudited)


(In millions, except share amounts)	(In millions, except share amounts)	March 31, 2021		December 31, 2020		March 31, 2020		(In millions, except share amounts)	June 30, 2021		December 31, 2020		June 30, 2020
Assets	Assets							Assets
Current assets	Current assets							Current assets
Cash and cash equivalents	Cash and cash equivalents	$	2,404	$	3,526	$	1,963	Cash and cash equivalents	$	2,861	$	3,526	$	2,809
Marketable securities	Marketable securities	114		269		10		Marketable securities	39		269		60
Accounts and notes receivable - net	Accounts and notes receivable - net	6,792		4,926		6,775		Accounts and notes receivable - net	6,792		4,926		6,772
Inventories	Inventories	4,321		4,882		4,401		Inventories	3,541		4,882		3,589
Other current assets	Other current assets	1,405		1,165		1,530		Other current assets	1,052		1,165		1,192

Total current assets	Total current assets	15,036		14,768		14,679		Total current assets	14,285		14,768		14,422
Investment in nonconsolidated affiliates	Investment in nonconsolidated affiliates	64		66		64		Investment in nonconsolidated affiliates	68		66		62
Property, plant and equipment - net of accumulated depreciation (March 31, 2021 - $3,874; December 31, 2020 - $3,857; March 31, 2020 - $3,406)		4,299		4,396		4,358
Property, plant and equipment								Property, plant and equipment	8,343		8,253		7,858
Less: Accumulated depreciation								Less: Accumulated depreciation	4,002		3,857		3,565
Net property, plant and equipment								Net property, plant and equipment	4,341		4,396		4,293
Goodwill	Goodwill	10,146		10,269		10,027		Goodwill	10,207		10,269		10,069
Other intangible assets	Other intangible assets	10,584		10,747		11,241		Other intangible assets	10,413		10,747		11,070
Deferred income taxes	Deferred income taxes	433		464		273		Deferred income taxes	442		464		290
Other assets	Other assets	1,987		1,939		2,336		Other assets	1,740		1,939		1,974

Total Assets	Total Assets	$	42,549	$	42,649	$	42,978	Total Assets	$	41,496	$	42,649	$	42,180
Liabilities and Equity	Liabilities and Equity							Liabilities and Equity
Current liabilities	Current liabilities							Current liabilities
Short-term borrowings and finance lease obligations	Short-term borrowings and finance lease obligations	$	1,250	$	3	$	1,996	Short-term borrowings and finance lease obligations	$	677	$	3	$	1,529
Accounts payable	Accounts payable	3,098		3,615		3,021		Accounts payable	3,070		3,615		2,891
Income taxes payable	Income taxes payable	165		123		143		Income taxes payable	234		123		369
Deferred revenue	Deferred revenue	2,247		2,662		1,996		Deferred revenue	748		2,662		431
Accrued and other current liabilities	Accrued and other current liabilities	2,239		2,145		2,043		Accrued and other current liabilities	2,523		2,145		2,309

Total current liabilities	Total current liabilities	8,999		8,548		9,199		Total current liabilities	7,252		8,548		7,529
Long-Term Debt	Long-Term Debt	1,102		1,102		614		Long-Term Debt	1,101		1,102		1,102
Other Noncurrent Liabilities	Other Noncurrent Liabilities							Other Noncurrent Liabilities
Deferred income tax liabilities	Deferred income tax liabilities	902		893		911		Deferred income tax liabilities	935		893		752
Pension and other post employment benefits - noncurrent	Pension and other post employment benefits - noncurrent	4,954		5,176		6,186		Pension and other post employment benefits - noncurrent	4,767		5,176		6,039
Other noncurrent obligations	Other noncurrent obligations	1,814		1,867		1,989		Other noncurrent obligations	1,816		1,867		1,957

Total noncurrent liabilities	Total noncurrent liabilities	8,772		9,038		9,700		Total noncurrent liabilities	8,619		9,038		9,850
Commitments and contingent liabilities	Commitments and contingent liabilities							Commitments and contingent liabilities
Stockholders’ equity	Stockholders’ equity							Stockholders’ equity
Common stock, $0.01 par value; 1,666,667,000 shares authorized; issued at March 31, 2021 - 738,321,000; December 31, 2020 - 743,458,000; and March 31, 2020 - 748,369,000		7		7		7
Common stock, $0.01 par value; 1,666,667,000 shares authorized; issued at June 30, 2021 - 734,421,000; December 31, 2020 - 743,458,000; and June 30, 2020 - 748,485,000								Common stock, $0.01 par value; 1,666,667,000 shares authorized; issued at June 30, 2021 - 734,421,000; December 31, 2020 - 743,458,000; and June 30, 2020 - 748,485,000	7		7		7
Additional paid-in capital	Additional paid-in capital	27,630		27,707		27,906		Additional paid-in capital	27,682		27,707		27,891

Retained earnings / (accumulated deficit)		268		0		(155)
Retained earnings								Retained earnings	941		0		508
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(3,367)		(2,890)		(3,933)		Accumulated other comprehensive loss	(3,245)		(2,890)		(3,845)
Total Corteva stockholders’ equity	Total Corteva stockholders’ equity	24,538		24,824		23,825		Total Corteva stockholders’ equity	25,385		24,824		24,561
Noncontrolling interests	Noncontrolling interests	240		239		254		Noncontrolling interests	240		239		240
Total equity	Total equity	24,778		25,063		24,079		Total equity	25,625		25,063		24,801
Total Liabilities and Equity	Total Liabilities and Equity	$	42,549	$	42,649	$	42,978	Total Liabilities and Equity	$	41,496	$	42,649	$	42,180

See Notes to the ~~interim~~Interim Consolidated Financial Statements beginning on page 8.

Table of Contents

Corteva, Inc.

Consolidated Statements of Cash Flows (Unaudited)


(In millions)	(In millions)	Three Months Ended March 31,				(In millions)	Six Months Ended June 30,
		2021		2020			2021		2020
Operating activities	Operating activities					Operating activities
Net income	Net income	$	603	$	282	Net income	$	1,576	$	1,048
Adjustments to reconcile net income to cash used for operating activities:	Adjustments to reconcile net income to cash used for operating activities:					Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization	Depreciation and amortization	304		283		Depreciation and amortization	617		583
Provision for deferred income tax		47		26
Provision for (benefit from) deferred income tax						Provision for (benefit from) deferred income tax	124		(136)
Net periodic pension and OPEB benefit, net	Net periodic pension and OPEB benefit, net	(318)		(85)		Net periodic pension and OPEB benefit, net	(641)		(168)
Pension and OPEB contributions	Pension and OPEB contributions	(84)		(95)		Pension and OPEB contributions	(149)		(167)
Net loss on sales of property, businesses, consolidated companies and investments		0		46
Net (gain) loss on sales of property, businesses, consolidated companies and investments						Net (gain) loss on sales of property, businesses, consolidated companies and investments	(1)		30
Restructuring and asset related charges - net	Restructuring and asset related charges - net	100		70		Restructuring and asset related charges - net	235		249
Other net loss	Other net loss	54		138		Other net loss	143		185
Changes in assets and liabilities, net	Changes in assets and liabilities, net					Changes in assets and liabilities, net
Accounts and notes receivable	Accounts and notes receivable	(2,012)		(1,685)		Accounts and notes receivable	(1,957)		(1,712)
Inventories	Inventories	467		398		Inventories	1,334		1,271
Accounts payable	Accounts payable	(448)		(557)		Accounts payable	(525)		(717)
Deferred revenue	Deferred revenue	(401)		(575)		Deferred revenue	(1,931)		(2,147)
Other assets and liabilities	Other assets and liabilities	(262)		(176)		Other assets and liabilities	532		812
Cash used for operating activities	Cash used for operating activities	(1,950)		(1,930)		Cash used for operating activities	(643)		(869)
Investing activities	Investing activities					Investing activities
Capital expenditures	Capital expenditures	(137)		(128)		Capital expenditures	(269)		(202)
Proceeds from sales of property, businesses and consolidated companies - net of cash divested	Proceeds from sales of property, businesses and consolidated companies - net of cash divested	20		11		Proceeds from sales of property, businesses and consolidated companies - net of cash divested	26		18

Investments in and loans to nonconsolidated affiliates						Investments in and loans to nonconsolidated affiliates	(1)		0

Purchases of investments	Purchases of investments	(40)		(67)		Purchases of investments	(56)		(361)
Proceeds from sales and maturities of investments	Proceeds from sales and maturities of investments	194		58		Proceeds from sales and maturities of investments	285		298
Other investing activities - net	Other investing activities - net	(1)		(4)		Other investing activities - net	(2)		(5)
Cash provided by (used for) investing activities		36		(130)
Cash used for investing activities						Cash used for investing activities	(17)		(252)
Financing activities	Financing activities					Financing activities
Net change in borrowings (less than 90 days)	Net change in borrowings (less than 90 days)	828		1,619		Net change in borrowings (less than 90 days)	254		966
Proceeds from debt	Proceeds from debt	419		875		Proceeds from debt	419		2,434
Payments on debt	Payments on debt	0		(1)		Payments on debt	0		(879)
Repurchase of common stock	Repurchase of common stock	(350)		(50)		Repurchase of common stock	(550)		(50)
Proceeds from exercise of stock options	Proceeds from exercise of stock options	38		14		Proceeds from exercise of stock options	66		17
Dividends paid to stockholders	Dividends paid to stockholders	(97)		(97)		Dividends paid to stockholders	(192)		(194)

Payment for acquisition of subsidiary's interest from the non-controlling interest						Payment for acquisition of subsidiary's interest from the non-controlling interest	0		(60)

Other financing activities	Other financing activities	(17)		(16)		Other financing activities	(24)		(20)
Cash provided by financing activities		821		2,344
Cash (used for) provided by financing activities						Cash (used for) provided by financing activities	(27)		2,214
Effect of exchange rate changes on cash, cash equivalents and restricted cash	Effect of exchange rate changes on cash, cash equivalents and restricted cash	(50)		(117)		Effect of exchange rate changes on cash, cash equivalents and restricted cash	(14)		(95)
(Decrease)/increase in cash, cash equivalents and restricted cash	(Decrease)/increase in cash, cash equivalents and restricted cash	(1,143)		167		(Decrease)/increase in cash, cash equivalents and restricted cash	(701)		998
Cash, cash equivalents and restricted cash at beginning of period	Cash, cash equivalents and restricted cash at beginning of period	3,873		2,173		Cash, cash equivalents and restricted cash at beginning of period	3,873		2,173
Cash, cash equivalents and restricted cash at end of period1	Cash, cash equivalents and restricted cash at end of period1	$	2,730	$	2,340	Cash, cash equivalents and restricted cash at end of period1	$	3,172	$	3,171

1. See page 1517 for reconciliation of cash and cash equivalents and restricted cash presented in interim ~~Condensed~~ Consolidated Balance Sheets to total cash, cash equivalents and restricted cash presented in the interim Consolidated Statements of Cash Flows.

See Notes to the ~~interim~~Interim Consolidated Financial Statements beginning on page 8.

Table of Contents

Corteva, Inc.

Consolidated Statements of Equity (Unaudited)


(In millions, except per share amounts)	(In millions, except per share amounts)	Common Stock		Additional Paid-in Capital "APIC"		(Accumulated deficit) Retained Earnings		Accumulated Other Comp (Loss) Income		Treasury Stock		Non-controlling Interests		Total Equity		(In millions, except per share amounts)	Common Stock		Additional Paid-in Capital "APIC"		(Accumulated Deficit) Retained Earnings		Accumulated Other Comp (Loss) Income		Treasury Stock		Non-controlling Interests		Total Equity
2020	2020															2020
Balance at January 1, 2020	Balance at January 1, 2020	$	7	$	27,997	$	(425)	$	(3,270)	$	—	$	246	$	24,555	Balance at January 1, 2020	$	7	$	27,997	$	(425)	$	(3,270)	$	—	$	246	$	24,555
Net income	Net income					272						10		282		Net income					272						10		282
Other comprehensive loss	Other comprehensive loss							(663)						(663)		Other comprehensive loss							(663)						(663)
Common dividends ($.13 per share)	Common dividends ($.13 per share)			(97)										(97)		Common dividends ($.13 per share)			(97)										(97)
Issuance of Corteva stock	Issuance of Corteva stock			14										14		Issuance of Corteva stock			14										14
Share-based compensation	Share-based compensation			2										2		Share-based compensation			2										2
Repurchase of common stock	Repurchase of common stock			(50)										(50)		Repurchase of common stock			(50)										(50)
Other - net	Other - net			40		(2)						(2)		36		Other - net			40		(2)						(2)		36
Balance at March 31, 2020	Balance at March 31, 2020	$	7	$	27,906	$	(155)	$	(3,933)	$	—	$	254	$	24,079	Balance at March 31, 2020	$	7	$	27,906	$	(155)	$	(3,933)	$	—	$	254	$	24,079
Net income																Net income					760						6		766
Other comprehensive income																Other comprehensive income							88						88
Common dividends ($.13 per share)																Common dividends ($.13 per share)					(97)								(97)
Issuance of Corteva stock																Issuance of Corteva stock			3										3
Share-based compensation																Share-based compensation			19										19
Acquisition of a noncontrolling interest in consolidated subsidiaries																Acquisition of a noncontrolling interest in consolidated subsidiaries			(37)								(15)		(52)
Other - net																Other - net											(5)		(5)

Balance at June 30, 2020																Balance at June 30, 2020	$	7	$	27,891	$	508	$	(3,845)	$	—	$	240	$	24,801


(In millions, except per share amounts)	(In millions, except per share amounts)	Common Stock		Additional Paid-in Capital "APIC"		(Accumulated deficit) Retained Earnings		Accumulated Other Comp (Loss) Income		Treasury Stock		Non-controlling Interests		Total Equity		(In millions, except per share amounts)	Common Stock		Additional Paid-in Capital "APIC"		Retained Earnings (Accumulated Deficit)		Accumulated Other Comp (Loss) Income		Treasury Stock		Non-controlling Interests		Total Equity
2021	2021															2021
Balance at January 1, 2021	Balance at January 1, 2021	$	7	$	27,707	$	0	$	(2,890)	$	—	$	239	$	25,063	Balance at January 1, 2021	$	7	$	27,707	$	0	$	(2,890)	$	—	$	239	$	25,063
Net income	Net income					600						3		603		Net income					600						3		603
Other comprehensive loss	Other comprehensive loss							(477)						(477)		Other comprehensive loss							(477)						(477)
Common dividends ($0.13 per share)	Common dividends ($0.13 per share)			(97)										(97)		Common dividends ($0.13 per share)			(97)										(97)
Issuance of Corteva stock	Issuance of Corteva stock			38										38		Issuance of Corteva stock			38										38

Repurchase of common stock	Repurchase of common stock			(18)		(332)								(350)		Repurchase of common stock			(18)		(332)								(350)
Other - net	Other - net											(2)		(2)		Other - net											(2)		(2)
Balance at March 31, 2021	Balance at March 31, 2021	$	7	$	27,630	$	268	$	(3,367)	$	—	$	240	$	24,778	Balance at March 31, 2021	$	7	$	27,630	$	268	$	(3,367)	$	—	$	240	$	24,778
Net income																Net income					970						3		973
Other comprehensive income																Other comprehensive income							122						122
Common dividends ($0.13 per share)																Common dividends ($0.13 per share)					(95)								(95)
Issuance of Corteva stock																Issuance of Corteva stock			28										28
Share-based compensation																Share-based compensation			23		(1)								22
Repurchase of common stock																Repurchase of common stock					(200)								(200)

Other - net																Other - net			1		(1)						(3)		(3)
Balance at June 30, 2021																Balance at June 30, 2021	$	7	$	27,682	$	941	$	(3,245)	$	—	$	240	$	25,625

See Notes to the ~~interim~~Interim Consolidated Financial Statements beginning on page 8.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


			Corteva, Inc.
			Notes to the Interim Consolidated Financial Statements (Unaudited)

Table of Contents


Note	Note		Page	Note		Page
1	1	Summary of Significant Accounting Policies	9	1	Summary of Significant Accounting Policies	9
2	2	Recent Accounting Guidance	9	2	Recent Accounting Guidance	9
3	3	Divestitures and Other Transactions	9	3	Divestitures and Other Transactions	9
4	4	Revenue	10	4	Revenue	11
5	5	Restructuring and Asset Related Charges - Net	13	5	Restructuring and Asset Related Charges - Net	14
6	6	Supplementary Information	14	6	Supplementary Information	16
7	7	Income Taxes	16	7	Income Taxes	18
8	8	Earnings Per Share of Common Stock	17	8	Earnings Per Share of Common Stock	19
9	9	Accounts and Notes Receivable - Net	18	9	Accounts and Notes Receivable - Net	20
10	10	Inventories	19	10	Inventories	21
11	11	Other Intangible Assets	19	11	Other Intangible Assets	21
12	12	Short-Term Borrowings, Long-Term Debt and Available Credit Facilities	20	12	Short-Term Borrowings, Long-Term Debt and Available Credit Facilities	22
13	13	Commitments and Contingent Liabilities	20	13	Commitments and Contingent Liabilities	23
14	14	Stockholders' Equity	26	14	Stockholders' Equity	29
15	15	Pension Plans and Other Post Employment Benefits	29	15	Pension Plans and Other Post Employment Benefits	32
16	16	Financial Instruments	29	16	Financial Instruments	32
17	17	Fair Value Measurements	35	17	Fair Value Measurements	38
18	18	Segment Information	36	18	Segment Information	39

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto contained in the company’s Annual Report on Form 10-K for the year ended December 31, 2020, collectively referred to as the “2020 Annual Report.” The interim Consolidated Financial Statements include the accounts of the company and all of its subsidiaries in which a controlling interest is maintained.

Certain reclassifications of prior year's data have been made to conform to current year's presentation.

During the first quarter 2020, the company recorded an increase of $40 million to APIC relating to net assets recorded as transferred as part of the 2019 Internal Reorganizations that were retained.

Since 2018, Argentina has been considered a hyper-inflationary economy under U.S. GAAP and therefore the U.S. Dollar (“USD”) is the functional currency for our related subsidiaries. Argentina contributes approximately 4 percent to our annual Sales and EBITDA. We remeasure ~~the~~ net monetary assets utilizing the official Argentine Peso (“Peso”) to USD exchange ~~rate.~~rate and translate our financial statements. The ability to draw down Peso cash balances is limited at this time due to government restrictions and market availability of U.S. Dollars. The devaluation of the Peso relative to the USD over the last several years has resulted in the recognition of exchange losses (refer to Note 6 ~~of these financial statements~~– Supplementary Information, to the interim Consolidated Financial Statements, and Note 9 of– Supplemental Information, to the company's 2020 ~~financial statements included in the Company's~~ Annual ~~Report on Form 10-K)~~Report). As of ~~March 31,~~June 30, 2021, a further ~~10%~~10 percent deterioration in the official Peso to USD exchange rate would reduce the USD value of our net monetary assets and negatively impact pre-tax earnings by approximately $20 million. We will continue to assess the implications to our operations and financial reporting.

NOTE 2 - RECENT ACCOUNTING GUIDANCE

Recently Adopted Accounting Guidance

In December 2019, the FASB issued ~~ASU~~Accounting Standards Update ("ASU") 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which was part of the FASB’s Simplification Initiative to identify, evaluate, and improve areas of ~~U.S.~~ GAAP for which cost and complexity can be reduced, while maintaining or improving the usefulness of the information provided to users of the financial statements. This ASU amends ASC 740, Income Taxes, by removing certain exceptions to the general principles, and clarifying and amending current guidance. The new standard is effective for fiscal years, and periods within those fiscal years, beginning after December 15, 2020. The company adopted this guidance on January 1, 2021 and it did not have a material impact on the company’s financial position, results of operation or cash flows.

NOTE 3 - DIVESTITURES AND OTHER TRANSACTIONS

Separation Agreements

In connection with the Distributions, DuPont, Corteva, and Dow (together, the “Parties” and each a “Party”) have entered into certain agreements to effect the Separation, provide for the allocation of DowDuPont’s assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among the Parties, and provide a framework for Corteva's relationship with Dow and DuPont following the ~~separations~~Separations and Distributions (collectively, the "Separation Agreements"). For additional information see Note 13 - Commitments and Contingent Liabilities.

DuPont

Pursuant to the Separation Agreements, DuPont and Corteva indemnifies the other against certain litigation, environmental, tax, workers' compensation and other liabilities that arose prior to the Corteva Distribution. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. At ~~March 31,~~June 30, 2021, the indemnification assets are ~~$28~~$31 million within accounts and notes receivable - net and ~~$51~~$50 million within other assets in the interim ~~Condensed~~ Consolidated Balance Sheet. At ~~March 31,~~June 30, 2021, the indemnification liabilities are $77 million within other noncurrent obligations in the interim ~~Condensed~~ Consolidated Balance Sheet.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Dow

Pursuant to the Separation Agreements, Dow and Corteva indemnifies the other against certain litigation, environmental, tax and other liabilities that arose prior to the Corteva Distribution. The term of this indemnification is generally indefinite and

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. At ~~March 31,~~June 30, 2021, the indemnification liabilities are ~~$52~~$54 million within accrued and other current liabilities and $14 million within other noncurrent obligations in the interim ~~Condensed~~ Consolidated Balance Sheet.

Performance Chemicals

On July 1, 2015, Historical DuPont completed the separation of its Performance Chemicals segment through the spin-off of all of the issued and outstanding stock of The Chemours Company (the "Chemours Separation"). In connection with the Chemours Separation, Historical DuPont and The Chemours Company ("Chemours") entered into a Separation Agreement (as amended, the "Chemours Separation Agreement"), discussed below, a Tax Matters Agreement and certain ancillary agreements, including an employee matters agreement, agreements related to transition and site services, and intellectual property cross licensing arrangements. In addition, the companies entered into certain supply agreements.

Chemours Separation Agreement

The Chemours Separation Agreement sets forth, among other things, the agreements between the company and Chemours regarding the principal transactions necessary to ~~effect~~affect the Chemours Separation and also sets forth ancillary agreements that govern certain aspects of the company’s relationship with Chemours after the separation. Among other matters, the Chemours Separation Agreement and the ancillary agreements provide for the allocation between Historical DuPont and Chemours of assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after the completion of the Chemours Separation.

Pursuant to the Chemours Separation Agreement, Chemours indemnifies the company against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the distribution. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In 2017, EID and Chemours amended the Chemours Separation Agreement ("2017 Amendment") to provide for a limited sharing of potential future perfluorooctanoic acid (“PFOA”) liabilities for a period of five years beginning July 6, 2017. In January 2021, Chemours, DuPont and Corteva entered into a binding memorandum of understanding ("MOU") amending the Chemours Separation Agreement, and thereby replacing the 2017 Amendment.

In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. At ~~March 31,~~June 30, 2021, the indemnification assets are ~~$63~~$64 million within accounts and notes receivable - net and ~~$259~~$255 million within other assets (along with the corresponding liabilities within accrued and other current liabilities and other noncurrent obligations in the interim ~~Condensed~~ Consolidated Balance ~~Sheet.) Additionally, at March 31,~~Sheet).

At June 30, 2021 indemnification liabilities related to the MOU, primarily associated with environmental remediation related to PFAS, were ~~$10~~$24 million within accrued and other current liabilities and ~~$44~~$75 million within other noncurrent obligations in the interim ~~Condensed~~ Consolidated Balance Sheet. During the three and six months ended ~~March 31,~~June 30, 2021, the company recorded charges of $34 million and $37 million, respectively, to (loss) income from discontinued operations after income taxes, related to the MOU. The charge in the three months ended June 30, 2021 is primarily related to an increase in the environmental remediation accrual for Chemours' Fayetteville Works facility for estimated costs for on-site surface water and groundwater remediation to address and abate PFAS discharges arising out of pre-July 1, 2015 conduct. The increase is the result of further detailed engineering and design work related to Chemours’ environmental remediation activities at the site under the Consent Order between Chemours and the North Carolina Department of Environmental Quality. Based on the upper end of the range of reasonably possible outcomes, the company’s potential exposure above the amount accrued relating to the Fayetteville Works facility is approximately $20 million at June 30, 2021.

In addition to the above, the company has recognized a liability of $12.5 million as of June 30, 2021 within accrued and other current liabilities in the interim Consolidated Balance Sheet related to the settlement agreement between Chemours, DuPont, EID, Corteva and the State of Delaware. During the three months ended June 30, 2021, the company recorded a charge of $3$11 million to (loss) income from discontinued operations after income taxes, related to the ~~MOU.~~settlement.

See Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for further discussion of the amendment to the Chemours Separation Agreement, MOU, ~~and~~ environmental matters indemnified by ~~Chemours.~~Chemours and the settlement with the State of Delaware.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 4 - REVENUE

Revenue Recognition

Products

Substantially all of Corteva's revenue is derived from product sales. Product sales consist of sales of Corteva's products to farmers, distributors, and manufacturers. Corteva considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year. However, the company has some long-term contracts which can span multiple years.

Revenue from product sales is recognized when the customer obtains control of the company's product, which occurs at a point in time according to shipping terms. Payment terms are generally less than one year from invoicing. The company elected the practical expedient and does not adjust the promised amount of consideration for the effects of a significant financing component when the company expects it will be one year or less between when a customer obtains control of the company's product and when payment is due. The company has elected to recognize shipping and handling activities when control has transferred to the customer as an expense in cost of goods sold. Taxes collected from customers relating to product sales and

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

remitted to governmental authorities are excluded from revenues. In addition, the company elected the practical expedient to expense any costs to obtain contracts as incurred, as the amortization period for these costs would have been one year or less.

The transaction price includes estimates of variable consideration, such as rights of return, rebates, and discounts, that are reductions in revenue. All estimates are based on the company's historical experience, anticipated performance, and the company's best judgment at the time the estimate is made. Estimates of variable consideration included in the transaction price utilize either the expected value method or most likely amount depending on the nature of the variable consideration. These estimates are reassessed each reporting period and are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur upon resolution of uncertainty associated with the variable consideration. The majority of contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as quantity times price per unit. For contracts with multiple performance obligations, the company allocates the transaction price to each performance obligation based on the relative standalone selling price. The standalone selling price is the observable price which depicts the price as if sold to a similar customer in similar circumstances.

Licenses of Intellectual Property

Corteva enters into licensing arrangements with customers under which it licenses its intellectual property. Revenue from the majority of intellectual property licenses is derived from sales-based royalties. Revenue for licensing agreements that contain sales-based royalties is recognized at the later of (i) when the subsequent sale occurs or (ii) when the performance obligation to which some or all of the royalty has been allocated is satisfied.

Remaining Performance Obligations

Remaining performance obligations represent the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. The company applies the practical expedient to disclose the transaction price allocated to the remaining performance obligations for only those contracts with an original duration of one year or more. The transaction price allocated to remaining performance obligations with an original duration of more than one year related to material rights granted to customers for contract renewal options were ~~$113~~$118 million, $115 million and $110 million at ~~March 31,~~June 30, 2021, ~~($115 million and $106 million at~~ December 31, 2020 and ~~March 31,~~June 30, 2020, ~~respectively).~~respectively. The company expects revenue to be recognized for the remaining performance obligations over the next 1 year to 6 years.

Contract Balances

Contract liabilities primarily reflect deferred revenue from prepayments under contracts with customers where the company receives advance payments for products to be delivered in future periods. Corteva classifies deferred revenue as current or noncurrent based on the timing of when the company expects to recognize revenue. Contract assets primarily include amounts related to ~~contractual~~conditional rights to consideration for completed performance not yet invoiced. Accounts receivable are recorded when the right to consideration becomes unconditional.

Contract Balances March 31, 2021 December 31, 2020 March 31, 2020
(In millions)
Accounts and notes receivable - trade1
$ 5,764 $ 3,917 $ 5,779
Contract assets - current2
$ 22 $ 22 $ 20
Contract assets - noncurrent3
$ 53 $ 54 $ 49
Deferred revenue - current $ 2,247 $ 2,662 $ 1,996
Deferred revenue - noncurrent4
$ 111 $ 116 $ 104

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


Contract Balances	June 30, 2021		December 31, 2020		June 30, 2020
(In millions)	June 30, 2021		December 31, 2020		June 30, 2020
Accounts and notes receivable - trade1	$	5,763	$	3,917	$	5,787
Contract assets - current2	$	23	$	22	$	21
Contract assets - noncurrent3	$	56	$	54	$	51
Deferred revenue - current	$	748	$	2,662	$	431
Deferred revenue - noncurrent4	$	111	$	116	$	109

1.Included in accounts and notes receivable - net in the interim ~~Condensed~~ Consolidated Balance Sheets.

2.Included in other current assets in the interim ~~Condensed~~ Consolidated Balance Sheets.

3.Included in other assets in the interim ~~Condensed~~ Consolidated Balance Sheets.

4.Included in other noncurrent obligations in the interim ~~Condensed~~ Consolidated Balance Sheets.

Revenue recognized during the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020 from amounts included in deferred revenue at the beginning of the period was ~~$924~~$2,464 million ~~($822~~and $2,271 million, ~~in the three months ended March 31, 2020).~~

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

respectively.

Disaggregation of Revenue

Corteva's operations are classified into two reportable segments: Seed and Crop Protection. The company disaggregates its revenue by major product line and geographic region, as the company believes it best depicts the nature, amount and timing of its revenue and cash flows. Net sales by major product line are included below:


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020
Corn	Corn	$	1,888	$	1,864		Corn	$	2,180	$	2,057	$	4,068	$	3,921
Soybean	Soybean	177		181			Soybean	1,160		1,085		1,337		1,266
Other oilseeds	Other oilseeds	296		248			Other oilseeds	271		219		567		467
Other	Other	131		162			Other	169		177		300		339
Seed	Seed	2,492		2,455			Seed	3,780		3,538		6,272		5,993
Herbicides	Herbicides	986		823			Herbicides	969		909		1,955		1,732
Insecticides	Insecticides	385		378			Insecticides	460		445		845		823
Fungicides	Fungicides	261		229			Fungicides	311		224		572		453
Other	Other	54		71			Other	107		75		161		146
Crop Protection	Crop Protection	1,686		1,501			Crop Protection	1,847		1,653		3,533		3,154
Total	Total	$	4,178	$	3,956		Total	$	5,627	$	5,191	$	9,805	$	9,147

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Sales are attributed to geographic regions based on customer location. Net sales by geographic region and segment are included below:


Seed	Seed	Three Months Ended March 31,				Seed	Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020				(In millions)	2021		2020		2021		2020
North America1	North America1	$	1,210	$	1,290			North America1	$	3,104	$	2,903	$	4,314	$	4,193
EMEA2	EMEA2	947		881				EMEA2	298		264		1,245		1,145
Latin America	Latin America	274		216				Latin America	234		206		508		422
Asia Pacific	Asia Pacific	61		68				Asia Pacific	144		165		205		233
Total	Total	$	2,492	$	2,455			Total	$	3,780	$	3,538	$	6,272	$	5,993


Crop Protection	Crop Protection	Three Months Ended March 31,				Crop Protection	Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020				(In millions)	2021		2020		2021		2020
North America1	North America1	$	533	$	475			North America1	$	738	$	663	$	1,271	$	1,138
EMEA2	EMEA2	655		586				EMEA2	412		379		1,067		965
Latin America	Latin America	244		218				Latin America	354		309		598		527
Asia Pacific	Asia Pacific	254		222				Asia Pacific	343		302		597		524
Total	Total	$	1,686	$	1,501			Total	$	1,847	$	1,653	$	3,533	$	3,154

1.Represents U.S. & Canada.

2.Europe, Middle East, and Africa ("EMEA").

1213

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 5 - RESTRUCTURING AND ASSET RELATED CHARGES - NET

2021 Restructuring Actions

As discussed in the 2020 Annual Report, on February 1, 2021, Corteva approved restructuring actions designed to right-size and optimize its footprint and organizational structure according to the business needs in each region with the focus on driving continued cost improvement and productivity. As a result of these actions, the company expects to record total pre-tax restructuring charges of approximately $130 million to $170 million, comprised of approximately $40 million to $50 million of severance and related benefit costs, $40 million to $60 million of asset related charges, $10 million to $15 million of asset retirement obligations and $40 million to $45 million of costs related to contract terminations (contract terminations includes early lease terminations). Future cash payments related to this charge are anticipated to be approximately $80 million to $100 million, primarily related to the payment of severance and related benefits, asset retirement obligations, and costs related to contract terminations. The restructuring actions associated with this charge are expected to be substantially complete in 2021.

The charges related to the 2021 Restructuring Actions related to the segments, as well as corporate expenses, were as follows:


	~~Three Months Ended March 31,~~
~~(In millions)~~	~~2021~~
~~Seed~~	$	14
~~Crop Protection~~	28
~~Corporate expenses~~	47
~~Total~~	$	89


	Three Months Ended June 30,		Six Months Ended June 30,
(In millions)	2021		2021
Seed	$	3	$	17
Crop Protection	9		37
Corporate expenses	9		56
Total	$	21	$	110

The below is a summary of charges incurred related to 2021 Restructuring Actions for the three and six months ended June 30, 2021:


	Three Months Ended June 30,		Six Months Ended June 30,
(In millions)	2021		2021
Severance and related benefit costs	$	10	$	49
Asset related charges	9		22
Contract termination charges	2		39
Total restructuring and asset charges - net	$	21	$	110

A reconciliation of the December 31, 2020 to the ~~March 31,~~June 30, 2021 liability balances related to the 2021 Restructuring Actions is summarized below:


(In millions)	(In millions)	Severance and Related Benefit Costs		Asset Related1		Contract Termination2		Total		(In millions)	Severance and Related Benefit Costs		Asset Related1		Contract Termination2		Total
Balance at December 31, 2020	Balance at December 31, 2020	0		0		0		$	0	Balance at December 31, 2020	$	0	$	0	$	0	$	0
Charges to income from continuing operations for the three months ended March 31, 2021		39		13		37		89
Charges to income from continuing operations										Charges to income from continuing operations	49		22		39		110
Payments	Payments	(1)		0		(6)		(7)		Payments	(9)		0		(23)		(32)
Asset write-offs	Asset write-offs	0		(13)		0		(13)		Asset write-offs	0		(22)		0		(22)
Balance at March 31, 2021		$	38	$	0	$	31	$	69
Balance at June 30, 2021										Balance at June 30, 2021	$	40	$	0	$	16	$	56

1.In addition, the ~~Company~~company has a liability recorded for asset retirement obligations of $6 million as of ~~March 31,~~June 30, 2021.

2.The liability for contract terminations includes lease obligations. The cash impact of these obligations will be substantially complete by 2022.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Execute to Win Productivity Program

During the first quarter of 2020, Corteva approved restructuring actions designed to improve productivity through optimizing certain operational and organizational structures primarily related to the Execute to Win Productivity Program. Through the ~~first~~second quarter of 2021, the company recorded net pre-tax restructuring charges of ~~$180~~$182 million inception-to-date under the Execute to Win Program, consisting of ~~$117~~$119 million of asset related charges and $63 million of severance and related benefit costs. The company does not anticipate any additional material charges from the Execute to Win Program as actions associated with this charge were substantially complete by the end of 2020.

The Execute to Win Productivity Program charges related to the segments, as well as corporate expenses, were as follows:


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020		(In millions)	2021		2020		2021		2020
Seed	Seed	$	0	$	3	Seed	$	0	$	0	$	0	$	3
Crop Protection	Crop Protection	4		18		Crop Protection	2		37		6		55
Corporate expenses	Corporate expenses	0		42		Corporate expenses	0		4		0		46
Total	Total	$	4	$	63	Total	$	2	$	41	$	6	$	104

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

The below is a summary of charges incurred related to the Execute to Win Productivity Program for the three and six months ended ~~March 31,~~June 30, 2021 and 2020:


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020		(In millions)	2021		2020		2021		2020
Severance and related benefit costs	Severance and related benefit costs	$	0	$	42	Severance and related benefit costs	$	0	$	4	$	0	$	46
Asset related charges	Asset related charges	4		21		Asset related charges	2		37		6		58
Total restructuring and asset related charges - net	Total restructuring and asset related charges - net	$	4	$	63	Total restructuring and asset related charges - net	$	2	$	41	$	6	$	104

A reconciliation of the December 31, 2020 to the ~~March 31,~~June 30, 2021 liability balances related to the Execute to Win Productivity Program is summarized below:


(In millions)	(In millions)	Severance and Related Benefit Costs		Asset Related		Total		(In millions)	Severance and Related Benefit Costs		Asset Related1		Total
Balance at December 31, 2020	Balance at December 31, 2020	$	53	$	3	$	56	Balance at December 31, 2020	$	53	$	3	$	56
Charges to income from continuing operations for the three months ended March 31, 2021		0		4		4
Charges to income from continuing operations								Charges to income from continuing operations	0		6		6
Payments	Payments	(11)		(3)		(14)		Payments	(20)		(3)		(23)

Asset write-offs	Asset write-offs	0		(4)		(4)		Asset write-offs	0		(6)		(6)
Balance at March 31, 2021		$	42	$	0	$	42
Balance at June 30, 2021								Balance at June 30, 2021	$	33	$	0	$	33

In addition, ~~to the above,~~ the company has a liability recorded for asset retirement obligations of ~~$20~~$18 million as of ~~March 31,~~June 30, 2021. The asset retirement obligations relate to the company’s required demolition and removal for buildings and equipment at third party leased sites and will be recognized as asset related charges over the remaining useful lives of the related assets. The company’s leases require these assets be removed from leased land within 12-24 months of operations being ceased. The company ceased substantially all operations in 2020 and the assets are expected to be removed within the contractual timeframe.

Other Asset Related Charges

During the three and six months ended ~~March 31,~~June 30, 2021, ~~and 2020,~~ the company recognized $7$112 million and ~~$10~~$119 million, respectively, in restructuring and asset related charges - net in the interim Consolidated Statement of Operations, from non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 6 - SUPPLEMENTARY INFORMATION


Other Income - Net	Other Income - Net	Three Months Ended March 31,				Other Income - Net	Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020				(In millions)	2021		2020		2021		2020
Interest income	Interest income	$	21	$	18			Interest income	$	18	$	9	$	39	$	27
Equity in earnings / (losses) of affiliates - net	Equity in earnings / (losses) of affiliates - net	3		(1)				Equity in earnings / (losses) of affiliates - net	2		(2)		5		(3)
Net loss on sales of businesses and other assets1		0		(46)
Net exchange losses2		(35)		(61)
Net gain (loss) on sales of businesses and other assets1								Net gain (loss) on sales of businesses and other assets1	1		16		1		(30)
Net exchange (losses) / gains2								Net exchange (losses) / gains2	(14)		1		(49)		(60)
Non-operating pension and other post employment benefit credit3	Non-operating pension and other post employment benefit credit3	325		91				Non-operating pension and other post employment benefit credit3	328		91		653		182
Miscellaneous income - net4		23		0
Miscellaneous expense - net4								Miscellaneous expense - net4	(37)		(26)		(14)		(26)
Other income - net	Other income - net	$	337	$	1			Other income - net	$	298	$	89	$	635	$	90

1.The ~~three~~six months ended ~~March 31,~~June 30, 2020 includes a loss of $(53) million relating to the sale of the La Porte site, for which the company signed an agreement in 2020, and closed during the first quarter of 2021.

2.Includes net pre-tax exchange losses of ~~$(23)~~$14 million and ~~$(9)~~$37 million associated with the devaluation of the Argentine peso for the three and six months ended ~~March 31,~~June 30, 2021, respectively, and $22 million and $31 million for the three and six months ended June 30, 2020, respectively.

3.Includes non-service related components of net periodic benefit credits (costs) (interest cost, expected return on plan assets, amortization of unrecognized gain (loss), amortization of prior service benefit and settlement loss).

4.Miscellaneous ~~income~~expense - net for the three and six months ended June 30, 2021 and 2020 includes ~~a gain from a remeasurement of an equity investment,~~ losses on sale of ~~available-for-sale securities,~~receivables, tax indemnification adjustments related to changes in indemnification balances as a result of the application of the terms of the Tax Matters Agreement between Corteva and Dow and/or DuPont, and other items. Miscellaneous expense - net for the three and six months ended June 30, 2021 also includes a gain from remeasurement of an equity investment and realized losses on sale of ~~receivables, and other items.~~available-for-sale securities.

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

The following table summarizes the impacts of the company's foreign currency hedging program on the company's results of operations. The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the U.S., whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income - net and the related tax impact is recorded in provision for ~~(benefit from)~~ income taxes on continuing operations in the interim Consolidated Statement of Operations.

(In millions) Three Months Ended
March 31,
2021 2020
Subsidiary Monetary Position (Losses) Gains
Pre-tax exchange losses $ (51) $ (226)
Local tax (expenses) / benefits (1) 23
Net after-tax impact from subsidiary exchange losses $ (52) $ (203)
Hedging Program Gains
Pre-tax exchange gains $ 16 $ 165
Tax expenses (4) (40)
Net after-tax impact from hedging program exchange gains $ 12 $ 125
Total Exchange Losses
Pre-tax exchange losses $ (35) $ (61)
Tax expenses (5) (17)
Net after-tax exchange losses $ (40) $ (78)


(In millions)	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Subsidiary Monetary Position Gains (Losses)
Pre-tax exchange gains (losses)	$	36	$	(13)	$	(15)	$	(239)
Local tax (expenses) / benefits	(13)		5		(14)		28
Net after-tax impact from subsidiary exchange gains (losses)	$	23	$	(8)	$	(29)	$	(211)

Hedging Program Gains
Pre-tax exchange (losses) gains	$	(50)	$	14	$	(34)	$	179
Tax benefits / (expenses)	12		(3)		8		(43)
Net after-tax impact from hedging program exchange (losses) gains	$	(38)	$	11	$	(26)	$	136

Total Exchange Losses
Pre-tax exchange (losses) gains	$	(14)	$	1	$	(49)	$	(60)
Tax (expenses) benefits	(1)		2		(6)		(15)
Net after-tax exchange (losses) gains	$	(15)	$	3	$	(55)	$	(75)

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash and cash equivalents and restricted cash (included in other current assets) presented in the interim ~~Condensed~~ Consolidated Balance Sheets to the total cash, cash equivalents and restricted cash presented in the interim Consolidated Statements of Cash Flows.


(In millions)	(In millions)	March 31, 2021		December 31, 2020		March 31, 2020		(In millions)	June 30, 2021		December 31, 2020		June 30, 2020
Cash and cash equivalents	Cash and cash equivalents	$	2,404	$	3,526	$	1,963	Cash and cash equivalents	$	2,861	$	3,526	$	2,809
Restricted cash	Restricted cash	326		347		377		Restricted cash	311		347		362
Total cash, cash equivalents and restricted cash	Total cash, cash equivalents and restricted cash	$	2,730	$	3,873	$	2,340	Total cash, cash equivalents and restricted cash	$	3,172	$	3,873	$	3,171

EID entered into a trust agreement in 2013 (as amended and restated in 2017), establishing and requiring EID to fund a trust (the "Trust") for cash obligations under certain non-qualified benefit and deferred compensation plans upon a change in control event as defined in the Trust agreement. Under the Trust agreement, the consummation of the Merger was a change in control event. Restricted cash at ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020 is related to the Trust.

1517

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 7 - INCOME TAXES

For periods between the Merger Effectiveness Time and the Corteva Distribution, Corteva and its subsidiaries were included in DowDuPont's consolidated federal income tax group and consolidated tax return. Generally, the consolidated tax liability of the DowDuPont U.S. tax group for each year was apportioned among the members of the consolidated group based on each member’s separate taxable income. Corteva, DuPont and Dow intend that to the extent Federal and/or State corporate income tax liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party’s sub-group attributes will be in accordance with a tax matters agreement. See Note 3 - Divestitures and Other Transactions, for further information related to indemnifications between Corteva, Dow and DuPont.

Each year the company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the company. As a result, there is an uncertainty in income taxes recognized in the company's financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the company's results of operations.

During the three and six months ended June 30, 2021, the company recognized $18 million and $25 million, respectively, of net tax benefits associated with changes in accruals for certain prior year tax positions in various jurisdictions.

During the three and six months ended June 30, 2020, the company recognized a tax benefit of $51 million to provision for income taxes on continuing operations related to a return to accrual adjustment associated with an elective change in accounting method for the 2019 tax year impact of the 2017 Tax Cuts and Jobs Act 's (“The Act”) foreign tax provisions.

During the three and six months ended June 30, 2020 the company recognized a tax benefit of $14 million to provision for income taxes on continuing operations related to a return to accrual adjustment to reflect a change in estimate on the impact of a tax law enactment in a foreign jurisdiction.

The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of the program, which resides in the U.S., is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions, which can drive material impacts on the company's effective tax rate. For further discussion of pre-tax and after-tax impacts of the company's foreign currency hedging program and net monetary asset programs, refer to Note 6 - Supplementary Information.

1618

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 8 - EARNINGS PER SHARE OF COMMON STOCK

The following tables provide earnings per share calculations for the periods indicated below:


Net Income for Earnings Per Share Calculations - Basic and Diluted	Net Income for Earnings Per Share Calculations - Basic and Diluted	Three Months Ended March 31,				Net Income for Earnings Per Share Calculations - Basic and Diluted	Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020				(In millions)	2021		2020		2021		2020
Income from continuing operations after income taxes	Income from continuing operations after income taxes	$	613	$	281			Income from continuing operations after income taxes	$	1,018	$	766	$	1,631	$	1,047
Net income attributable to continuing operations noncontrolling interests	Net income attributable to continuing operations noncontrolling interests	3		10				Net income attributable to continuing operations noncontrolling interests	3		6		6		16

Income from continuing operations available to Corteva common stockholders	Income from continuing operations available to Corteva common stockholders	610		271				Income from continuing operations available to Corteva common stockholders	1,015		760		1,625		1,031
(Loss) income from discontinued operations available to Corteva common stockholders	(Loss) income from discontinued operations available to Corteva common stockholders	(10)		1				(Loss) income from discontinued operations available to Corteva common stockholders	(45)		0		(55)		1
Net income available to common stockholders	Net income available to common stockholders	$	600	$	272			Net income available to common stockholders	$	970	$	760	$	1,570	$	1,032


Earnings Per Share Calculations - Basic	Earnings Per Share Calculations - Basic	Three Months Ended March 31,				Earnings Per Share Calculations - Basic	Three Months Ended June 30,				Six Months Ended June 30,
(Dollars per share)	(Dollars per share)	2021		2020				(Dollars per share)	2021		2020		2021		2020
Earnings per share of common stock from continuing operations	Earnings per share of common stock from continuing operations	$	0.82	$	0.36			Earnings per share of common stock from continuing operations	$	1.37	$	1.01	$	2.19	$	1.37
Loss per share of common stock from discontinued operations	Loss per share of common stock from discontinued operations	(0.01)		0				Loss per share of common stock from discontinued operations	(0.06)		0		(0.07)		0
Earnings per share of common stock	Earnings per share of common stock	$	0.81	$	0.36			Earnings per share of common stock	$	1.31	$	1.01	$	2.12	$	1.37


Earnings Per Share Calculations - Diluted	Earnings Per Share Calculations - Diluted	Three Months Ended March 31,				Earnings Per Share Calculations - Diluted	Three Months Ended June 30,				Six Months Ended June 30,
(Dollars per share)	(Dollars per share)	2021		2020				(Dollars per share)	2021		2020		2021		2020
Earnings per share of common stock from continuing operations	Earnings per share of common stock from continuing operations	$	0.81	$	0.36			Earnings per share of common stock from continuing operations	$	1.37	$	1.01	$	2.18	$	1.37
Loss per share of common stock from discontinued operations	Loss per share of common stock from discontinued operations	(0.01)		0				Loss per share of common stock from discontinued operations	(0.06)		0		(0.07)		0
Earnings per share of common stock	Earnings per share of common stock	$	0.80	$	0.36			Earnings per share of common stock	$	1.31	$	1.01	$	2.11	$	1.37


Share Count Information	Share Count Information	Three Months Ended March 31,		Share Count Information	Three Months Ended June 30,			Six Months Ended June 30,
(Shares in millions)	(Shares in millions)	2021	2020			(Shares in millions)	2021	2020	2021	2020
Weighted-average common shares - basic	Weighted-average common shares - basic	743.4	749.9			Weighted-average common shares - basic	737.3	749.2	740.3	749.6
Plus dilutive effect of equity compensation plans1	Plus dilutive effect of equity compensation plans1	6.2	2.6			Plus dilutive effect of equity compensation plans1	6.0	2.4	6.1	2.4

Weighted-average common shares - diluted	Weighted-average common shares - diluted	749.6	752.5			Weighted-average common shares - diluted	743.3	751.6	746.4	752.0
Potential shares of common stock excluded from EPS calculations2	Potential shares of common stock excluded from EPS calculations2	2.9	9.1			Potential shares of common stock excluded from EPS calculations2	2.1	11.9	2.1	11.0

1.Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

2.These outstanding potential shares of common stock relating to stock options, restricted stock units and performance-based restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been anti-dilutive.

1719

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE - NET


(In millions)	(In millions)	March 31, 2021		December 31, 2020		March 31, 2020		(In millions)	June 30, 2021		December 31, 2020		June 30, 2020
Accounts receivable – trade1	Accounts receivable – trade1	$	5,231	$	3,754	$	5,367	Accounts receivable – trade1	$	4,318	$	3,754	$	4,396
Notes receivable – trade1,2	Notes receivable – trade1,2	533		163		412		Notes receivable – trade1,2	1,445		163		1,391
Other3	Other3	1,028		1,009		996		Other3	1,029		1,009		985
Total accounts and notes receivable - net	Total accounts and notes receivable - net	$	6,792	$	4,926	$	6,775	Total accounts and notes receivable - net	$	6,792	$	4,926	$	6,772

1.Accounts receivable – trade and notes receivable - trade are net of allowances of ~~$203~~$216 million at ~~March 31,~~June 30, 2021, $208 million at December 31, 2020, and ~~$203~~$207 million at ~~March 31,~~June 30, 2020. Allowances are equal to the estimated uncollectible amounts and are based on the expected credit losses and were developed using a loss-rate method.

2.Notes receivable – trade primarily consists of receivables for deferred payment loan programs for the sale of seed products to customers. These loans have terms of one year or less and are primarily concentrated in North America. The company maintains a rigid pre-approval process for extending credit to customers in order to manage overall risk and exposure associated with credit losses. As of ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020 there were no significant impairments related to current loan agreements.

3.Other includes receivables in relation to indemnification assets, value added tax, general sales tax and other taxes. No individual group represents more than 10 percent of total receivables. In addition, Other includes amounts due from nonconsolidated affiliates of ~~$115~~$92 million, $106 million, and ~~$140~~$114 million as of ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020, respectively.

Accounts and notes receivable are carried at the expected amount to be collected, which approximates fair value. The company establishes the allowance for doubtful receivables using a loss-rate method where the loss rate is developed using past events, historical experience, current conditions and forecasts that affect the collectability of the financial assets.

The following table summarizes changes in the allowance for doubtful receivables for the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020:


(In millions)
2020
Balance at December 31, 2019	$	174
Net provision for credit losses	60124
Write-offs charged against allowance	~~(1)~~(6)
Recoveries collected	~~(30)~~(78)
Other	(7)
Balance at ~~March 31,~~June 30, 2020	$	~~203~~207

2021
Balance at December 31, 2020	$	208
Net ~~benefit~~provision for credit losses	~~(5)~~48
Recoveries collected	(51)
Other	11



Balance at ~~March 31,~~June 30, 2021	$	~~203~~216

The company enters into various factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds. These financing arrangements result in a transfer of the company's receivables and risks to the third-party. As these transfers qualify as true sales under the applicable accounting guidance, the receivables are derecognized from the interim ~~Condensed~~ Consolidated Balance Sheets upon transfer, and the company receives a payment for the receivables from the third-party within a mutually agreed upon time period. For arrangements involving an element of recourse, which is typically provided through a guarantee of accounts in the event of customer default, the guarantee obligation is measured using market data from similar transactions and reported as a current liability in the interim ~~Condensed~~ Consolidated Balance Sheets.

Trade receivables sold under these agreements were ~~$11~~$177 million and ~~$15~~$188 million for the three and six months ended ~~March 31,~~June 30, 2021, respectively, and ~~March 31,~~$161 million and $176 million for the three and six months ended June 30, 2020, respectively. The trade receivables sold that remained outstanding under these agreements which include an element of recourse as of ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020 were ~~$128~~$135 million, $157 million, and ~~$43~~$146 million, respectively. The net proceeds received are included in cash ~~provided by~~used for operating activities in the interim Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

receivables in other income - net in the interim Consolidated Statements of Operations. ~~Loss~~The loss on sale of receivables was $41 million and $43 million for the three and six months ended ~~March 31,~~June 30, 2021, respectively, and $36 million and $38 million for the three and six months ended June 30, 2020, ~~were not material. The guarantee obligations recorded as of March 31, 2021, December 31, 2020, and March 31, 2020 in the interim Condensed Consolidated Balance Sheets were not material.~~respectively. See Note 13 - Commitments and Contingent Liabilities for additional information on the company’s guarantees.

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

NOTE 10 - INVENTORIES

(In millions) March 31, 2021 December 31, 2020 March 31, 2020
Finished products $ 2,508 $ 2,584 $ 2,721
Semi-finished products 1,386 1,813 1,260
Raw materials and supplies 427 485 420
Total inventories $ 4,321 $ 4,882 $ 4,401


(In millions)	June 30, 2021		December 31, 2020		June 30, 2020
Finished products	$	1,680	$	2,584	$	1,831
Semi-finished products	1,406		1,813		1,364
Raw materials and supplies	455		485		394
Total inventories	$	3,541	$	4,882	$	3,589

NOTE 11 - OTHER INTANGIBLE ASSETS

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows:


(In millions)	(In millions)	March 31, 2021						December 31, 2020						March 31, 2020						(In millions)	June 30, 2021						December 31, 2020						June 30, 2020
		Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net			Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net		Gross		Accumulated Amortization		Net
Intangible assets subject to amortization (Definite-lived):	Intangible assets subject to amortization (Definite-lived):																			Intangible assets subject to amortization (Definite-lived):
Germplasm	Germplasm	$	6,265	$	(380)	$	5,885	$	6,265	$	(317)	$	5,948	$	6,265	$	(126)	$	6,139	Germplasm	$	6,265	$	(444)	$	5,821	$	6,265	$	(317)	$	5,948	$	6,265	$	(190)	$	6,075
Customer-related	Customer-related	1,956		(404)		1,552		1,984		(380)		1,604		1,956		(293)		1,663		Customer-related	1,966		(434)		1,532		1,984		(380)		1,604		1,961		(322)		1,639
Developed technology	Developed technology	1,485		(565)		920		1,451		(525)		926		1,463		(409)		1,054		Developed technology	1,485		(603)		882		1,451		(525)		926		1,463		(462)		1,001
Trademarks/trade names1	Trademarks/trade names1	2,013		(112)		1,901		2,019		(99)		1,920		166		(88)		78		Trademarks/trade names1	2,013		(132)		1,881		2,019		(99)		1,920		161		(85)		76
Favorable supply contracts	Favorable supply contracts	475		(326)		149		475		(302)		173		475		(231)		244		Favorable supply contracts	475		(349)		126		475		(302)		173		475		(255)		220
Other2	Other2	405		(238)		167		405		(239)		166		400		(218)		182		Other2	404		(243)		161		405		(239)		166		405		(227)		178
Total other intangible assets with finite lives	Total other intangible assets with finite lives	12,599		(2,025)		10,574		12,599		(1,862)		10,737		10,725		(1,365)		9,360		Total other intangible assets with finite lives	12,608		(2,205)		10,403		12,599		(1,862)		10,737		10,730		(1,541)		9,189

Intangible assets not subject to amortization (Indefinite-lived):	Intangible assets not subject to amortization (Indefinite-lived):																			Intangible assets not subject to amortization (Indefinite-lived):
IPR&D	IPR&D	10		—		10		10		—		10		10		—		10		IPR&D	10		—		10		10		—		10		10		—		10
Trade name1	Trade name1													1,871		—		1,871		Trade name1													1,871		—		1,871

Total other intangible assets	Total other intangible assets	10		—		10		10		—		10		1,881		—		1,881		Total other intangible assets	10		—		10		10		—		10		1,881		—		1,881
Total	Total	$	12,609	$	(2,025)	$	10,584	$	12,609	$	(1,862)	$	10,747	$	12,606	$	(1,365)	$	11,241	Total	$	12,618	$	(2,205)	$	10,413	$	12,609	$	(1,862)	$	10,747	$	12,611	$	(1,541)	$	11,070

1.Beginning on October 1, 2020, the company changed its indefinite life assertion of its trade name asset to definite lived with a useful life of 25 years. This change is the result of the launch of BrevantTM seed in the retail channel in the U.S. Prior to changing the useful life of the trade name asset, the company tested the asset for the impairment under ASC 350- Intangibles, Goodwill and Other, concluding the asset was not impaired.

2.Primarily consists of sales and farmer networks, marketing and manufacturing alliances and noncompetition agreements.

The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was ~~$183~~$180 million and ~~$163~~$363 million for the three and six months ended ~~March 31,~~June 30, 2021, respectively, and $176 million and $339 million for the three and six months ended June 30, 2020, respectively. The current estimated aggregate pre-tax amortization expense from continuing operations for the remainder of 2021 and each of the next five years is approximately ~~$537~~$358 million, ~~$700~~$701 million, ~~$620~~$621 million, ~~$606~~$607 million, ~~$569~~$570 million and ~~$555~~$559 million, respectively.

1921

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 12 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

The following tables summarize Corteva's short-term borrowings and finance lease obligations:


Short-term borrowings and finance lease obligations	Short-term borrowings and finance lease obligations							Short-term borrowings and finance lease obligations
(In millions)	(In millions)	March 31, 2021		December 31, 2020		March 31, 2020		(In millions)	June 30, 2021		December 31, 2020		June 30, 2020
Commercial paper	Commercial paper	$	1,218	$	0	$	1,918	Commercial paper	$	494	$	0	$	671
Repurchase facility	Repurchase facility	30		0		30		Repurchase facility	150		0		800
Other loans - various currencies	Other loans - various currencies	0		1		45		Other loans - various currencies	31		1		55
Long-term debt payable within one year	Long-term debt payable within one year	1		1		1		Long-term debt payable within one year	1		1		1
Finance lease obligations payable within one year	Finance lease obligations payable within one year	1		1		2		Finance lease obligations payable within one year	1		1		2
Total short-term borrowings and finance lease obligations	Total short-term borrowings and finance lease obligations	$	1,250	$	3	$	1,996	Total short-term borrowings and finance lease obligations	$	677	$	3	$	1,529

The estimated fair value of the company's short-term borrowings, including interest rate financial instruments, was determined using Level 2 inputs within the fair value hierarchy. Based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities, the fair value of the company's short-term borrowings and finance lease obligations was approximately carrying value.

The fair value of the company’s long-term borrowings, including debt due within one year, was ~~$1,121~~$1,139 million, $1,168 million, and ~~$612~~$1,141 million as of ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020, respectively, and was determined using quoted market prices for the same or similar issues, or current rates offered to the company for debt of the same remaining maturities (Level 2 inputs).

Debt Offering

In May 2020, EID issued $500 million of 1.70 percent Senior Notes due 2025 and $500 million of 2.30 percent Senior Notes due 2030 (the May 2020 Debt Offering). The proceeds of this offering are intended to be used for general corporate purposes.

Repurchase Facility

In February 2021, the company entered into a new committed receivable repurchase facility of up to $1 billion (the "2021 Repurchase Facility") which expires in December 2021. Under the 2021 Repurchase Facility, Corteva may sell a portfolio of available and eligible outstanding customer notes receivables to participating institutions and simultaneously agree to repurchase at a future date. The 2021 Repurchase Facility is considered a secured borrowing with the customer notes receivables inclusive of those that are sold and repurchased, equal to 105 percent of the outstanding amounts borrowed utilized as collateral. Borrowings under the 2021 Repurchase Facility have an interest rate of LIBOR+0.85 percent.

As of ~~March 31,~~June 30, 2021, ~~$32~~$158 million of notes receivable, recorded in accounts and notes receivable - net, were pledged as collateral against outstanding borrowings under the 2021 Repurchase Facility of ~~$30~~$150 million, recorded in short-term borrowings and finance lease obligations on the interim ~~Condensed~~ Consolidated Balance Sheet.

Revolving Credit Facilities

In November 2018, EID entered into a ~~$3.0~~$3 billion 5-year revolving credit facility and a ~~$3.0~~$3 billion 3-year revolving credit facility (the “Revolving Credit Facilities”). The Revolving Credit Facilities became effective in May 2019. Corteva, Inc. became a party at the time of the Corteva Distribution. In May 2021, the company entered into an amendment that extended the maturity date of the 3-year revolving credit facility from May 2022 to May 2023. Other than the change in maturity date, there were no material modifications to the terms of the credit facility. The Revolving Credit Facilities may serve as a substitute to the company's commercial paper program, and can be used, from time to time, for general corporate purposes including, but not limited to, the funding of seasonal working capital needs. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the Revolving Credit Facilities contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60.

In March 2020, the company drew down $500 million under the ~~$3.0~~$3 billion 3-year revolving credit facility as a result of the volatility and increased borrowing costs of commercial paper resulting from the unstable market conditions caused by the COVID-19 pandemic and repaid that borrowing in full in June 2020. There were no additional borrowings and the unused commitments under the 3-year revolving credit facility were ~~$3.0~~$3 billion as of ~~March 31,~~June 30, 2021.

2022

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 13 - COMMITMENTS AND CONTINGENT LIABILITIES

Guarantees

Indemnifications

In connection with acquisitions and divestitures, ~~as of March 31, 2021,~~ the company has indemnified respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. In addition, the company indemnifies its duly elected or appointed directors and officers to the fullest extent permitted by Delaware law, against liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future payments is generally unlimited. See pages 910 and 2224 for additional information relating to the indemnification obligations under the Chemours Separation Agreement and the Corteva Separation Agreement.

Obligations for Customers and Other Third Parties

The company has directly guaranteed various debt obligations under agreements with third parties related to customers and other third parties. At ~~March 31,~~June 30, 2021, December 31, 2020 and ~~March 31,~~June 30, 2020, the company had directly guaranteed ~~$108~~$115 million, $94 million, and ~~$90~~$112 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the company could be required to make under the guarantees in the event of default by the guaranteed party. All of the maximum future payments at ~~March 31,~~June 30, 2021 had terms less than one year. The maximum future payments include ~~$23~~$22 million, $17 million and $20 million at ~~March 31,~~June 30, 2021, ~~and $17 million at~~ December 31, 2020 and ~~March 31,~~June 30, 2020, respectively, of guarantees related to the various factoring agreements that the company enters into with third-party financial institutions to sell its trade receivables. See Note 9 - Accounts and Notes Receivable - Net, for additional information.

The maximum future payments also include agreements with lenders to establish programs that provide financing for select customers. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. The total amounts owed from customers to the lenders relating to these agreements was ~~$178~~$648 million, $16 million and ~~$125~~$622 million at ~~March 31,~~June 30, 2021, December 31, 2020 and ~~March 31,~~June 30, 2020, respectively.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

Litigation

Indemnifications under Separation Agreements

The company has entered into various agreements where the company is indemnified for certain liabilities. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. See Note 3 - Divestitures and Other Transactions, to the interim Consolidated Financial Statements for additional information related to indemnifications.

Chemours/Performance Chemicals

Refer to Note 3 - Divestitures and Other Transactions, to the interim Consolidated Financial Statements for additional discussion of the Chemours Separation Agreement.

In 2017, EID and Chemours amended the Chemours Separation Agreement to provide for a limited sharing of potential future liabilities related to alleged historical releases of perfluorooctanoic acids and its ammonium salts (“PFOA”) for a five-year period that began on July 6, 2017. In addition, in 2017, Chemours and EID each paid $335 million to settle multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water as a result of the historical manufacture or use of PFOA at

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

the Washington Works plant outside Parkersburg, West Virginia. This plant was previously owned and/or operated by the performance chemicals segment of EID and is now owned and/or operated by Chemours. The 2017 settlement did not resolve

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

claims of certain class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. ~~About~~Since the 2017 settlement, 96 claims alleging personal injury were filed in the Ohio MDL ~~since the 2017 settlement~~ and a number of additional pre-suit claims for personal injury were asserted.

~~For additional information regarding environmental indemnification, see discussion on page 25.~~

On January 22, 2021, Chemours, DuPont, Corteva and EID entered into a binding memorandum of understanding containing a settlement to resolve legal disputes originating from the Delaware Litigation and Pending Arbitration, and to establish a cost sharing arrangement and escrow account to be used to support and manage potential future legacy per- and polyfluoroalkyl substances (“PFAS”) liabilities arising out of pre-July 1, 2015 conduct (the “MOU”). The MOU replaces the 2017 amendment to the Chemours Separation Agreement. According to the terms of the cost sharing arrangement within the MOU, Corteva and DuPont together, on one hand, and Chemours, on the other hand, agreed to a 50-50 split of certain qualified expenses related to PFAS liabilities incurred over a term not to exceed twenty years or $4 billion of qualified spend and escrow account contributions (see below for discussion of escrow account) in the aggregate. DuPont’s and Corteva’s 50% share under the MOU will be limited to $2 billion, including qualified expenses and escrow contributions. These expenses and escrow account contributions will be subject to the existing Letter Agreement, under which DuPont and Corteva will each bear 50% of the first $300 million (up to $150 million each), and thereafter DuPont bears 71% and Corteva bears the remaining 29%.

In order to support and manage any potential future PFAS liabilities, the parties have also agreed to establish an escrow account. The MOU provides that (1) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 million into an escrow account and DuPont and Corteva shall together deposit $100 million in the aggregate into an escrow account and (2) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 million into an escrow account and DuPont and Corteva shall together deposit $50 million in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Over this period, Chemours will deposit a total of $500 million in the account and DuPont and Corteva will deposit an additional $500 million pursuant to the terms of the Letter Agreement. Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700 million, Chemours will make 50% of the deposits and DuPont and Corteva together will make 50% of the deposits necessary to restore the balance of the escrow account to $700 million. Such payments will be made in a series of consecutive annual equal installments commencing on September 30, 2029 pursuant to the escrow account replenishment terms as set forth in the MOU.

After the term of this arrangement, Chemours’ indemnification obligations under the original 2015 Chemours Separation Agreement, would continue unchanged, subject in each case to certain exceptions set out in the MOU. Under the MOU, Chemours waived specified claims regarding the construct of its 2015 spin-off transaction, and the parties will dismiss the pending arbitration regarding those claims (as discussed below). Additionally, the parties have agreed to resolve the Ohio MDL PFOA personal injury litigation (as discussed below). The parties are expected to cooperate in good faith to enter into additional agreements reflecting the terms set forth in the MOU.

Corteva Separation Agreement

On April 1, 2019, in connection with the Dow Distribution, Corteva, DuPont and Dow entered into the Corteva Separation Agreement, the Tax Matters Agreement, the Employee Matters Agreement, and certain other agreements (collectively, the “Corteva Separation Agreements”). The Corteva Separation Agreements allocate among Corteva, DuPont and Dow certain liabilities and obligations among the parties and provides for indemnification obligation among the parties. Under the Corteva Separation Agreements, DuPont will indemnify Corteva against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the Corteva Distribution and (ii) Dow indemnifies Corteva against certain litigation and other liabilities that relate to the Historical Dow business, but were transferred over as part of the common control combination with DAS, and Corteva indemnifies DuPont and Dow for certain liabilities. The term of this indemnification is generally indefinite with exceptions, and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. See Note 3 - Divestitures and Other Transactions, to the interim Consolidated Financial Statements for additional information relating to the Separation.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

DuPont

Under the Corteva Separation Agreement, certain legacy EID liabilities from discontinued and/or divested operations and businesses of EID (including Performance Chemicals) (a “stray liability”) were allocated to Corteva or DuPont. For those stray liabilities allocated to Corteva (which may include a specified amount of liability associated with that liability), Corteva is responsible for liabilities in an amount up to that specified amount plus an additional $200 million and, for those stray liabilities allocated to DuPont (which may include a specified amount of liability associated with that liability), DuPont is responsible for liabilities up to a specified amount plus an additional $200 million. Once each company has met the $200 million threshold, Corteva and DuPont will share future liabilities proportionally on the basis of 29% and 71%, respectively; provided, however, that for PFAS, DuPont will manage such liabilities with Corteva and DuPont sharing the costs on a 50% - 50% basis starting from $1 and up to $300 million (with such amount, up to $150 million, to be credited to each company’s $200 million threshold) and once the $300 million threshold is met, then the companies will share proportionally on the basis of 29% and 71% respectively, subject to a $1 million de minimis requirement. As of June 30, 2021, the aggregate of cash spent and liabilities accrued exceed the stray liability thresholds, including PFAS, noted above. Therefore, any future liabilities will be shared at the reduced rates noted above.

Litigation related to legacy EID businesses unrelated to Corteva’s current businesses

PFAS, PFOA, PFOS and Other Related Liabilities

For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs").

EID is a party to various legal proceedings relating to the use of PFOA by its former Performance Chemicals segment for which potential liabilities would be subject to the cost sharing arrangement under the MOU as long as it remains effective. Management believes that it is reasonably possible that EID could incur liabilities related to PFOA in excess of amounts accrued. However, any such losses are not estimable at this time due to various reasons, including, among others, that the underlying matters are in their early stages and have significant factual issues to be resolved. The company has recorded a liability of ~~$21~~$23 million and an indemnification asset of ~~$16~~$17 million at ~~March 31,~~June 30, 2021, related to testing drinking water in and around certain former EID sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national health advisory level established from time to time by the EPA.

Leach Settlement and Ohio MDL Settlement

EID has residual liabilities under its 2004 settlement of a West Virginia state court class action, Leach v. EID, which alleged that PFOA from EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. The settlement class has about 80,000 members. In addition to relief that was provided to class members years ago, the settlement requires EID to continue providing PFOA water treatment to 6 area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members. As of ~~March 31,~~June 30, 2021, approximately $2 million had been disbursed from the account since its establishment in 2012 and the remaining balance is approximately $1 million.

The Leach settlement permits class members to pursue personal injury claims for 6 health conditions (and no others) that an expert panel appointed under the settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. After the panel reported its findings, approximately 3,550 personal injury lawsuits were filed in federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”). The Ohio MDL was settled in early 2017 for $670.7 million in cash, with Chemours and EID (without indemnification from Chemours) each paying half.

Post-MDL Settlement PFOA Personal Injury Claims

The 2017 Ohio MDL settlement did not resolve claims of plaintiffs who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. The first trial for these claims, a kidney cancer case, resulted in a hung jury, while the second, Travis and Julie Abbot v. E.I du Pont de Nemours and Company (the “Abbot Case”), a testicular cancer case, resulted in a jury verdict of $40 million in compensatory damages and $10 million for loss of consortium. Following entry of the judgment by the court, EID filed post-trial motions to reduce the verdict, and to appeal the verdict on the basis of procedural and substantive legal errors made by the trial court. The trial court recently granted EID’s motion to reduce the loss of consortium award to conform with state tort reform laws limiting these damages to $250,000. The company is continuing its other appeals to reduce the jury verdict or eliminate its liability, in whole or part.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

In January 2021, Chemours, DuPont and Corteva agreed to settle the remaining approximately 95 matters, as well as unfiled matters, remaining in the Ohio MDL, with the exception of the Abbot case, for $83 million, with Chemours contributing $29 million to the settlement, and DuPont and Corteva contributing $27 million each. The company recorded a liability for its share

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

of the settlement, with a charge to (loss) income from discontinued operations after income taxes, during the year ended December 31, 2020, and paid ~~$16~~$11 million and $27 million during the three and six months ended ~~March 31, 2021. Following this~~June 30, 2021, respectively. As agreed to in the settlement, the ~~parties have agreed~~plaintiffs' counsel filed a motion to ~~petition the court for the dissolution of~~dissolve the MDL.

Other PFOA Matters

EID is a party to other PFOA lawsuits that do not involve claims for personal injury. Defense costs and any future liabilities that may arise out of these lawsuits are subject to the MOU and the cost sharing arrangement disclosed above. Under the MOU, fraudulent conveyance claims associated with these matters are not qualified expenses, unless Corteva, Inc. and EID would prevail on the merits of these claims.

New York. EID is a defendant in about 50 lawsuits, including a putative class action, brought by persons who live in and around Hoosick Falls, New York. These lawsuits assert claims for medical monitoring and property damage based on alleged PFOA releases from manufacturing facilities owned and operated by co-defendants in Hoosick Falls and allege that EID and 3M supplied some of the materials used at these facilities. EID is also one of more than ten defendants in a lawsuit brought by the Town of East Hampton, New York alleging PFOA and PFOS contamination of the town’s well water. Additionally, EID, along with 3M, Chemours and Dyneon, have been named defendants in complaints filed by eight water districts in Nassau County, New York alleging that the drinking water they provide to customers is contaminated with PFAS and seeking reimbursement for clean-up costs. The water district complaints also include allegations of fraudulent transfer.

New Jersey. At ~~March 31,~~June 30, 2021, 2 lawsuits were pending, one brought by a local water utility and the second a putative class action, against EID alleging that PFOA from EID’s former Chambers Works facility contaminated drinking water sources. The putative class action was voluntarily dismissed without prejudice by the plaintiff.

In late March of 2019, the New Jersey State Attorney General filed 4 lawsuits against EID, Chemours, 3M and others alleging that operations at and discharges from former EID sites in New Jersey (Chambers Works, Pompton Lakes, Parlin and Repauno) damaged the State’s natural resources. Two of these lawsuits (those involving the Chambers Works and Parlin sites) allege contamination from PFAS. The Ridgewood Water District in New Jersey filed suit in the first quarter 2019 against EID, 3M, Chemours, and Dyneon alleging losses related to the investigation, remediation and monitoring of polyfluorinated surfactants, including PFOA, in water supplies. DuPont and Corteva were subsequently added as defendants to these lawsuits.

Alabama / Others. EID is one of more than thirty defendants in a lawsuit by the Alabama water utility alleging contamination from PFCs, including PFOA, used by co-defendant carpet manufacturers to make their products more stain and grease resistant. In addition, the states of Alaska, Michigan, Mississippi, New Hampshire, South Dakota, and Vermont recently filed lawsuits against EID, Chemours, 3M and others, claiming, among other things, PFC (including PFOA) contamination of groundwater and drinking water. The complaints seek reimbursement for past and future costs to investigate and remediate the alleged contamination and compensation for the loss of value and use of the state’s natural resources. Motions to dismiss the Michigan, Vermont and New Hampshire cases have been denied. ~~Additionally, the State of Delaware has indicated it may file a similar natural resource claim related to alleged PFAS contamination and other contaminants.~~

Ohio. EID is a defendant in 3 lawsuits: an action by the State of Ohio based on alleged damage to natural resources, a putative nationwide class action brought on behalf of anyone who has detectable levels of PFAS in their blood serum, and an action by the City of Dayton claiming losses related to the investigation, remediation and monitoring of PFAS in water supplies.

Netherlands. In April 2021, 4 municipalities in the Netherlands filed complaints alleging contamination of land and groundwater resulting from the emission of PFOA and GenX by Corteva, DuPont and Chemours. The municipalities seek to recover costs incurred due to the alleged emissions, including damages for investigation costs, construction project delays, depreciation of land, soil remediation, liabilities to contractors, and attorneys’ fees.

Delaware. On July 13, 2021, Chemours, DuPont, EID and Corteva entered into a settlement agreement with the State of Delaware reflecting the companies’ and the State’s agreement to settle and fully resolve claims alleged against the companies regarding their historical Delaware operations, manufacturing, use and disposal of all chemical compounds, including PFAS. Under the settlement, the companies will collectively pay $50 million to fund environmental projects, including sampling and community environmental justice and equity grants, which shall be utilized to fund the Natural Resources and Sustainability Trust (the “NRST Trust”). If the companies, individually or jointly, within 8 years of the

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

settlement, enter into a proportionally similar agreement to settle or resolve claims of another state for PFAS-related natural resource damages, for an amount greater than $50 million, the companies shall make a supplemental payment directly to the NRST Trust (“Supplemental Payment”) in an amount equal to such other states’ recovery in excess of $50 million. Supplemental Payment(s), if any, will not exceed $25 million in the aggregate. All amounts paid by the companies under the settlement are subject to the MOU and the Corteva Separation Agreement with Chemours bearing responsibility for 50%, or $25 million, of the $50 million payment due to the NRST and DuPont and Corteva each bearing $12.5 million of the remaining amount. Under the settlement, if the state sues other parties and those parties seek contribution from the companies, the companies will have protection from contribution up to the amounts previously paid under the settlement agreement. The companies will also receive a credit up to the amount of the payment if the state seeks natural resource damage claims against the companies outside the scope of the settlement’s release of claims.

Aqueous Firefighting Foams. Approximately ~~985~~1,280 cases have been filed against 3M and other defendants, including EID and Chemours, and more recently also including Corteva and DuPont, alleging PFOS or PFOA contamination of soil and groundwater from the use of aqueous firefighting foams. Most of those cases claim some form of property damage and seek to recover the costs of responding to this contamination and damages for the loss of use and enjoyment of property and diminution in value. Most of these cases have been transferred to a multidistrict litigation proceeding in federal district court in South Carolina. Approximately ~~910~~1,165 of these cases were filed on behalf of firefighters who allege personal injuries (primarily kidney and testicular cancer) as a result of aqueous firefighting ~~foams.~~foams, while 60 are from municipal water districts. Most of these recent cases assert claims that the EID and Chemours separation constituted a fraudulent conveyance. A schedule of initial trials is expected to be established in the second ~~quarter~~half of 2021.

EID did not make firefighting foams, PFOS, or PFOS products. While EID made surfactants and intermediaries that some manufacturers used in making foams, which may have contained PFOA as an unintended byproduct or an impurity, EID’s

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

products were not formulated with PFOA, nor was PFOA an ingredient of these products. EID has never made or sold PFOA as a commercial product.

Fayetteville Works Facility, North Carolina

Prior to the separation of Chemours, EID introduced GenX as a polymerization processing aid and a replacement for PFOA at the Fayetteville Works facility in Bladen County, North Carolina. The facility is now owned and operated by Chemours, which continues to manufacture and use GenX.

At ~~March 31,~~June 30, 2021, several actions are pending in federal court against Chemours and EID relating to PFC discharges from the Fayetteville Works facility. One of these is a consolidated putative class action that asserts claims for medical monitoring and property damage on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority and Brunswick County, that seek actual and punitive damages as well as injunctive relief. In another action ~~over~~with approximately 100 property owners near the Fayetteville Works facility filed a complaint against Chemours and EID in May 2020. The plaintiffs seek compensatory and punitive damages for their claims of private nuisance, trespass, and negligence allegedly caused by release of PFAS.

In addition to the federal court actions, there is an action on behalf of about 100 plaintiffs who own wells and property near the Fayetteville Works facility. The plaintiffs seek damages for nuisance allegedly caused by releases of certain PFCs from the site. The plaintiffs’ claims for medical monitoring, punitive damages, public nuisance, trespass, unjust enrichment, failure to warn, and negligent manufacture were dismissed.

Generally, site-related expenses related GenX claims are subject to the cost sharing arrangements as defined in the MOU.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Environmental

Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At ~~March 31,~~June 30, 2021, the company had accrued obligations of ~~$333~~$335 million for probable environmental remediation and restoration costs, including ~~$56~~$57 million for the remediation of Superfund sites. These obligations are included in accrued and other current liabilities and other noncurrent obligations in the interim ~~Condensed~~ Consolidated Balance Sheet. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to ~~$577~~$569 million above the amount accrued at ~~March 31,~~June 30, 2021. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration.

For a discussion of the allocation of environmental liabilities under the Chemours Separation Agreement and the Corteva Separation Agreement, see the previous discussion on page ~~22.~~24.

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

The above noted ~~$333~~$335 million accrued obligations includes the following:


		As of March 31, 2021							As of June 30. 2021
(In millions)	(In millions)	Indemnification Asset		Accrual balance3,4		Potential exposure above amount accrued3		(In millions)	Indemnification Asset		Accrual balance3,4		Potential exposure above amount accrued3
Environmental Remediation Stray Liabilities	Environmental Remediation Stray Liabilities							Environmental Remediation Stray Liabilities
Chemours related obligations - subject to indemnity1,2	Chemours related obligations - subject to indemnity1,2	$	152	$	152	$	280	Chemours related obligations - subject to indemnity1,2	$	149	$	149	$	275
Other discontinued or divested businesses obligations1	Other discontinued or divested businesses obligations1	0		78		177		Other discontinued or divested businesses obligations1	0		77		181

Environmental remediation liabilities primarily related to DuPont - subject to indemnity from DuPont2	Environmental remediation liabilities primarily related to DuPont - subject to indemnity from DuPont2	34		34		65		Environmental remediation liabilities primarily related to DuPont - subject to indemnity from DuPont2	37		37		62

Environmental remediation liabilities not subject to indemnity	Environmental remediation liabilities not subject to indemnity	0		69		55		Environmental remediation liabilities not subject to indemnity	0		72		51
Total	Total	$	186	$	333	$	577	Total	$	186	$	335	$	569

1.Represents liabilities that are subject to the $200 million thresholds and sharing arrangements as discussed on page ~~22,~~24, under Corteva Separation Agreement.

2.The company has recorded an indemnification asset related to these accruals, including $30 million related to the Superfund sites.

3.Accrual balance represents management’s best estimate of the costs of remediation and restoration, although it is reasonably possible that the potential exposure, as indicated, could range above the amounts accrued, as there are inherent uncertainties in these ~~estimates~~estimates.

4.Accrual balance excludes indemnification liabilities of ~~$54~~$99 million to Chemours, related to the cost sharing arrangement under the MOU (see page 10).

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 14 - STOCKHOLDERS' EQUITY

Share Buyback Plan

On August 5, 2021, Corteva, Inc. announced that its Board of Directors authorized a $1.5 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

On June 26, 2019, Corteva, Inc. announced that ~~the~~its Board of Directors ~~of Corteva, Inc.~~ authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

During the three and six months ended ~~March 31,~~June 30, 2021, the company purchased and retired ~~7,646,000~~4,324,000 shares and 11,970,000 shares, respectively, in the open market for a total cost of ~~$350 million.~~$200 million and $550 million, respectively. During the ~~three~~six months ended ~~March 31,~~June 30, 2020, the company purchased and retired 1,865,000 shares in the open market for a total cost of $50 million.

Shares repurchased pursuant to Corteva's share buyback plan are immediately retired upon purchase. Repurchased common stock is reflected as a reduction of stockholders' equity. The company's accounting policy related to its share repurchases is to reduce its common stock based on the par value of the shares and to reduce its retained earnings for the excess of the repurchase price over the par value. When Corteva has an accumulated deficit balance, the excess over the par value is applied to ~~additional paid-in capital.~~APIC. When Corteva has retained earnings, the excess is charged entirely to retained earnings.

Noncontrolling Interest

In June 2020, the company completed the acquisition of the remaining 46.5 percent interest in the Phytogen Seed Company, LLC joint venture from J. G. Boswell Company. As the purchase of the remaining interest did not result in a change of control, the difference between the carrying value of the noncontrolling interest and the consideration paid, net of taxes was recorded within equity.

Corteva, Inc. owns ~~100%~~100 percent of the outstanding common shares of EID. However, EID has preferred stock outstanding to third parties which is accounted for as a non-controlling interest in Corteva's interim ~~Condensed~~ Consolidated Balance Sheets. Each share of EID Preferred Stock - $4.50 Series and EID Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EID and was unaffected by the Corteva Distribution.

Below is a summary of the EID Preferred Stock at ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020, which is classified as noncontrolling interests in Corteva's interim ~~Condensed~~ Consolidated Balance Sheets.


Shares in thousands			Number of Shares
Authorized			23,000
$4.50 Series, callable at $120			1,673
$3.50 Series, callable at $102			700

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Other Comprehensive (Loss) Income

The changes and after-tax balances of components comprising accumulated other comprehensive loss are summarized below:


(In millions)	(In millions)	Cumulative Translation Adjustment1		Derivative Instruments		Pension Benefit Plans		Other Benefit Plans		Unrealized Gain (Loss) on Investments		Total		(In millions)	Cumulative Translation Adjustment1		Derivative Instruments		Pension Benefit Plans		Other Benefit Plans		Unrealized Gain (Loss) on Investments		Total

2020	2020													2020
Balance January 1, 2020	Balance January 1, 2020	$	(1,944)	$	2	$	(1,247)	$	(81)	$	0	$	(3,270)	Balance January 1, 2020	$	(1,944)	$	2	$	(1,247)	$	(81)	$	0	$	(3,270)
Other comprehensive (loss) income before reclassifications	Other comprehensive (loss) income before reclassifications	(672)		1		(2)		3		0		(670)		Other comprehensive (loss) income before reclassifications	(575)		(22)		(9)		2		0		(604)
Amounts reclassified from accumulated other comprehensive loss	Amounts reclassified from accumulated other comprehensive loss	0		5		2		0		0		7		Amounts reclassified from accumulated other comprehensive loss	0		26		3		0		0		29
Net other comprehensive (loss) income	Net other comprehensive (loss) income	(672)		6		0		3		0		(663)		Net other comprehensive (loss) income	(575)		4		(6)		2		0		(575)
Balance March 31, 2020		$	(2,616)	$	8	$	(1,247)	$	(78)	$	0	$	(3,933)
Balance June 30, 2020														Balance June 30, 2020	$	(2,519)	$	6	$	(1,253)	$	(79)	$	0	$	(3,845)

2021	2021													2021
Balance January 1, 2021	Balance January 1, 2021	$	(1,970)	$	(67)	$	(1,433)	$	590	$	(10)	$	(2,890)	Balance January 1, 2021	$	(1,970)	$	(67)	$	(1,433)	$	590	$	(10)	$	(2,890)
Other comprehensive (loss) income before reclassifications	Other comprehensive (loss) income before reclassifications	(403)		71		(4)		1		4		(331)		Other comprehensive (loss) income before reclassifications	(160)		109		(5)		1		3		(52)
Amounts reclassified from accumulated other comprehensive loss	Amounts reclassified from accumulated other comprehensive loss	0		(6)		12		(158)		6		(146)		Amounts reclassified from accumulated other comprehensive loss	0		(13)		21		(318)		7		(303)
Net other comprehensive (loss) income	Net other comprehensive (loss) income	(403)		65		8		(157)		10		(477)		Net other comprehensive (loss) income	(160)		96		16		(317)		10		(355)

Balance March 31, 2021		$	(2,373)	$	(2)	$	(1,425)	$	433	$	0	$	(3,367)
Balance June 30, 2021														Balance June 30, 2021	$	(2,130)	$	29	$	(1,417)	$	273	$	0	$	(3,245)

1.The cumulative translation adjustment loss for the ~~three~~six months ended ~~March 31,~~June 30, 2020 was primarily driven by the ~~strengthening~~weakening of ~~the USD against~~ the Brazilian Real ~~(“BRL”~~("BRL") and the South African Rand ("ZAR"). against the USD. The cumulative translation adjustment loss for the ~~three~~six months ended ~~March 31,~~June 30, 2021 was primarily driven by ~~strengthening~~the weakening of ~~the USD against~~ the Swiss Franc ("CHF")~~, Brazilian Real~~ and the European Euro ("~~BRL"~~EUR") ~~and European Euro.~~against the USD.

The tax benefit (expense) on the net activity related to each component of other comprehensive ~~(loss)~~ income was as follows:


(In millions)	(In millions)	Three Months Ended March 31,				(In millions)	Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020					2021		2020		2021		2020
Derivative instruments	Derivative instruments	$	(18)	$	5			Derivative instruments	$	(7)	$	(3)	$	(25)	$	2
Pension benefit plans - net	Pension benefit plans - net	(2)		(4)				Pension benefit plans - net	(3)		1		(5)		(3)
Other benefit plans - net	Other benefit plans - net	49		0				Other benefit plans - net	48		0		97		0

Benefit from income taxes related to other comprehensive (loss) income items		$	29	$	1
Benefit from (provision for) income taxes related to other comprehensive income items								Benefit from (provision for) income taxes related to other comprehensive income items	$	38	$	(2)	$	67	$	(1)

2730

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

A summary of the reclassifications out of accumulated other comprehensive loss is provided as follows:


(In millions)	(In millions)	Three Months Ended March 31,				(In millions)	Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020					2021		2020		2021		2020
Derivative Instruments1:	Derivative Instruments1:	$	(5)	$	7			Derivative Instruments1:	$	(10)	$	28	$	(15)	$	35
Tax benefit2	Tax benefit2	(1)		(2)				Tax benefit2	3		(7)		2		(9)
After-tax	After-tax	$	(6)	$	5			After-tax	$	(7)	$	21	$	(13)	$	26
Amortization of pension benefit plans:	Amortization of pension benefit plans:							Amortization of pension benefit plans:

Prior service benefit3,4								Prior service benefit3,4	$	(1)	$	(1)	$	(1)	$	(1)
Actuarial losses3,4	Actuarial losses3,4	$	14	$	1			Actuarial losses3,4	13		1		27		2

Settlement loss3,4	Settlement loss3,4	1		2				Settlement loss3,4	0		1		1		3
Total before tax	Total before tax	$	15	$	3			Total before tax	$	12	$	1	$	27	$	4
Tax benefit2	Tax benefit2	(3)		(1)				Tax benefit2	(3)		0		(6)		(1)
After-tax	After-tax	$	12	$	2			After-tax	$	9	$	1	$	21	$	3
Amortization of other benefit plans:	Amortization of other benefit plans:							Amortization of other benefit plans:
Prior service benefit3,4	Prior service benefit3,4	$	(230)	$	0			Prior service benefit3,4	$	(231)	$	0	$	(461)	$	0
Actuarial gains3,4	Actuarial gains3,4	23		0				Actuarial gains3,4	24		0		47		0

Curtailment gain								Curtailment gain	(1)		0		(1)		0
Total before tax	Total before tax	$	(207)	$	0			Total before tax	$	(208)	$	0	$	(415)	$	0
Tax benefit2	Tax benefit2	49		0				Tax benefit2	48		0		97		0
After-tax	After-tax	$	(158)	$	0			After-tax	$	(160)	$	0	$	(318)	$	0

Unrealized Loss on Investments4	Unrealized Loss on Investments4	$	6	$	0			Unrealized Loss on Investments4	$	1	$	0	$	7	$	0
Tax benefit2	Tax benefit2	0		0				Tax benefit2	0		0		0		0
After-tax	After-tax	$	6	$	0			After-tax	$	1	$	0	$	7	$	0
Total reclassifications for the period, after-tax	Total reclassifications for the period, after-tax	$	(146)	$	7			Total reclassifications for the period, after-tax	$	(157)	$	22	$	(303)	$	29

1.Reflected in cost of goods sold.

2.Reflected in provision for ~~(benefit from)~~ income taxes from continuing operations.

3.These accumulated other comprehensive (loss) income components are included in the computation of net periodic benefit credit of the company's pension and other benefit plans. See Note 15 - Pension Plans and Other Post Employment Benefits, for additional information.

4.Reflected in other income - net.

2831

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 15 - PENSION PLANS AND OTHER POST EMPLOYMENT BENEFITS

The following sets forth the components of the company's net periodic (credit) benefit ~~(credit)~~ cost for defined benefit pension plans and other post employment benefits:


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020
Defined Benefit Pension Plans:	Defined Benefit Pension Plans:						Defined Benefit Pension Plans:
Service cost	Service cost	$	7	$	5		Service cost	$	5	$	8	$	12	$	13
Interest cost	Interest cost	91		141			Interest cost	91		140		182		281
Expected return on plan assets	Expected return on plan assets	(230)		(251)			Expected return on plan assets	(228)		(249)		(458)		(500)
Amortization of unrecognized loss	Amortization of unrecognized loss	14		1			Amortization of unrecognized loss	13		1		27		2

Amortization of prior service benefit							Amortization of prior service benefit	(1)		(1)		(1)		(1)
Settlement loss	Settlement loss	1		2			Settlement loss	0		1		1		3
Net periodic benefit credit		$	(117)	$	(102)
Net periodic (credit) benefit cost							Net periodic (credit) benefit cost	$	(120)	$	(100)	$	(237)	$	(202)
Other Post Employment Benefits:	Other Post Employment Benefits:						Other Post Employment Benefits:
Service cost	Service cost	$	0	$	1		Service cost	$	0	$	0	$	0	$	1
Interest cost	Interest cost	6		16			Interest cost	5		17		11		33
Amortization of unrecognized loss	Amortization of unrecognized loss	23		0			Amortization of unrecognized loss	24		0		47		0
Amortization of prior service benefit	Amortization of prior service benefit	(230)		0			Amortization of prior service benefit	(231)		0		(461)		0
Net periodic benefit (credit) cost		$	(201)	$	17

Curtailment gain							Curtailment gain	(1)		0		(1)		0
Net periodic (credit) benefit cost							Net periodic (credit) benefit cost	$	(203)	$	17	$	(404)	$	34

NOTE 16 - FINANCIAL INSTRUMENTS

At ~~March 31,~~June 30, 2021, ~~the company had $1,602 million ($2,511 million and $1,536 million at~~ December 31, 2020 and ~~March 31,~~June 30, 2020, ~~respectively)~~the company had $1,923 million, $2,511 million and $2,073 million, respectively, of held-to-maturity securities (primarily time deposits and money market funds) classified as cash equivalents in the interim Consolidated Balance Sheets, as these securities had maturities of three months or less at the time of purchase; and ~~$49~~$39 million, ~~($43~~$43 million and ~~$10~~$60 million at June 30, 2021, December 31, 2020 and ~~March 31,~~June 30, 2020, ~~respectively)~~respectively, of held-to-maturity securities (primarily time deposits) classified as marketable securities in the interim Consolidated Balance Sheets as these securities had maturities of more than three months to less than one year at the time of purchase. The company’s investments in held-to-maturity securities are held at amortized cost, which approximates fair value. ~~Additionally, at March~~At December 31, ~~2021,~~2020, the company had ~~$65~~$226 million ~~($226 million at December 31, 2020)~~ of available-for-sale ~~securities. The above noted~~debt securities ~~are included in cash and cash equivalents,~~classified as marketable securities ~~and other current assets~~ in the interim ~~Condensed~~ Consolidated Balance ~~Sheets.~~Sheet.

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, the company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency and commodity price risks. The company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. The company has not designated any non-derivatives as hedging instruments.

The company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges, and multinational grain exporters. The company is exposed to credit loss in the event of nonperformance by these counterparties. The company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.

2932

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The notional amounts of the company's derivative instruments were as follows:


Notional Amounts (In millions)	Notional Amounts (In millions)	March 31, 2021		December 31, 2020		March 31, 2020		Notional Amounts (In millions)	June 30, 2021		December 31, 2020		June 30, 2020
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:							Derivatives designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	$	1,030	$	1,164	$	751	Foreign currency contracts	$	767	$	1,164	$	721
Commodity contracts	Commodity contracts	$	239	$	383	$	418	Commodity contracts	$	143	$	383	$	165
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:							Derivatives not designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	$	715	$	647	$	644	Foreign currency contracts	$	878	$	647	$	770
Commodity contracts	Commodity contracts	$	154	$	0	$	59	Commodity contracts	$	5	$	0	$	19

Foreign Currency Risk

The company's objective in managing exposure to foreign currency fluctuations is to reduce earnings and cash flow volatility associated with foreign currency rate changes and to mitigate the exposure of certain investments in foreign subsidiaries against changes in the Euro/USD exchange rate. Accordingly, the company enters into various contracts that change in value as foreign exchange rates change to protect the value of its existing foreign currency-denominated assets, liabilities, commitments, investments and cash flows.

The company uses foreign exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The primary business objective of this hedging program is to maintain an approximately balanced position in foreign currencies so that exchange gains and losses resulting from exchange rate changes, after related tax effects, are minimized. The company also uses foreign currency exchange contracts to offset a portion of the company’s exposure to certain forecasted transactions as well as the translation of foreign currency-denominated earnings. The company also uses commodity contracts to offset risks associated with foreign currency devaluation in certain countries.

Commodity Price Risk

Commodity price risk management programs serve to reduce exposure to price fluctuations on purchases of inventory such as corn and soybeans. The company enters into over-the-counter and exchange-traded derivative commodity instruments to hedge the commodity price risk associated with agricultural commodity exposures.

Derivatives Designated as Cash Flow Hedges

Commodity Contracts

The company enters into over-the-counter and exchange-traded derivative commodity instruments, including options, futures and swaps, to hedge the commodity price risk associated with agriculture commodity exposures.

While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two years. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is ~~not~~ probable of not occurring.

The following table summarizes the after-tax effect of commodity contract cash flow hedges on accumulated other comprehensive loss:


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020
Beginning balance	Beginning balance	$	(16)	$	2		Beginning balance	$	10	$	(15)	$	(16)	$	2
Additions and revaluations of derivatives designated as cash flow hedges	Additions and revaluations of derivatives designated as cash flow hedges	30		(22)			Additions and revaluations of derivatives designated as cash flow hedges	73		(22)		103		(44)
Clearance of hedge results to earnings	Clearance of hedge results to earnings	(4)		5			Clearance of hedge results to earnings	(10)		21		(14)		26
Ending balance	Ending balance	$	10	$	(15)		Ending balance	$	73	$	(16)	$	73	$	(16)

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

At ~~March 31,~~June 30, 2021, an after-tax net ~~loss~~gain of $8$63 million is expected to be reclassified from accumulated other comprehensive loss into earnings over the next twelve months.

Foreign Currency Contracts

The company enters into forward contracts to hedge the foreign currency risk associated with forecasted transactions within certain foreign subsidiaries.

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

The following table summarizes the after-tax effect of foreign currency cash flow hedges on accumulated other comprehensive loss:


		Three Months Ended March 31,					Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020		(In millions)	2021		2020		2021		2020
Beginning balance	Beginning balance	$	(17)	$	0	Beginning balance	$	6	$	16	$	(17)	$	0
Additions and revaluations of derivatives designated as cash flow hedges	Additions and revaluations of derivatives designated as cash flow hedges	25		16		Additions and revaluations of derivatives designated as cash flow hedges	(30)		3		(5)		19
Clearance of hedge results to earnings	Clearance of hedge results to earnings	(2)		0		Clearance of hedge results to earnings	3		0		1		0
Ending balance	Ending balance	$	6	$	16	Ending balance	$	(21)	$	19	$	(21)	$	19

At ~~March 31,~~June 30, 2021, an after-tax net ~~gain~~loss of $6$21 million is expected to be reclassified from accumulated other comprehensive loss into earnings over the next twelve months.

Derivatives Designated as Net Investment Hedges

Foreign Currency Contracts

The company has designated €450 million of forward contracts to exchange EUR as net investment hedges. The purpose of these forward contracts is to mitigate FX exposure related to a portion of the company’s Euro net investments in certain foreign subsidiaries against changes in Euro/USD exchange rates. These hedges will expire and be settled in 2023, unless terminated early at the discretion of the company.

The company elected to apply the spot method in testing for effectiveness of the hedging relationship.

Derivatives not Designated in Hedging Relationships

Foreign Currency Contracts

The company uses foreign exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The company also uses foreign currency exchange contracts to offset a portion of the company’s exposure to the translation of certain foreign currency-denominated earnings so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated earnings over the relevant aggregate period.

Commodity Contracts

The company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as corn and soybeans. The company uses forward agreements, with durations less than one year, to buy and sell USD priced commodities in order to reduce its exposure to currency devaluation for a portion of its local currency cash balances. Counterparties to the forward sales agreements are multinational grain exporters and subject to the company’s financial risk management procedures.

3134

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Fair Value of Derivative Instruments

Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim ~~Condensed~~ Consolidated Balance Sheets. The presentation of the company's derivative assets and liabilities is as follows:


			March 31, 2021								June 30, 2021
(In millions)	(In millions)	Balance Sheet Location	Gross		Counterparty and Cash Collateral Netting1		Net Amounts Included in the interim Condensed Consolidated Balance Sheet		(In millions)	Balance Sheet Location	Gross		Counterparty and Cash Collateral Netting1		Net Amounts Included in the interim Consolidated Balance Sheet
Asset derivatives:	Asset derivatives:								Asset derivatives:
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:								Derivatives designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Other current assets	$	38	$	0	$	38	Foreign currency contracts	Other current assets	$	1	$	0	$	1
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:								Derivatives not designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Other current assets	52		(32)		20		Foreign currency contracts	Other current assets	36		(20)		16

Total asset derivatives	Total asset derivatives		$	90	$	(32)	$	58	Total asset derivatives		$	37	$	(20)	$	17

Liability derivatives:	Liability derivatives:								Liability derivatives:
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:								Derivatives designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Accrued and other current liabilities	$	16	$	0	$	16	Foreign currency contracts	Accrued and other current liabilities	$	21	$	0	$	21
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:								Derivatives not designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Accrued and other current liabilities	46		(30)		16		Foreign currency contracts	Accrued and other current liabilities	72		(20)		52

Total liability derivatives	Total liability derivatives		$	62	$	(30)	$	32	Total liability derivatives		$	93	$	(20)	$	73

3235

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


			December 31, 2020								December 31, 2020
(In millions)	(In millions)	Balance Sheet Location	Gross		Counterparty and Cash Collateral Netting1		Net Amounts Included in the Condensed Consolidated Balance Sheet		(In millions)	Balance Sheet Location	Gross		Counterparty and Cash Collateral Netting1		Net Amounts Included in the Consolidated Balance Sheet
Asset derivatives:	Asset derivatives:								Asset derivatives:
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:								Derivatives designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Other current assets	$	15	$	0	$	15	Foreign currency contracts	Other current assets	$	15	$	0	$	15
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:								Derivatives not designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Other current assets	40		(40)		0		Foreign currency contracts	Other current assets	40		(40)		0
Total asset derivatives	Total asset derivatives		$	55	$	(40)	$	15	Total asset derivatives		$	55	$	(40)	$	15

Liability derivatives:	Liability derivatives:								Liability derivatives:
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:								Derivatives designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Accrued and other current liabilities	$	38	$	0	$	38	Foreign currency contracts	Accrued and other current liabilities	$	38	$	0	$	38
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:								Derivatives not designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Accrued and other current liabilities	97		(40)		57		Foreign currency contracts	Accrued and other current liabilities	97		(40)		57
Total liability derivatives	Total liability derivatives		$	135	$	(40)	$	95	Total liability derivatives		$	135	$	(40)	$	95


			March 31, 2020								June 30, 2020
(In millions)	(In millions)	Balance Sheet Location	Gross		Counterparty and Cash Collateral Netting1		Net Amounts Included in the interim Condensed Consolidated Balance Sheet		(In millions)	Balance Sheet Location	Gross		Counterparty and Cash Collateral Netting1		Net Amounts Included in the interim Consolidated Balance Sheet
Asset derivatives:	Asset derivatives:								Asset derivatives:
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:								Derivatives designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Other current assets	$	36	$	0	$	36	Foreign currency contracts	Other current assets	$	19	$	0	$	19
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:								Derivatives not designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Other current assets	230		(110)		120		Foreign currency contracts	Other current assets	101		(57)		44
Total asset derivatives	Total asset derivatives		$	266	$	(110)	$	156	Total asset derivatives		$	120	$	(57)	$	63

Liability derivatives:	Liability derivatives:								Liability derivatives:
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:								Derivatives not designated as hedging instruments:
Foreign currency contracts	Foreign currency contracts	Accrued and other current liabilities	$	108	$	(103)	$	5	Foreign currency contracts	Accrued and other current liabilities	$	65	$	(56)	$	9
Total liability derivatives	Total liability derivatives		$	108	$	(103)	$	5	Total liability derivatives		$	65	$	(56)	$	9

1. Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.

3336

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Effect of Derivative Instruments


		Amount of (Loss) Gain Recognized in OCI1 - Pre-Tax						Amount of Gain (Loss) Recognized in OCI - Pre-Tax1
		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:						Derivatives designated as hedging instruments:
Net investment hedges:	Net investment hedges:						Net investment hedges:
Foreign currency contracts	Foreign currency contracts	$	21	$	9		Foreign currency contracts	$	(7)	$	(5)	$	14	$	4
Cash flow hedges:	Cash flow hedges:						Cash flow hedges:
Foreign currency contracts	Foreign currency contracts	31		19			Foreign currency contracts	(37)		4		(6)		23
Commodity contracts	Commodity contracts	36		(34)			Commodity contracts	92		(26)		128		(60)
Total derivatives designated as hedging instruments	Total derivatives designated as hedging instruments	$	88	$	(6)		Total derivatives designated as hedging instruments	$	48	$	(27)	$	136	$	(33)

1.OCI is defined as other comprehensive income (loss).


		Amount of Gain (Loss) Recognized in Income - Pre-Tax1						Amount of (Loss) Gain Recognized in Income - Pre-Tax1
		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020
Derivatives designated as hedging instruments:	Derivatives designated as hedging instruments:						Derivatives designated as hedging instruments:
Cash flow hedges:	Cash flow hedges:						Cash flow hedges:
Foreign currency contracts2	Foreign currency contracts2	$	1	$	0		Foreign currency contracts2	$	(2)	$	0	$	(1)	$	0
Commodity contracts2	Commodity contracts2	4		(7)			Commodity contracts2	12		(28)		16		(35)
Total derivatives designated as hedging instruments	Total derivatives designated as hedging instruments	$	5	$	(7)		Total derivatives designated as hedging instruments	$	10	$	(28)	$	15	$	(35)
Derivatives not designated as hedging instruments:	Derivatives not designated as hedging instruments:						Derivatives not designated as hedging instruments:
Foreign currency contracts3	Foreign currency contracts3	$	16	$	165		Foreign currency contracts3	$	(50)	$	14	$	(34)	$	179
Foreign currency contracts2	Foreign currency contracts2	2		0			Foreign currency contracts2	(30)		17		(28)		17
Commodity contracts2	Commodity contracts2	(12)		9			Commodity contracts2	(5)		1		(17)		10
Total derivatives not designated as hedging instruments	Total derivatives not designated as hedging instruments	6		174			Total derivatives not designated as hedging instruments	(85)		32		(79)		206
Total derivatives	Total derivatives	$	11	$	167		Total derivatives	$	(75)	$	4	$	(64)	$	171

1.For cash flow hedges, this represents the portion of the gain (loss) reclassified from accumulated OCI into income during the period.

2.Recorded in cost of goods sold.

3.Gain recognized in other income (expense) - net was partially offset by the related gain on the foreign currency-denominated monetary assets and liabilities of the company's operations. See Note 6 - Supplementary Information, for additional information.

Debt Securities

The company's investment in debt securities are classified as available-for-sale. At March 31, 2021, the fair value and amortized cost of the company's investments in debt securities with contractual maturities within one to five years was $65 million.

The estimated fair value of the available-for-sale securities ~~as of March 31, 2021 and~~at December 31, 2020 was determined using Level 1 inputs within the fair value hierarchy. Level 1 measurements were based on quoted market prices in active markets for identical assets and liabilities. The available-for-sale securities ~~as of March 31, 2021 and~~at December 31, 2020 are held by certain foreign subsidiaries in which the USD is not the functional currency. The fluctuations in foreign exchange are recorded in accumulated other comprehensive loss within the interim Consolidated Statements of Equity. These fluctuations are subsequently reclassified from accumulated other comprehensive loss to earnings in the period in which the marketable securities are sold and the gains and losses on these securities offset a portion of the foreign exchange fluctuations in earnings for the company.

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

The following table provides the investing results from available-for-sale securities for the three and six months ended ~~March 31,~~June 30, 2021:

~~Investing Results~~

Three Months Ended
March 31,

~~(In millions)~~

~~2021~~

~~Proceeds from sales of available-for-sale securities~~

~~161~~

~~Gross realized losses~~

~~(6)~~

~~Total~~

~~155~~

~~The following table provides the fair value and gross unrealized losses~~


Investing Results	Three Months Ended June 30,		Six Months Ended June 30,
(In millions)	2021		2021
Proceeds from sales of available-for-sale securities	$	65	$	226

Gross realized losses	(1)		(7)
Total	$	64	$	219

Table of ~~the company's investments in debt securities at March 31, 2021, aggregated by investment category:~~Contents

March 31, 2021 12 months or more
(In millions) Fair value Gross unrealized losses
U.S. Treasuries $ 65 $ 0
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 17 - FAIR VALUE MEASUREMENTS

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:

March 31, 2021 Significant Other Observable Inputs
(In millions) Level 1 Level 2
Assets at fair value:
Marketable securities $ — $ 49
Debt securities:
U.S. treasuries1
65 —
Derivatives relating to:2
Foreign currency — 90
Total assets at fair value $ 65 $ 139
Liabilities at fair value:
Derivatives relating to:2
Foreign currency — 62
Total liabilities at fair value $ — $ 62


June 30, 2021	Significant Other Observable Inputs (Level 2)
(In millions)
Assets at fair value:

Marketable securities	$	39
Derivatives relating to:2
Foreign currency	37

Total assets at fair value	$	76
Liabilities at fair value:
Derivatives relating to:2
Foreign currency	93

Total liabilities at fair value	$	93


December 31, 2020		Significant Other Observable Inputs

(In millions)	Level 1	Level 2
Assets at fair value:

Marketable securities		$	—	$	43
Debt securities:
U.S. treasuries1		226		—
Derivatives relating to:2
Foreign currency		—		55
Total assets at fair value		$	226	$	98
Liabilities at fair value:
Derivatives relating to:2
Foreign currency		—		135
Total liabilities at fair value		$	—	$	135

~~Table of Contents~~

~~NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~


~~March 31,~~June 30, 2020	Significant Other Observable Inputs (Level 2)
(In millions)
Assets at fair value:

Marketable securities	$	1060
Derivatives relating to:2

Foreign currency	~~266~~120
Total assets at fair value	$	~~276~~180
Liabilities at fair value:
Derivatives relating to:2
Foreign currency	~~108~~65
Total liabilities at fair value	$	~~108~~65

1. The company's investments in debt securities, which are available-for-sale, are included in "marketable securities" in the interim ~~Condensed~~ Consolidated Balance Sheets.

2. See Note 16 - Financial Instruments for the classification of derivatives in the interim ~~Condensed~~ Consolidated Balance Sheets.

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 18 - SEGMENT INFORMATION

Corteva’s reportable segments reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance, which is at the operating segment level (seed and crop protection). For purposes of allocating resources to the segments and assessing segment performance, segment operating EBITDA is the primary measure used by Corteva’s CODM. The company defines segment operating EBITDA as earnings (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating (benefits) costs - net, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Effective January 1, 2021, on a prospective basis, the company excludes from segment operating EBITDA net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Non-operating (benefits) costs - net consists of non-operating pension and other post-employment benefit (OPEB) costs, tax indemnification adjustments and environmental remediation and legal costs associated with legacy EID businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.


As of and for the Three Months Ended March 31, (In millions)		Seed		Crop Protection		Total
As of and for the Three Months Ended June 30, (In millions)								As of and for the Three Months Ended June 30, (In millions)	Seed		Crop Protection		Total
2021	2021							2021
Net sales	Net sales	$	2,492	$	1,686	$	4,178	Net sales	$	3,780	$	1,847	$	5,627
Segment operating EBITDA	Segment operating EBITDA	$	617	$	321	$	938	Segment operating EBITDA	$	1,123	$	370	$	1,493
Segment assets1	Segment assets1	$	24,799	$	13,349	$	38,148	Segment assets1	$	23,804	$	12,996	$	36,800

2020	2020							2020
Net sales	Net sales	$	2,455	$	1,501	$	3,956	Net sales	$	3,538	$	1,653	$	5,191
Segment operating EBITDA	Segment operating EBITDA	$	581	$	238	$	819	Segment operating EBITDA	$	956	$	309	$	1,265
Segment assets1	Segment assets1	$	25,857	$	13,251	$	39,108	Segment assets1	$	24,356	$	13,034	$	37,390

1. Segment assets at December 31, 2020 were $23,751 million and $13,099 million for Seed and Crop Protection, respectively.


For the Six Months Ended June 30, (In millions)	Seed		Crop Protection		Total
2021
Net sales	$	6,272	$	3,533	$	9,805
Segment operating EBITDA	$	1,740	$	691	$	2,431

2020
Net sales	$	5,993	$	3,154	$	9,147
Segment operating EBITDA	$	1,537	$	547	$	2,084

3639

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Reconciliation to interim Consolidated Financial Statements


Income from continuing operations after income taxes to segment operating EBITDA (In millions)	Income from continuing operations after income taxes to segment operating EBITDA (In millions)	Three Months Ended March 31,				Income from continuing operations after income taxes to segment operating EBITDA (In millions)	Three Months Ended June 30,						Six Months Ended June 30,
		2021		2020			Income from continuing operations after income taxes to segment operating EBITDA (In millions)		2021			2020			2021			2020
Income from continuing operations after income taxes	Income from continuing operations after income taxes	$	613	$	281				$	1,018		$	766		$	1,631		$	1,047
Provision for income taxes on continuing operations	Provision for income taxes on continuing operations	178		127				Provision for income taxes on continuing operations		284			78			462			205
Income from continuing operations before income taxes	Income from continuing operations before income taxes	791		408				Income from continuing operations before income taxes		1,302			844			2,093			1,252
Depreciation and amortization	Depreciation and amortization	304		283				Depreciation and amortization		313			300			617			583
Interest income	Interest income	(21)		(18)				Interest income		(18)			(9)			(39)			(27)
Interest expense	Interest expense	7		10				Interest expense		7			14			14			24
Exchange losses - net		35		61
Exchange losses (gains) - net								Exchange losses (gains) - net		14			(1)			49			60
Non-operating benefits - net	Non-operating benefits - net	(311)		(73)				Non-operating benefits - net		(315)			(91)			(626)			(164)

Mark-to-market gains on certain foreign currency contracts not designated as hedges1		(1)
Mark-to-market losses on certain foreign currency contracts not designated as hedges1								Mark-to-market losses on certain foreign currency contracts not designated as hedges1		23						22
Significant items	Significant items	100		123				Significant items		135			179			235			302

Corporate expenses	Corporate expenses	34		25				Corporate expenses		32			29			66			54
Segment operating EBITDA	Segment operating EBITDA	$	938	$	819			Segment operating EBITDA		$	1,493		$	1,265		$	2,431		$	2,084

1.Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. ~~There was no activity in~~For the three and six months ended ~~March 31, 2020.~~June 30, 2020, the unrealized mark-to-market gain was $27 million. Refer to page 4856 for further discussion of the company’s Non-GAAP financial measures.


Segment assets to total assets (in millions)	Segment assets to total assets (in millions)	March 31, 2021		December 31, 2020		March 31, 2020		Segment assets to total assets (in millions)	June 30, 2021		December 31, 2020		June 30, 2020
Total segment assets	Total segment assets	$	38,148	$	36,850	$	39,108	Total segment assets	$	36,800	$	36,850	$	37,390
Corporate assets	Corporate assets	4,401		5,799		3,870		Corporate assets	4,696		5,799		4,790
Total assets	Total assets	$	42,549	$	42,649	$	42,978	Total assets	$	41,496	$	42,649	$	42,180

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Significant Pre-tax (Charges) Benefits Not Included in Segment Operating EBITDA

The three and six months ended ~~March 31,~~June 30, 2021 and 2020, respectively, included the following significant pre-tax (charges) benefits which are excluded from segment operating EBITDA:


(In millions)	(In millions)	Seed		Crop Protection		Corporate		Total		(In millions)	Seed		Crop Protection		Corporate		Total
For the Three Months Ended March 31, 2021
For the Three Months Ended June 30, 2021										For the Three Months Ended June 30, 2021
Restructuring and Asset Related Charges - Net 1	Restructuring and Asset Related Charges - Net 1	$	(21)	$	(32)	$	(47)	$	(100)	Restructuring and Asset Related Charges - Net 1	$	(115)	$	(11)	$	(9)	$	(135)

Total	Total	$	(21)	$	(32)	$	(47)	$	(100)	Total	$	(115)	$	(11)	$	(9)	$	(135)


(In millions)	(In millions)	Seed		Crop Protection		Corporate		Total		(In millions)	Seed		Crop Protection		Corporate		Total
For the Three Months Ended March 31, 2020
For the Three Months Ended June 30, 2020										For the Three Months Ended June 30, 2020
Restructuring and Asset Related Charges - Net 1	Restructuring and Asset Related Charges - Net 1	$	(10)	$	(18)	$	(42)	$	(70)	Restructuring and Asset Related Charges - Net 1	$	(135)	$	(40)	$	(4)	$	(179)
Loss on Divestiture2		—		(53)		—		(53)

Total	Total	$	(10)	$	(71)	$	(42)	$	(123)	Total	$	(135)	$	(40)	$	(4)	$	(179)


(In millions)	Seed		Crop Protection		Corporate		Total
For the Six Months Ended June 30, 2021
Restructuring and Asset Related Charges - Net 1	$	(136)	$	(43)	$	(56)	$	(235)

Total	$	(136)	$	(43)	$	(56)	$	(235)


(In millions)	Seed		Crop Protection		Corporate		Total
For the Six Months Ended June 30, 2020
Restructuring and Asset Related Charges - Net 1	$	(145)	$	(58)	$	(46)	$	(249)
Loss on Divestiture2	—		(53)		—		(53)
Total	$	(145)	$	(111)	$	(46)	$	(302)

1.Includes Board approved restructuring plans and asset related charges as well as accelerated prepaid amortization expense. See Note 5 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements for additional information.

2.Includes a loss recorded in other income - net related to the sale of the La Porte site.

3741

Table of Contents

Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statements About Forward-Looking Statements

This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates,” ~~"outlook,"~~“outlook,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s strategy for growth, product development, regulatory approval, market position, liquidity, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results, as well as its expectations related to its separation of Corteva from DowDuPont and the agreements related thereto, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva’s industry; (vi) effect of competition from manufacturers of generic products; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) risks related to oil and commodity markets; (x) competitor’s establishment of an intermediary platform for distribution of Corteva's products; (xi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xii) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xiii) effect of volatility in Corteva’s input costs; (xiv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva and other cost savings initiatives; (xv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xvi) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) risks related to the indemnification obligations of legacy EID liabilities in connection with the separation of Corteva; (xix) effect of compliance with laws and requirements and adverse judgments on litigation; (xx) risks related to Corteva’s global operations; (xxi) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; (xxii) risks related to COVID-19; (xxiii) risks related to activist stockholders; (xxiv) Corteva’s intellectual property rights or defend against intellectual property claims asserted by others; (xxv) effect of counterfeit products; (xxvi) Corteva’s dependence on intellectual property cross-license agreements; ~~and~~ (xxvii) other risks related to the separation from ~~DowDuPont.~~DowDuPont; (xxviii) risks related to the Biden executive order Promoting Competition in the American Economy; and (xxix) risks associated with our CEO transition, including failure to timely identify a successor CEO.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s 2020 Annual Report, ~~on Form 10-K,~~ as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.

3842

Table of Contents

Recent Developments

COVID-19 Pandemic

On March 11, 2020, the World Health Organization (“WHO”) declared the novel coronavirus disease (“COVID-19”) a pandemic. The global health crisis caused by COVID-19 and the related government actions and stay at home orders have negatively impacted economic activity and increased political instability across the globe. Since the crisis began Corteva has engaged its global Integrated Health Services Pandemic & Infectious Disease Team to take actions and implement guidelines and protocols in response to the COVID-19 pandemic described in its 2020 Annual Report, Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, COVID-19 Pandemic.

When COVID-19 is demonstrably contained, the company anticipates a rebound in economic activity, depending on the rate, pace, and effectiveness of the containment efforts deployed by various national, state, and local governments, vaccination rates, and the ability of COVD-19 variants to overcome containment efforts, available vaccines, and medical treatments. Corteva will continue to actively monitor the situation and may take further actions altering its business operations that it determines are in the best interests of its stakeholders, or as required by federal, state, or local authorities. It is not clear what the potential effects any such alterations or modifications may have on the company's business, including the effects on its customers, employees, and prospects, or on its financial results for 2021 and beyond. With the ongoing volatility in global markets, the company will continue to monitor various factors that could impact earnings and cash flows of the business, including, but not limited to the inflation of, or unavailability of raw material inputs and transportation and logistics services, currency fluctuations, expectations of future planted area (as influenced by consumer demand, ethanol markets and government policies and regulations), trade and purchasing of commodities globally and relative commodity prices.

2021 Restructuring Actions

On February 1, 2021, Corteva approved restructuring actions designed to right-size and optimize footprint and organizational structure according to the business needs in each region with the focus on driving continued cost improvement and productivity. As a result of these actions, the company expects to record total pre-tax restructuring charges of approximately $130 million to $170 million, comprised of approximately $40 million to $50 million of severance and related benefit costs, $40 million to $60 million of asset related charges, $10 million to $15 million of asset retirement obligations and $40 million to $45 million of costs related to contract terminations (contract terminations includes early lease terminations). Future cash payments related to this charge are anticipated to be approximately $80 million to $100 million, primarily related to the payment of severance and related benefits, asset retirement obligations, and costs related to contract terminations. The restructuring actions associated with this charge are expected to be substantially complete in 2021.

During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the company recorded pre-tax charges of ~~$89~~$110 million, recognized in restructuring and asset related charges - net in the company's interim Consolidated Statement of Operations, primarily related to the payment of severance and related benefits and contract termination charges.

The 2021 Restructuring Actions are expected to contribute to the company’s ongoing cost and productivity improvement efforts through achieving an estimated $70 million of savings on a run rate basis by 2023. See Note 5 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements for additional information.

Share Buyback Plan

On June 26, 2019, Corteva, Inc. announced that its Board of Directors authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The company expects to complete the share repurchase program in 2021. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. During the three and six months ended ~~March 31,~~June 30, 2021, the company purchased and retired ~~7,646,000~~4,324,000 shares and 11,970,000 shares, respectively, in the open market for a total cost of ~~$350 million.~~$200 million and $550 million, respectively. During the ~~three~~six months ended ~~March 31,~~June 30, 2020, the company purchased and retired 1,865,000 shares in the open market for a total cost of $50 million.

3943

Table of Contents

Overview

The following is a summary of results from continuing operations for the three months ended ~~March 31,~~June 30, 2021:

•The company reported net sales of ~~$4,178~~$5,627 million, up 68 percent versus the same quarter last year, reflecting a 35 percent increase in volume, a 2 percent favorable impact from currency and a 31 percent increase in price. ~~Volume and price gains were driven by continued penetration of new products, coupled with favorable overall market fundamentals.~~

•Cost of goods sold ("COGS") totaled ~~$2,420~~$3,010 million in the ~~first~~second quarter of 2021, up from ~~$2,269~~$2,829 million in the ~~first~~second quarter of 2020, primarily driven by increased volumes and higher input costs, freight and logistics, which are primarily market-driven, partially offset by ongoing cost and productivity actions.

•Restructuring and asset related charges - net were ~~$100~~$135 million in the ~~first~~second quarter of 2021, ~~an increase~~a decrease from ~~$70~~$179 million in the ~~first~~second quarter of 2020. The charges infor the ~~first quarter of~~three months ended June 30, 2021 primarily relate to $112 million of non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits, and $21 million related to severance and related benefit costs, and asset related ~~charges, and contract termination~~ charges associated with 2021 Restructuring Actions.

•The provision for income taxes for the three months ended June 30, 2021 includes net tax benefits of $18 million associated with changes in accruals for certain prior year tax positions in various jurisdictions.

•Income from continuing operations after income taxes was ~~$613~~$1,018 million, as compared to ~~$281~~$766 million in the same quarter last year.

•Operating EBITDA was ~~$904~~$1,461 million for the three months ended ~~March 31,~~June 30, 2021, up from ~~$794~~$1,236 million for the three months ended ~~March 31,~~June 30, 2020 primarily driven by volume gains and strong price execution, ~~and volume gains,~~ which ~~collectively~~ more than offset cost headwinds. The company experienced ~~market-driven~~ cost headwinds in the quarter including ~~cost increases in~~higher input costs, freight and logistics, which are primarily market-driven, and higher commission expense. The headwinds are partially offset by the company's ongoing execution on its productivity programs. Refer to page 56 for further discussion of the company's Non-GAAP financial measures.

The following is a summary of results from continuing operations for the six months ended June 30, 2021:

•The company reported net sales of $9,805 million, up 7 percent versus the same period last year, reflecting a 4 percent increase in volume and a 2 percent increase in local price and a 1 percent favorable impact from currency.

•COGS totaled $5,430 million in the six months ended 2021, up from $5,098 million in the six months ended 2020, primarily driven by increased volumes and higher input costs, freight and logistics, which are primarily market-driven, partially offset by ongoing cost and productivity actions.

•Restructuring and asset related charges - net were $235 million in the six months ended 2021, a decrease from $249 million in the six months ended 2020. The charges for the six months ended June 30, 2021 primarily relate to $119 million of non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits, and $110 million relate to severance and related benefit costs and asset related charges, and contract termination charges associated with 2021 Restructuring Activities.

•The provision for income taxes for the six months ended June 30, 2021 includes net tax benefits of $25 million associated with changes in accruals for certain prior year tax positions in various jurisdictions.

•Income from continuing operations after income taxes was $1,631 million, as ~~well as raw materials. These~~compared to $1,047 million in the same period last year.

•Operating EBITDA was $2,365 million, up from $2,030 million for the six months ended June 30, 2020, primarily driven by strong price execution, volume gains, and favorable mix, which more than offset cost headwinds. The company experienced cost headwinds ~~were~~in the quarter, including higher input costs, freight and logistics, which are primarily market-driven, and higher commission expense. The headwinds are partially offset by the company’s ongoing execution on its productivity programs. Refer to page 4856 for further discussion of the company's Non-GAAP financial measures.

Table of Contents

In addition to the financial highlights above, the following events occurred during or subsequent to the ~~three~~six months ended ~~March 31,~~June 30, 2021:

•The company returned approximately ~~$450~~$750 million to shareholders during the ~~three~~six months ended ~~March 31,~~June 30, 2021 under its previously announced share repurchase program and through common stock dividends.

•On August 5, 2021, Corteva, Inc. announced that its Board of Directors authorized a $1.5 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

•

On July 21, 2021, the company's Board of Directors approved an increase in the common stock dividend of $0.13 per share to $0.14 per share.

4045

Table of Contents

Selected Financial Data

In millions, except per share amounts Three Months Ended
March 31,
2021 2020
Net sales $ 4,178 $ 3,956
Cost of goods sold $ 2,420 $ 2,269
Percent of net sales 58 % 57 %
Research and development expense $ 281 $ 280
Percent of net sales 7 % 7 %
Selling, general and administrative expenses $ 733 $ 757
Percent of net sales 18 % 19 %
Effective tax rate on continuing operations 22.5 % 31.1 %
Income from continuing operations after income taxes $ 613 $ 281
Income from continuing operations available to Corteva common stockholders $ 610 $ 271
Basic earnings per share of common stock from continuing operations $ 0.82 $ 0.36
Diluted earnings per share of common stock from continuing operations $ 0.81 $ 0.36


In millions, except per share amounts	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
Net sales	$	5,627		$	5,191		$	9,805		$	9,147

Cost of goods sold	$	3,010		$	2,829		$	5,430		$	5,098
Percent of net sales	53		%	54		%	55		%	56		%

Research and development expense	$	293		$	273		$	574		$	553
Percent of net sales	5		%	5		%	6		%	6		%

Selling, general and administrative expenses	$	998		$	965		$	1,731		$	1,722
Percent of net sales	18		%	19		%	18		%	19		%

Effective tax rate on continuing operations	21.8		%	9.2		%	22.1		%	16.4		%

Income from continuing operations after income taxes	$	1,018		$	766		$	1,631		$	1,047

Income from continuing operations available to Corteva common stockholders	$	1,015		$	760		$	1,625		$	1,031

Basic earnings per share of common stock from continuing operations	$	1.37		$	1.01		$	2.19		$	1.37
Diluted earnings per share of common stock from continuing operations	$	1.37		$	1.01		$	2.18		$	1.37

4146

Table of Contents

Results of Operations

Net Sales

Net sales were ~~$4,178~~$5,627 million and ~~$3,956~~$5,191 million for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The increase was primarily driven by a 5 percent increase in volume versus the prior year period. Volume increases were driven by seasonal timing and increased soybean acres in North America, together with continued adoption of new technology in both segments. Currency and local price ~~both increased 3~~represented increases of 2 percent and 1 percent, respectively.


	Three Months Ended June 30,
	2021				2020
	Net Sales ($ Millions)		%		Net Sales ($ Millions)		%
Worldwide	$	5,627	100	%	$	5,191	100	%
North America1	3,842		68	%	3,566		69	%
EMEA2	710		13	%	643		12	%
Latin America	588		10	%	515		10	%
Asia Pacific	487		9	%	467		9	%


	Q2 2021 vs. Q2 2020				Percent Change Due To:
	Net Sales Change				Local Price &						Portfolio /
$ In millions	$		%		Product Mix		Volume		Currency		Other
North America1	$	276	8	%	—	%	6	%	2	%	—	%
EMEA2	67		10	%	5	%	(1)	%	6	%	—	%
Latin America	73		14	%	6	%	5	%	3	%	—	%
Asia Pacific	20		4	%	2	%	(2)	%	5	%	(1)	%
Total	$	436	8	%	1	%	5	%	2	%	—	%

1.Represents U.S. & Canada.

2.Europe, Middle East, and Africa ("EMEA").

Net sales were $9,805 million and $9,147 million for the six months ended June 30, 2021 and 2020, respectively. The increase was primarily driven by a 4 percent increase in volume versus the prior-year ~~period, primarily~~period. Gains were driven by the ~~ongoing~~continued penetration of new products ~~coupled with favorable overall market fundamentals. Gains were reported in most regions, led by double-digit growth in Latin America.~~and strong execution globally. Local price and currency represented increases of 2 percent and 1 percent, respectively.


		Three Months Ended March 31,									Six Months Ended June 30,
		2021				2020					2021				2020
		Net Sales ($ Millions)		%		Net Sales ($ Millions)		%			Net Sales ($ Millions)		%		Net Sales ($ Millions)		%
Worldwide	Worldwide	$	4,178	100	%	$	3,956	100	%	Worldwide	$	9,805	100	%	$	9,147	100	%
North America1	North America1	1,743		42	%	1,765		45	%	North America1	5,585		57	%	5,331		58	%
EMEA2	EMEA2	1,602		38	%	1,467		37	%	EMEA2	2,312		24	%	2,110		23	%
Latin America	Latin America	518		12	%	434		11	%	Latin America	1,106		11	%	949		11	%
Asia Pacific	Asia Pacific	315		8	%	290		7	%	Asia Pacific	802		8	%	757		8	%

Q1 2021 vs. Q1 2020 Percent Change Due To:
Net Sales Change Local Price & Portfolio /
$ In millions $ % Product Mix Volume Currency Other
North America1
$ (22) (1) % 1 % (3) % 1 % — %
EMEA2
135 9 % 3 % 3 % 3 % — %
Latin America 84 19 % 14 % 24 % (19) % — %
Asia Pacific 25 9 % 3 % 6 % 4 % (4) %
Total $ 222 6 % 3 % 3 % — % — %

Table of Contents


	First Half 2021 vs. First Half 2020				Percent Change Due To:
	Net Sales Change				Local Price &						Portfolio /
$ In millions	$		%		Product Mix		Volume		Currency		Other
North America1	$	254	5	%	—	%	4	%	1	%	—	%
EMEA2	202		10	%	4	%	1	%	5	%	—	%
Latin America	157		17	%	9	%	14	%	(6)	%	—	%
Asia Pacific	45		6	%	2	%	1	%	5	%	(2)	%
Total	$	658	7	%	2	%	4	%	1	%	—	%

1.Represents U.S. & Canada.

2.Europe, Middle East, and Africa ("EMEA").

Cost of Goods Sold

COGS was ~~$2,420~~$3,010 million ~~(58~~(53 percent of net sales) and ~~$2,269~~$2,829 million ~~(57~~(54 percent of net sales) for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The increase was primarily driven by higher input costs, freight and logistics, which are primarily market-driven, an increase in volumes in both crop protection and ~~seed. Also,~~seed and unfavorable currency, offset by ongoing cost and productivity actions. The market driven trends are expected to continue as global supply chains and logistics remain constrained across industries.

COGS was $5,430 million (55 percent of net sales) and $5,098 million (56 percent of net sales) for the ~~company experienced~~six months ended June 30, 2021 and 2020, respectively. The increase was primarily driven by higher ~~seed~~input costs, freight ~~costs due to lower service capacity combined with~~and logistics, which are primarily market-driven, an increase in volumes ~~all~~in both crop protection and seed and unfavorable currency. The increases in costs are partially offset by ongoing cost and productivity actions. The market-driven trends are expected to continue as global supply chains and logistics remain constrained across industries.

Research and Development Expense

R&D expense was ~~$281~~$293 million (7(5 percent of net sales) and ~~$280~~$273 million (7(5 percent of net sales) for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The increase was primarily driven by increases in variable compensation and unfavorable currency.

R&D expense was ~~essentially flat, as compared to prior year, as~~$574 million (6 percent of net sales) and $553 million (6 percent of net sales) for the six months ended June 30, 2021 and 2020, respectively. The increase was primarily driven by increases in ~~spending to support new product launches were offset by ongoing cost~~variable compensation, unfavorable currency and ~~productivity actions.~~increases in laboratory costs.

Selling, General and Administrative Expenses

SG&A expenses were ~~$733~~$998 million (18 percent of net sales) and ~~$757~~$965 million (19 percent of net sales) for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The ~~decrease~~increase was primarily driven by increases in commission expense and unfavorable currency, partially offset by lower bad debt expense ~~due~~and ongoing cost and productivity actions taken to ~~a reduction in~~curtail spending.

SG&A expenses were $1,731 million (18 percent of net sales) and $1,722 million (19 percent of net sales) for the ~~reserve percentage used based on improvements in the loss history,~~six months ended June 30, 2021 and 2020, respectively. The increase was primarily driven by higher commission expense, unfavorable currency, and selling expenses to drive sales, partially offset by lower bad debt expense, functional spend, and travel expense due to COVID-19 related restrictions put into place late in the first quarter of ~~2020, and favorable currency, partially offset by higher commission expense due to an increase in sales.~~2020.

Amortization of Intangibles

Intangible asset amortization was ~~$183~~$180 million and ~~$163~~$176 million for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively, and $363 million and $339 million for the six months ended June 30, 2021 and 2020, respectively. The increase was primarily driven by amortization of the trade name asset that was changed from indefinite lived intangible asset to definite lived in the fourth quarter of 2020. See Note 11 - Other Intangible Assets, to the interim Consolidated Financial Statements for additional information.

4248

Table of Contents

Restructuring and Asset Related Charges - Net

Restructuring and asset related charges - net were ~~$100~~$135 million and ~~$70~~$179 million for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The charges in the ~~first~~second quarter of 2021 primarily relate to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits under the Execute to Win Productivity Program and severance and related benefit costs, ~~contract termination~~asset related charges, and ~~asset related~~contract termination charges associated with 2021 Restructuring Actions. The charges in the ~~first~~second quarter of 2020 ~~primarily relate~~related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits and severance and related benefit costs and asset related charges under the Execute to Win Productivity Program.

~~In addition, during the three months ended March 31, 2021 and 2020, the company recognized $7 million and $10 million, respectively, in restructuring~~Restructuring and asset related charges - net were $235 million and $249 million for the six months ended June 30, 2021 and 2020, respectively. The charges in the ~~interim Consolidated Statement~~first half of ~~Operations, from~~2021 primarily related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance ~~traits.~~traits under the Execute to Win Productivity Program and severance and related benefit costs, asset related charges, and contract termination charges associated with 2021 Restructuring Actions. The charges in the first half of 2020 primarily related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits and asset related charges and severance and related benefit costs under the Execute to Win Productivity Program.

See Note 5 - Restructuring and Asset Related Charges, Net, to the interim Consolidated Financial Statements for additional information.

Other Income - Net

Other income - net was ~~$337~~$298 million and $1$89 million for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The increase was primarily due to an increase in non-operating pension and other ~~post employment~~post-employment benefit credit, driven by the December 2020 OPEB plan amendments as discussed in the 2020 Annual Report. The increase was partially offset by a net exchange loss during the three months ended June 30, 2021 compared to a net exchange gain during the three months ended June 30, 2020.

Other income - net was $635 million and $90 million for the six months ended June 30, 2021 and 2020, respectively. The increase was primarily due to an increase in non-operating pension and other post-employment benefit credit, driven by the December 2020 OPEB plan amendments as discussed in the 2020 Annual Report. In addition, Other income - net for the ~~quarter~~six months ended ~~March 31,~~June 30, 2020 includes a $(53) million loss on the sale of the La Porte site. ~~See Note 6 - Supplementary Information, to the interim Consolidated Financial Statements for additional information.~~

~~Pre-tax net exchange losses were $35 million and $61 million for the three months ended March 31, 2021 and 2020, respectively.~~ The company routinely uses forward exchange contracts to offset its net exposures, by currency denominated monetary assets and liabilities of its operations. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes. The net pre-tax exchange gains and losses are recorded in other income - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the interim Consolidated Statement of Operations.

See Note 6 - Supplementary Information, to the interim Consolidated Financial Statements for additional information.

Interest Expense

Interest expense was $7 million and ~~$10~~$14 million for the three months ended ~~March 31,~~June 30, 2021 and 2020, respectively, and $14 million and $24 million for the six months ended June 30, 2021 and 2020, respectively. The change was primarily driven by lower average commercial paper balances and lower interest rates, partially offset by higher average long-term borrowings.

Provision for Income Taxes on Continuing Operations

The company’s provision for income taxes on continuing operations was ~~$178~~$284 million for the three months ended ~~March 31,~~June 30, 2021 on pre-tax income from continuing operations of ~~$791~~$1,302 million, resulting in an effective tax rate of ~~22.5~~21.8 percent. The effective tax rate was unfavorably impacted by geographic mix of earnings. Those unfavorable impacts were partially offset by $18 million of net tax benefits associated with changes in accruals for certain prior year tax positions in various jurisdictions, as well as tax benefits related to the issuance of stock-based compensation.

The company’s provision for income taxes on continuing operations was $78 million for the three months ended June 30, 2020 on pre-tax income from continuing operations of $844 million, resulting in an effective tax rate of 9.2 percent. The effective tax rate was favorably impacted by geographic mix of earnings, $20 million of net tax benefits associated with changes in accruals for certain prior year tax positions in various jurisdictions, which includes a tax benefit of $14 million related to a return to accrual adjustment to reflect a change in estimate on the impact of a tax law enactment in a foreign jurisdiction. In addition, during the three months ended June 30, 2020, the company recognized a tax benefit of $51 million to provision for income

Table of Contents

taxes on continuing operations related to a return to accrual adjustment associated with an elective change in accounting method for the 2019 tax year impact of the 2017 Tax Cuts and Jobs Act's (“The Act”) foreign tax provisions.

The company’s provision for income taxes on continuing operations was $462 million for the six months ended June 30, 2021 on pre-tax income from continuing operations of $2,093 million, resulting in an effective tax rate of 22.1 percent. The effective tax rate was unfavorably impacted by the tax impact of certain net exchange losses recognized on the re-measurement of the net monetary asset positions which were not tax-deductible in their local jurisdictions, as well as geographic mix of earnings. Those unfavorable impacts were partially offset by ~~$(7)~~$25 million of net tax benefits associated with changes in accruals for certain prior year tax positions in various jurisdictions, as well as tax benefits related to the issuance of stock-based compensation.

The company’s provision for income taxes on continuing operations was ~~$127~~$205 million for the ~~three~~six months ended ~~March 31,~~June 30, 2020 on pre-tax income from continuing operations of ~~$408~~$1,252 million, resulting in an effective tax rate of ~~31.1 percent.~~16.4%. The effective tax rate was favorably impacted by geographic mix of earnings, $18 million of net tax benefits associated with changes in accruals for certain prior year tax positions in various jurisdictions, which includes a tax benefit of $14 million related to a return to accrual adjustment to reflect a change in estimate on the impact of a tax law enactment in a foreign jurisdiction. In addition, during the six months ended June 30, 2020, the company recognized a tax benefit of $51 million to provision for income taxes on continuing operations related to a return to accrual adjustment associated with an elective change in accounting method for the 2019 tax year impact of the The Act's foreign tax provisions. The effective tax rate was unfavorably impacted by the tax impact of certain net exchange losses recognized on the re-measurement of the net monetary asset positions which were not tax-deductible in their local jurisdictions, as well as tax charges related to the issuance of stock-based compensation.

(Loss) Income from Discontinued Operations After Tax

(Loss) income from discontinued operations after tax was $(45) million and $(55) million for the three and six months ended June 30, 2021, respectively, and $0 million and $1 million for the three and six months ended June 30, 2020. The three and six months ended June 30, 2021 primarily reflects charges relating to PFAS environmental remediation activities for legacy operations at the Fayetteville Works facility and the settlement with the State of Delaware for PFAS related natural resource damage claims. Refer to Note 3 - Divestitures and Other Transactions, to the interim Consolidated Financial Statements for additional information.

EID Analysis of Operations

As discussed in Note 1 - Basis of Presentation, to the EID interim Consolidated Financial Statements, EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The below relates to EID only and is presented to provide an Analysis of Operations, only for the differences between EID and Corteva, Inc.

~~Table of~~ ~~Contents~~

Interest Expense

EID’s interest expense was ~~$22~~$20 million and ~~$42~~$45 million for the three months ended ~~March 31,~~June 30, 2021, respectively, and $42 million and $87 million for the six months ended June 30, 2021 and 2020, respectively. The change was primarily driven by the items noted on page ~~43,~~49, under the header "Interest Expense," and by lower ~~interest expense incurred~~average borrowings on the related party loan between EID and Corteva, Inc. See Note 2 - Related Party Transactions, to the EID interim Consolidated Financial Statements for further information.

Provision for Income Taxes on Continuing Operations

EID’s provision for income taxes on continuing operations was ~~$174~~$281 million for the three months ended ~~March 31,~~June 30, 2021 on pre-tax income from continuing operations of ~~$776~~$1,289 million, resulting in an effective tax rate of ~~22.4~~21.8 percent. EID’s provision for income taxes on continuing operations was ~~$119~~$71 million for the three months ended ~~March 31,~~June 30, 2020 on pre-tax income from continuing operations of ~~$376~~$813 million, resulting in an effective tax rate of ~~31.6~~8.7 percent.

EID’s provision for income taxes on continuing operations was $455 million for the six months ended June 30, 2021 on pre-tax income from continuing operations of $2,065 million, resulting in an effective tax rate of 22.0 percent. EID’s provision for income taxes on continuing operations was $190 million for the six months ended June 30, 2020 on pre-tax income from continuing operations of $1,189 million, resulting in an effective tax rate of 16.0 percent.

EID’s effective tax rates for the three and six months ended ~~March 31,~~June 30, 2021 and 2020 were driven by the items noted on page ~~43,~~49, under the header “Provision for Income Taxes on Continuing Operations” and a tax benefit related to the interest expense incurred on the related party loan between EID and Corteva, Inc. See Note 2 - Related Party Transactions, to the EID interim Consolidated Financial Statements for further information.

Table of Contents

Corporate Outlook

The company is increasing its net sales outlook for 2021 and expects an approximate 37 – 48 percent increase in net sales. Additionally, the company is ~~reaffirming its previous~~increasing earnings expectations for 2021 ~~Corporate Outlook on~~and expects an increase in Operating EBITDA and Operating Earnings Per Share ~~refer to the 2020 Annual Report, and expects an increase~~ of ~~approximately 15 -~~ 20 – 25 percent and ~~23 - 30~~33 – 40 percent, respectively.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company’s control, such as Significant Items, without unreasonable effort (refer to page 4957 for Significant Items recorded in the three and six months ended ~~March 31,~~June 30, 2021 and 2020). During 2021, the company expects to record $130 million to $170 million for the 2021 Restructuring Actions and approximately $130 million for non-cash accelerated prepaid royalty amortization expense as restructuring and asset related charges. See Note 5 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements for additional information on the company’s 2021 Restructuring Actions and accelerated prepaid royalty amortization.

Recent Accounting Pronouncements

See Note 2 - Recent Accounting Guidance, to the interim Consolidated Financial Statements for a description of recent accounting pronouncements.

4451

Table of Contents

Segment Reviews

The company operates in two reportable segments: Seed and Crop Protection.

Seed

The company’s seed segment is a global leader in developing and supplying advanced germplasm and traits that produce optimum yield for farms around the world. The segment is a leader in many of the company’s key seed markets, including North America corn and soybeans, Europe corn and sunflower, as well as Brazil, India, South Africa and Argentina corn. The segment offers trait technologies that improve resistance to weather, disease, insects and herbicides used to control weeds, and trait technologies that enhance food and nutritional characteristics. In addition, the segment provides digital solutions that assist farmer decision-making with a view to optimize product selection and, ultimately, help maximize yield and profitability.

Crop Protection

The crop protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment offers crop protection solutions that provide farmers the tools they need to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The segment is a leader in global herbicides, insecticides, nitrogen stabilizers and pasture and range management herbicides.

Summarized below are comments on individual segment net sales and segment operating EBITDA for the three and six months ended ~~March 31,~~June 30, 2021 compared with the same period in 2020. The company defines segment operating EBITDA as earnings (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating costs-net, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating costs-net consists of non-operating pension and other post-employment benefit (OPEB) credits, tax indemnification adjustments and environmental remediation and legal costs associated with legacy EID businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Beginning January 1, 2021, the company excludes net unrealized gains or losses from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. See Note 18 - Segment Information, to the interim Consolidated Financial Statements for details related to significant pre-tax benefits (charges) excluded from segment operating EBITDA. All references to prices are based on local price unless otherwise specified.

A reconciliation of segment operating EBITDA to income from continuing operations after income taxes for the three and six months ended ~~March 31,~~June 30, 2021 and 2020 is included in Note 18 - Segment Information, to the interim Consolidated Financial Statements.


Seed	Seed	Three Months Ended March 31,				Seed	Three Months Ended June 30,				Six Months Ended June 30,
In millions	In millions	2021		2020				In millions	2021		2020		2021		2020
Net sales	Net sales	$	2,492	$	2,455			Net sales	$	3,780	$	3,538	$	6,272	$	5,993
Segment operating EBITDA	Segment operating EBITDA	$	617	$	581			Segment operating EBITDA	$	1,123	$	956	$	1,740	$	1,537


Seed	Seed	Q1 2021 vs. Q1 2020				Percent Change Due To:								Seed	Q2 2021 vs. Q2 2020				Percent Change Due To:
		Net Sales Change				Local Price &						Portfolio /			Net Sales Change				Local Price &						Portfolio /
$ In millions	$ In millions	$		%		Product Mix		Volume		Currency		Other		$ In millions	$		%		Product Mix		Volume		Currency		Other
North America	North America	$	(80)	(6)	%	(1)	%	(6)	%	1	%	—	%	North America	$	201	7	%	—	%	6	%	1	%	—	%
EMEA	EMEA	66		7	%	3	%	2	%	2	%	—	%	EMEA	34		13	%	10	%	(1)	%	4	%	—	%
Latin America	Latin America	58		27	%	9	%	39	%	(21)	%	—	%	Latin America	28		14	%	10	%	—	%	4	%	—	%
Asia Pacific	Asia Pacific	(7)		(10)	%	5	%	(12)	%	(3)	%	—	%	Asia Pacific	(21)		(13)	%	—	%	(16)	%	3	%	—	%
Total	Total	$	37	2	%	2	%	1	%	(1)	%	—	%	Total	$	242	7	%	1	%	4	%	2	%	—	%

4552

Table of Contents


Seed	Seed	Q1 2021 vs. Q1 2020				Percent Change Due To:								Seed	Q2 2021 vs. Q2 2020				Percent Change Due To:
		Net Sales Change				Local Price &						Portfolio /			Net Sales Change				Local Price &						Portfolio /
$ In millions	$ In millions	$		%		Product Mix		Volume		Currency		Other		$ In millions	$		%		Product Mix		Volume		Currency		Other
Corn	Corn	$	24	1	%	2	%	—	%	(1)	%	—	%	Corn	$	123	6	%	3	%	2	%	1	%	—	%
Soybeans	Soybeans	(4)		(2)	%	(4)	%	—	%	2	%	—	%	Soybeans	75		7	%	(2)	%	8	%	1	%	—	%
Other oilseeds	Other oilseeds	48		19	%	4	%	18	%	(3)	%	—	%	Other oilseeds	52		24	%	4	%	11	%	9	%	—	%
Other	Other	(31)		(19)	%	(5)	%	(12)	%	(2)	%	—	%	Other	(8)		(5)	%	(5)	%	(2)	%	2	%	—	%
Total	Total	$	37	2	%	2	%	1	%	(1)	%	—	%	Total	$	242	7	%	1	%	4	%	2	%	—	%


Seed	First Half 2021 vs. First Half 2020				Percent Change Due To:
	Net Sales Change				Local Price &						Portfolio /
$ In millions	$		%		Product Mix		Volume		Currency		Other
North America	$	121	3	%	(1)	%	3	%	1	%	—	%
EMEA	100		9	%	5	%	1	%	3	%	—	%
Latin America	86		20	%	9	%	20	%	(9)	%	—	%
Asia Pacific	(28)		(12)	%	2	%	(15)	%	1	%	—	%
Total	$	279	5	%	1	%	3	%	1	%	—	%


Seed	First Half 2021 vs. First Half 2020				Percent Change Due To:
	Net Sales Change				Local Price &						Portfolio /
$ In millions	$		%		Product Mix		Volume		Currency		Other
Corn	$	147	4	%	3	%	1	%	—	%	—	%
Soybeans	71		6	%	(2)	%	7	%	1	%	—	%
Other oilseeds	100		21	%	4	%	14	%	3	%	—	%
Other	(39)		(12)	%	(5)	%	(7)	%	—	%	—	%
Total	$	279	5	%	1	%	3	%	1	%	—	%

Seed

Seed net sales were ~~$2,492~~$3,780 million in the ~~first~~second quarter of 2021, up 27 percent from ~~$2,455~~$3,538 million in the ~~first~~second quarter of 2020. ~~Gains~~The increase was due to a 4 percent increase in volume, a 2 percent favorable impact from currency and a 1 percent increase in local price.

Higher volumes were driven by more normalized delivery timing in North America compared to the prior-year period, coupled with increased soybean acreage in North America. In addition, the company delivered $80 million in sales in the second quarter primarily due to robust early demand for corn in Latin America. This increase was also driven by canola growth in Canada, which represents early settlement of the season compared to the year-ago period. Favorable currency impacts were primarily driven by the Canadian Dollar. The increase in local price was led by strong execution in Latin America and EMEA.

Segment operating EBITDA was $1,123 million in the second quarter of 2021, up 17 percent from $956 million in the second quarter of 2020. Volume gains, lower royalties, reduced bad debt expense, ongoing cost and productivity actions, and continued price execution more than offset higher input costs from unfavorable yields on European corn and sunflower. Segment operating EBITDA margin improved by more than 260 basis points versus the prior-year period.

Seed net sales were $6,272 million for the first six months of 2021, up 5 percent from $5,993 million for the first six months of 2020. The increase was due to a 23 percent increase in volume, a 1 percent increase in local price and a 1 percent ~~increase in volume, partially offset by a 1 percent~~favorable impact from currency.

~~Pricing~~The increase in volume was driven by higher soybean sales in North America, market share gains in the Brazil Safrinha, earlier shipments in the Brazil summer season, and canola growth in Canada. Local price gains were driven by strong adoption of new ~~Seed~~seed technology, including price execution in ~~EMEA~~Latin America and ~~Latin America,~~EMEA, with corn price up 2%3 percent globally. Volume growth was driven by record corn and sunflower volume in EMEA due to a shift in customer demand on local supply concerns and an early start to the spring, coupled with strong Safrinha sales in Brazil and early demand in other parts of Latin America. GainsThese gains were partially offset by ~~impact of seasonal timing of deliveries~~competitive pricing pressure in North ~~America. Unfavorable~~ America soybeans, where price was down 2 percent. Favorable

Table of Contents

currency impacts ~~led by~~primarily from the ~~Brazilian Real, were partially~~Canadian Dollar and the Euro more than offset ~~by favorable~~unfavorable impacts from the ~~Euro.~~Brazilian Real.

Segment operating EBITDA was ~~$617~~$1,740 million infor the first ~~quarter~~six months of 2021, up 613 percent from ~~$581~~$1,537 million infor the first ~~quarter~~six months of 2020. ~~Price~~Continued price execution, lower ~~SG&A driven by an improvement in~~royalties, lower bad debt ~~a gain on the remeasurement of an equity investment~~expense, volume gains, and ongoing cost and productivity actions more than offset higher input costs from unfavorable yields on European corn and sunflower and higher freight ~~costs and the unfavorable impact of currency.~~costs. Segment operating EBITDA margin improved by more than ~~100~~200 basis points versus the prior-year period.


Crop Protection	Crop Protection	Three Months Ended March 31,				Crop Protection	Three Months Ended June 30,				Six Months Ended June 30,
In millions	In millions	2021		2020				In millions	2021		2020		2021		2020
Net sales	Net sales	$	1,686	$	1,501			Net sales	$	1,847	$	1,653	$	3,533	$	3,154
Segment Operating EBITDA	Segment Operating EBITDA	$	321	$	238			Segment Operating EBITDA	$	370	$	309	$	691	$	547


Crop Protection	Crop Protection	Q1 2021 vs. Q1 2020				Percent Change Due To:								Crop Protection	Q2 2021 vs. Q2 2020				Percent Change Due To:
		Net Sales Change				Local Price &						Portfolio /			Net Sales Change				Local Price &						Portfolio /
$ In millions	$ In millions	$		%		Product Mix		Volume		Currency		Other		$ In millions	$		%		Product Mix		Volume		Currency		Other
North America	North America	$	58	12	%	6	%	5	%	1	%	—	%	North America	$	75	11	%	2	%	8	%	1	%	—	%
EMEA	EMEA	69		12	%	3	%	4	%	5	%	—	%	EMEA	33		9	%	2	%	(2)	%	9	%	—	%
Latin America	Latin America	26		12	%	18	%	10	%	(16)	%	—	%	Latin America	45		15	%	3	%	8	%	4	%	—	%
Asia Pacific	Asia Pacific	32		14	%	2	%	12	%	5	%	(5)	%	Asia Pacific	41		14	%	3	%	6	%	7	%	(2)	%
Total	Total	$	185	12	%	6	%	6	%	1	%	(1)	%	Total	$	194	12	%	3	%	5	%	4	%	—	%

Crop Protection	Crop Protection	Q1 2021 vs. Q1 2020				Percent Change Due To:								Crop Protection	Q2 2021 vs. Q2 2020				Percent Change Due To:
		Net Sales Change				Local Price &						Portfolio /			Net Sales Change				Local Price &						Portfolio /
$ In millions	$ In millions	$		%		Product Mix		Volume		Currency		Other		$ In millions	$		%		Product Mix		Volume		Currency		Other
Herbicides	Herbicides	$	163	20	%	5	%	12	%	3	%	—	%	Herbicides	$	60	7	%	2	%	1	%	4	%	—	%
Insecticides	Insecticides	7		2	%	8	%	(4)	%	(2)	%	—	%	Insecticides	15		3	%	2	%	(3)	%	4	%	—	%
Fungicides	Fungicides	32		14	%	5	%	14	%	(1)	%	(4)	%	Fungicides	87		39	%	4	%	28	%	9	%	(2)	%
Other	Other	(17)		(24)	%	(1)	%	(19)	%	(4)	%	—	%	Other	32		43	%	6	%	34	%	3	%	—	%
Total	Total	$	185	12	%	6	%	6	%	1	%	(1)	%	Total	$	194	12	%	3	%	5	%	4	%	—	%


Crop Protection	First Half 2021 vs. First Half 2020				Percent Change Due To:
	Net Sales Change				Local Price &						Portfolio /
$ In millions	$		%		Product Mix		Volume		Currency		Other
North America	$	133	12	%	3	%	7	%	2	%	—	%
EMEA	102		11	%	2	%	2	%	7	%	—	%
Latin America	71		13	%	9	%	9	%	(5)	%	—	%
Asia Pacific	73		14	%	3	%	8	%	6	%	(3)	%
Total	$	379	12	%	4	%	6	%	3	%	(1)	%

Crop Protection	First Half 2021 vs. First Half 2020				Percent Change Due To:
	Net Sales Change				Local Price &						Portfolio /
$ In millions	$		%		Product Mix		Volume		Currency		Other
Herbicides	$	223	13	%	4	%	6	%	3	%	—	%
Insecticides	22		3	%	5	%	(3)	%	1	%	—	%
Fungicides	119		26	%	4	%	21	%	4	%	(3)	%
Other	15		10	%	3	%	8	%	(1)	%	—	%
Total	$	379	12	%	4	%	6	%	3	%	(1)	%

4654

Table of Contents

Crop Protection

Crop protection net sales were ~~$1,686~~$1,847 million in the ~~first~~second quarter of 2021, up 12 percent from ~~$1,501~~$1,653 million in the ~~first~~second quarter of 2020. ~~Gains were~~The increase was due to a 5 percent increase in volume, a 4 percent favorable impact from currency and a 3 percent increase in local price.

The increase in volume was driven by continued penetration of new products, including ArylexTM herbicide and PyraxaltTM insecticide, coupled by early demand in Latin America, which shifted approximately $50 million in sales from the third quarter. These volume gains were partially offset by an approximate $60 million impact from our decision to phase out select low-margin products. Favorable currency impacts were primarily from the Euro. The increase in local price was driven by strategic price increases in North America, coupled with strong price execution globally.

Segment operating EBITDA was $370 million in the second quarter of 2021, up 20 percent from $309 million in the second quarter of 2020. Volume gains from new products, continued pricing execution, productivity, and favorable impacts from currency more than offset higher input costs, including raw material costs. Segment operating EBITDA margin improved by more than 130 basis points versus the prior-year period.

Crop protection net sales were $3,533 million for the first six months of 2021, up 12 percent from $3,154 million for the first six months of 2020. The increase was due to a 6 percent ~~increases~~increase in volume, ~~and~~a 4 percent increase in local price ~~respectively,~~ and a 13 percent favorable impact from currency, partially offset by a 1 percent ~~impact from portfolio.~~unfavorable portfolio impact.

Volume gains were ~~driven~~led by ~~strong demand for~~continued penetration of new products, ~~globally,~~ including ArylexTM, and EnlistTM~~, and Rinskor~~TM herbicides and ~~Isoclast~~TM ~~and Pyraxalt~~TM ~~insecticides.~~Pyraxalt™ insecticide. These volume gains were partially offset by an approximate ~~$70~~$130 million impact from ~~the company's~~our decision to phase out select low-margin ~~generic~~ products. ~~Local~~The increase in local price ~~rose due to increases~~was primarily driven by gains in Latin America ~~coupled with favorable product mix globally~~ and ~~strategic price increases in~~ North America. Favorable currency impacts primarily from the Euro more than offset unfavorable impacts from the Brazilian Real. The portfolio impact was driven by prior-year divestitures in Asia Pacific.

Segment operating EBITDA was ~~$321~~$691 million infor the first ~~quarter~~six months of 2021, up 3526 percent from ~~$238~~$547 million infor the first ~~quarter~~six months of 2020. ~~Price and volume gains~~Favorable mix, continued penetration of new products, and ongoing cost and productivity actions more than offset higher input costs, including raw ~~materials~~material costs. Segment operating EBITDA margin improved by more than ~~300~~220 basis points versus ~~prior-year.~~

~~While~~ the company has experienced some supply chain challenges and higher costs during the quarter ended March 31, 2021, as a result of freight and logistic service capacities remaining contracted and not yet having returned to pre-pandemic levels and weather-related events in the Gulf Coast, its supply chain strategies have to-date largely enabled availability of product and deliveries to customers.

prior-year period.

4755

Table of Contents

Non-GAAP Financial Measures

The company presents certain financial measures that do not conform to U.S. GAAP and are considered non-GAAP measures. These measures include Operating EBITDA and operating earnings per share. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the company and a more useful comparison of year over year results. These non-GAAP measures supplement the company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided below.

Operating EBITDA is defined as earnings (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating (benefits) costs - net, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating (benefits) costs - net consists of non-operating pension and OPEB credits, tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating earnings per share is defined as "Earnings per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of non-operating (benefits) costs - net, the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

Reconciliation of Income from Continuing Operations after Income Taxes to Operating EBITDA


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020

Income from continuing operations after income taxes (GAAP)	Income from continuing operations after income taxes (GAAP)	$	613	$	281		Income from continuing operations after income taxes (GAAP)	$	1,018	$	766	$	1,631	$	1,047
Provision for income taxes on continuing operations	Provision for income taxes on continuing operations	178		127			Provision for income taxes on continuing operations	284		78		462		205
Income from continuing operations before income taxes (GAAP)	Income from continuing operations before income taxes (GAAP)	791		408			Income from continuing operations before income taxes (GAAP)	1,302		844		2,093		1,252
Depreciation and amortization	Depreciation and amortization	304		283			Depreciation and amortization	313		300		617		583
Interest income	Interest income	(21)		(18)			Interest income	(18)		(9)		(39)		(27)
Interest expense	Interest expense	7		10			Interest expense	7		14		14		24
Exchange losses - net		35		61
Exchange losses (gains) - net							Exchange losses (gains) - net	14		(1)		49		60
Non-operating benefits - net	Non-operating benefits - net	(311)		(73)			Non-operating benefits - net	(315)		(91)		(626)		(164)

Mark-to-market gains on certain foreign currency contracts not designated as hedges1		(1)
Mark-to-market losses on certain foreign currency contracts not designated as hedges1							Mark-to-market losses on certain foreign currency contracts not designated as hedges1	23				22
Significant items charge	Significant items charge	100		123			Significant items charge	135		179		235		302

Operating EBITDA (Non-GAAP)	Operating EBITDA (Non-GAAP)	$	904	$	794		Operating EBITDA (Non-GAAP)	$	1,461	$	1,236	$	2,365	$	2,030

4856

Table of Contents

Significant Items

Three Months Ended
March 31,
(In millions) 2021 2020
Restructuring and asset related charges - net $ (100) $ (70)
Loss on divestiture — (53)
Total pretax significant items charge (100) (123)
Total tax benefit impact of significant items1
23 23
Tax only significant item benefit2
— (19)
Total significant items charge, after tax $ (77) $ (119)


	Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	2021		2020		2021		2020
Restructuring and asset related charges - net	$	(135)	$	(179)	$	(235)	$	(249)
Loss on divestiture	—		—		—		(53)
Total pretax significant items charge	(135)		(179)		(235)		(302)
Total tax benefit impact of significant items1	28		36		51		59
Tax only significant item benefit2	—		29		—		10
Total significant items charge, after tax	$	(107)	$	(114)	$	(184)	$	(233)

1.Unless specifically addressed above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

2.The tax only significant item benefits for the three and six months ended ~~March 31,~~June 30, 2020 ~~includes an after tax charge~~are primarily related to a benefit due to an elective change in accounting method that alters the 2019 impact of the business separation on The Act's foreign tax provisions and a state tax valuation allowance in the U.S. based on a change in judgment about the realizability of a deferred tax asset.

Reconciliation of Income from Continuing Operations Attributable to Corteva and Earnings Per Share of Common Stock from Continuing Operations - Diluted to Operating Earnings and Operating Earnings Per Share


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020

Income from continuing operations attributable to Corteva (GAAP)	Income from continuing operations attributable to Corteva (GAAP)	$	610	$	271		Income from continuing operations attributable to Corteva (GAAP)	$	1,015	$	760	$	1,625	$	1,031
Less: Non-operating benefits - net, after tax	Less: Non-operating benefits - net, after tax	237		57			Less: Non-operating benefits - net, after tax	237		67		474		124
Less: Amortization of intangibles (existing as of Separation), after tax	Less: Amortization of intangibles (existing as of Separation), after tax	(143)		(114)			Less: Amortization of intangibles (existing as of Separation), after tax	(140)		(137)		(283)		(251)

Less: Mark-to-market gains on certain foreign currency contracts not designated as hedges, after tax1		1
Less: Mark-to-market losses on certain foreign currency contracts not designated as hedges, after tax1							Less: Mark-to-market losses on certain foreign currency contracts not designated as hedges, after tax1	(18)				(17)
Less: Significant items charge, after tax	Less: Significant items charge, after tax	(77)		(119)			Less: Significant items charge, after tax	(107)		(114)		(184)		(233)
Operating Earnings (Non-GAAP)	Operating Earnings (Non-GAAP)	$	592	$	447		Operating Earnings (Non-GAAP)	$	1,043	$	944	$	1,635	$	1,391


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
		2021		2020				2021		2020		2021		2020

Earnings per share of common stock from continuing operations - diluted (GAAP)	Earnings per share of common stock from continuing operations - diluted (GAAP)	$	0.81	$	0.36		Earnings per share of common stock from continuing operations - diluted (GAAP)	$	1.37	$	1.01	$	2.18	$	1.37
Less: Non-operating benefits - net, after tax	Less: Non-operating benefits - net, after tax	0.31		0.08			Less: Non-operating benefits - net, after tax	0.32		0.09		0.64		0.16
Less: Amortization of intangibles (existing as of Separation), after tax	Less: Amortization of intangibles (existing as of Separation), after tax	(0.19)		(0.15)			Less: Amortization of intangibles (existing as of Separation), after tax	(0.19)		(0.19)		(0.38)		(0.33)

Less: Mark-to-market gains on certain foreign currency contracts not designated as hedges, after tax1		—
Less: Mark-to-market losses on certain foreign currency contracts not designated as hedges, after tax1							Less: Mark-to-market losses on certain foreign currency contracts not designated as hedges, after tax1	(0.02)				(0.02)
Less: Significant items charge, after tax	Less: Significant items charge, after tax	(0.10)		(0.16)			Less: Significant items charge, after tax	(0.14)		(0.15)		(0.25)		(0.31)
Operating Earnings Per Share (Non-GAAP)	Operating Earnings Per Share (Non-GAAP)	$	0.79	$	0.59		Operating Earnings Per Share (Non-GAAP)	$	1.40	$	1.26	$	2.19	$	1.85
Diluted Shares Outstanding (in millions)	Diluted Shares Outstanding (in millions)	749.6		752.5			Diluted Shares Outstanding (in millions)	743.3		751.6		746.4		752.0

4957

Table of Contents

Liquidity and Capital Resources

Information related to the company's liquidity and capital resources can be found in the company’s 2020 Annual Report, Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Liquidity & Capital Resources. The discussion below provides the updates to this information for the ~~three~~six months ended ~~March 31,~~June 30, 2021.


(In millions)	(In millions)	March 31, 2021		December 31, 2020		March 31, 2020		(In millions)	June 30, 2021		December 31, 2020		June 30, 2020
Cash, cash equivalents and marketable securities	Cash, cash equivalents and marketable securities	$	2,518	$	3,795	$	1,973	Cash, cash equivalents and marketable securities	$	2,900	$	3,795	$	2,869
Total debt	Total debt	$	2,352	$	1,105	$	2,610	Total debt	$	1,778	$	1,105	$	2,631

The company's cash, cash equivalents and marketable securities at ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020 were ~~$2,518~~$2,900 million, $3,795 million and ~~$1,973~~$2,869 million, respectively. Total debt at ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020 was ~~$2,352~~$1,778 million, $1,105 million, and ~~$2,610~~$2,631 million, respectively. The increase in debt balances from December 31, 2020 was primarily due to funding the company’s seasonal working capital ~~needs.~~needs and capital expenditures. See further information in Note 12 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities, to the interim Consolidated Financial Statements.

The company believes its ability to generate cash from operations and access to capital markets and commercial paper markets will be adequate to meet anticipated cash requirements to fund its operations, including seasonal working capital, capital spending, funding of the MOU escrow account, and pension obligations. Corteva's strong financial position, liquidity and credit ratings will provide access as needed to capital markets and commercial paper markets to fund seasonal working capital needs. The company's liquidity needs can be met through a variety of sources, including cash provided by operating activities, commercial paper, syndicated credit lines, bilateral credit lines, long-term debt markets, bank financing and committed receivable repurchase facilities. Corteva considers the borrowing costs and lending terms when selecting the source to fund its operations and working capital needs. During the ~~three~~six months ended ~~March 31,~~June 30, 2021, the company has experienced increased operating costs for ~~steel~~freight and ~~other~~raw materials. The company also has experienced increased costs for materials used in various capital expenditures and capacity expansion ~~projects, and expects this trend to continue. This has~~projects. The increases in costs have been due, in part to, inflation and the rising demand from the economic recovery from the lifting of COVID-19 pandemic restrictions and government stimulus in some regions, while the supply for certain materials have not returned to pre-pandemic levels. The company expects this trend to continue as global supply chains and logistics remain constrained across industries.

The company had access to approximately $6.4 billion at ~~March 31,~~June 30, 2021, ~~and~~$6.4 billion at December 31, 2020, ~~respectively~~ and ~~$5.8~~$6.3 billion at ~~March 31,~~June 30, 2020, in committed and uncommitted unused credit lines. In addition to the unused credit facilities, the company has a $1 billion 2021 Repurchase Facility (as defined below). These facilities provide support to meet the company’s short-term liquidity needs and for general corporate purposes which may include funding of discretionary and nondiscretionary contributions to certain benefit plans, severance payments, repayment and refinancing of debt, working capital, capital expenditures, repurchases and redemptions of securities, and funding Corteva's costs and expenses.

In March 2020, the company drew down $500 million under the three year revolving credit facility to finance its short term liquidity needs as a result of the volatility and increased borrowing costs of commercial paper resulting from the unstable market conditions caused by the COVID-19 pandemic, and repaid that borrowing in full in June 2020. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. The Revolving Credit Facilities also contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At ~~March 31,~~June 30, 2021 the company was in compliance with these covenants.

The company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations affecting manufacturing plants, mineral producing properties or research facilities located in the U.S. and the consolidated subsidiaries owning such plants, properties and facilities subject to certain limitations. The outstanding long-term debt also contains customary default provisions.

The company has meaningful seasonal working capital needs based in part on providing financing to its customers. Working capital is funded through multiple methods including cash, commercial paper, the 2021 Repurchase Facility, the Revolving Credit Facilities, and factoring.

Table of Contents

In February 2021, in line with seasonal working capital requirements, the company entered into a committed receivable repurchase agreement of up to $1.0 billion (the "2021 Repurchase Facility"), which expires in December 2021. Under the 2021 Repurchase Facility, Corteva may sell a portfolio of available and eligible outstanding customer notes receivables to participating institutions and simultaneously agree to repurchase at a future date. See further discussion of this facility in Note 12 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities, to the interim Consolidated Financial Statements.

~~Table of~~ ~~Contents~~

The company has factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds in an effort to reduce its receivables risk. For arrangements that include an element of recourse, the company provides a guarantee of the trade receivables in the event of customer default. Refer to Note 9 - Accounts and Notes Receivable - Net, to the interim Consolidated Financial Statements for more information.

The company also organizes agreements with third-party financial institutions who directly provide financing for select customers of the company's seed and crop protection products in each region. Terms of the third-party loans are less than a year and programs are renewed on an annual basis. In some cases, the company guarantees a portion of the extension of such credit to such customers. Refer to Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements for more information on the company’s guarantees.

The company's cash, cash equivalents and marketable securities at ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020 are ~~$2.5~~$2.9 billion, $3.8 billion, and ~~$2.0~~$2.9 billion respectively, of which ~~$2.4~~$2.7 billion, $3.1 billion, and $2.7 billion at ~~March 31,~~June 30, 2021, ~~$3.1 billion at~~ December 31, 2020, and ~~$1.5 billion at March 31,~~June 30, 2020, respectively, was held by subsidiaries in foreign countries, including United States territories. The 2017 Tax Cuts and Jobs Act ("The Act") required companies to pay a one-time transition tax on the untaxed earnings of foreign subsidiaries. Upon actual repatriation, such earnings could be subject to withholding taxes, foreign and/or U.S. state income taxes, and taxes resulting from the impact of foreign currency movements. The Act also introduced a 100 percent dividends received deduction regarding earnings of foreign subsidiaries. The cash held by foreign subsidiaries is generally used to finance the subsidiaries' operational activities and future foreign investments. At ~~March 31,~~June 30, 2021, management believed that sufficient liquidity is available in the U.S. with global operating cash flows, borrowing capacity from existing committed credit facilities, and access to capital markets and commercial paper markets.

Summary of Cash Flows

Cash used for operating activities was ~~$1,950~~$643 million for the ~~three~~six months ended ~~March 31,~~June 30, 2021 compared to ~~$1,930~~$869 million for the ~~three~~six months ended ~~March 31,~~June 30, 2020. The change in cash used for operating activities was driven by ~~an increase~~higher earnings partially offset by changes in working ~~capital requirements.~~capital.

Cash ~~provided by (used for)~~used for investing activities was ~~$36~~$17 million for the ~~three~~six months ended ~~March 31,~~June 30, 2021 compared to ~~$(130)~~$252 million for the ~~three~~six months ended ~~March 31,~~June 30, 2020. The change was primarily due to ~~higher net proceeds from~~lower purchases of investments, ~~in available-for-sale securities,~~ partly offset by higher capital expenditures. The company is increasing its expected 2021 capital expenditures to $600 - $650 million, which is primarily driven by increases in costs for materials used in various capital expenditures and capacity expansion projects.

Cash (used for) provided by financing activities was ~~$0.8~~$(27) million for the six months ended June 30, 2021 compared to $2.2 billion for the ~~three~~six months ended ~~March 31, 2021 compared to $2.3 billion for the three months ended March 31,~~June 30, 2020. The change was primarily due to lower borrowings partially offset by higher repurchases of Corteva common stock.

In January 2021, the ~~Company's~~company's Board of Directors authorized a common stock dividend of $0.13 per share, payable on March 15, 2021, to the shareholders of record on March 1, 2021. In April 2021, the company's Board of Directors authorized a common stock dividend of $0.13 per share, payable on June 15, 2021, to the shareholders of record on May 14, 2021. In July 2021, the company’s Board of Directors approved an increase in the common stock dividend of $0.13 per share to $0.14 per share. In July 2021, the company's Board of Directors authorized a common stock dividend of $0.14 per share, payable on September 15, 2021, to the shareholders of record on August 13, 2021.

On August 5, 2021, the company's Board of Directors authorized a $1.5 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date.

On June 26, 2019, the company's Board of Directors authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The company repurchased ~~$650~~$850 million under its share buyback plan since the Corteva Distribution and expects to ~~repurchase~~complete the ~~remaining $350 million~~program in 2021.

For the full year 2021, the company expects to repurchase at least $850 million under the share buyback plans discussed above. The total amount, timing, price and volume of purchases will be based on market conditions, relevant securities laws and other market and company specific factors.

Table of Contents

During the three and six months ended ~~March 31,~~June 30, 2021, the company purchased and retired ~~7,646,000~~4,324,000 shares and 11,970,000 shares, respectively, in the open market for a total cost of ~~$350 million.~~$200 million and $550 million, respectively. During the ~~three~~six months ended ~~March 31,~~June 30, 2020, the company purchased and retired 1,865,000 shares for a total cost of $50 million. See Note 14 - Stockholders' Equity, to the interim Consolidated Financial Statements for additional information related to the share buyback plan.

EID Liquidity Discussion

As discussed in Note 1 - Basis of Presentation, to the EID interim Consolidated Financial Statements, EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The below relates to EID only and is presented to provide a Liquidity discussion for the differences between EID and Corteva, Inc.

Cash used for operating activities

EID’s cash used for operating activities was ~~$1.9 billion~~$663 million and $920 million for the ~~three~~six months ended ~~March 31,~~June 30, 2021 and 2020, respectively. The change was primarily driven by the items above under the header, "Summary of Cash Flow".

~~Table of~~ ~~Contents~~

Cash provided by financing activities

EID’s cash (used for) provided by financing activities was ~~$0.8 billion~~$(7) million for the ~~three~~six months ended ~~March 31,~~June 30, 2021 compared to ~~$2.3 billion~~$2,265 million for the ~~three~~six months ended ~~March 31,~~June 30, 2020. The change was primarily driven by lower ~~borrowings~~proceeds from issuance of long-term debt and higher payments on long-term debt on related party debt.

See Note 2 - Related Party Transactions, to the EID interim Consolidated Financial Statements for further information on the related party loan between EID and Corteva, Inc.

Guarantees and Off-Balance Sheet Arrangements

For detailed information related to Guarantees, Indemnifications, and Obligations for Equity Affiliates and Others, see the company’s 2020 Annual Report, Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Off-Balance Sheet Arrangements and Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

Contractual Obligations

Information related to the company's contractual obligations at December 31, 2020 can be found on page 73 of the company's 2020 Annual Report. There have been no material changes to the company’s contractual obligations outside the ordinary course of business from those reported in the company’s 2020 Annual Report.

Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

See Note 16 - Financial Instruments, to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the company's 2020 Annual Report, for information on the company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

5260

Table of Contents

Item 4. CONTROLS AND PROCEDURES

Corteva, Inc.

a) Evaluation of Disclosure Controls and Procedures

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of ~~March 31,~~June 30, 2021, the company's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

b) Changes in Internal Control over Financial Reporting

There have been no changes in the company's internal control over financial reporting that occurred during the quarter ended ~~March 31,~~June 30, 2021 that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

E. I. du Pont de Nemours and Company

a) Evaluation of Disclosure Controls and Procedures

EID maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in their reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of ~~March 31,~~June 30, 2021, EID's CEO and CFO, together with management, conducted an evaluation of the effectiveness of EID's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

b) Changes in Internal Control over Financial Reporting

There have been no changes in EID's internal control over financial reporting that occurred during the quarter ended ~~March 31,~~June 30, 2021 that have materially affected, or are reasonably likely to materially affect, EID's internal control over financial reporting.

5361

Table of Contents

PART II. OTHER INFORMATION

Item 1.LEGAL PROCEEDINGS

The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EID businesses unrelated to Corteva’s current businesses but allocated to Corteva as part of the Separation of Corteva from DuPont. Often these proceedings raise complex factual and legal issues, which are subject to risks and uncertainties and which could require significant amounts of senior leadership team’s time. Litigation and other claims, along with regulatory proceedings, against the company could also materially adversely affect its operations, reputation, and/or result in the incurrence of unexpected expenses and liability. Even when the company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the company, including avoidance of future distraction and litigation defense cost, and its shareholders. Information regarding certain of these matters is set forth below and in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements. Even when the Company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the Company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company, including avoidance of future distraction and litigation defense cost, and its shareholders.

Litigation related to Corteva’s current businesses

Canadian Competition Bureau Formal Inquiry

On January 30, 2020, the Canadian Competition Bureau (the “Bureau”) filed a court order for the company to produce records and information as part of a formal inquiry under civil sections of Canada’s competition laws. The inquiry is in response to allegations by the Farmers Business Network ("FBN") that Corteva and other seeds and crop protection manufacturers and wholesalers unilaterally or in coordination refused, restricted and/or impaired supply of products to FBN in western Canada. This inquiry follows an informal request for information from the Bureau pursuant to which the company voluntarily provided documents and engaged in discussions with the Bureau outlining how its conduct was and continues to be compliant with Canadian competition laws. Corteva continues to cooperate with the Bureau’s inquiries, but believes the likelihood of material liability is remote.

Federal Trade Commission Investigation

On May 26, 2020, Corteva received a subpoena from the Federal Trade Commission (“FTC”) directing it to submit documents pertaining to its crop protection products generally, as well as business plans, rebate programs, offers, pricing and marketing materials specifically related to its acetochlor, oxamyl and rimsulfuron and other related products in order to determine whether Corteva engaged in unfair methods of competition through anticompetitive conduct. Corteva has cooperated with the FTC’s subpoena, and continues to believe the likelihood of material liability is remote.

Chlorpyrifos Lawsuits

As of July 2021, there were 17 pending personal injury lawsuits filed against the former Dow Agrisciences, LLC in California, alleging injuries related to chlorpyrifos exposure, the active ingredient in Lorsban®, an insecticide used by commercial farms for field fruit, nut and vegetable crop. Corteva ended its production of Lorsban® in 2020. Chlorpyrifos products are restricted-use pesticides, which are not available for purchase or use by the general public, and may only be sold to, and used by, certified applicators or someone under the certified applicator's direct supervision. These lawsuits do not relate to Dursban®, a residential-type chlorpyrifos product that was authorized for indoor purposes, which was discontinued over two decades ago prior to the Merger and Corteva’s formation and Separation.

Currently, 10 cases filed in Monterey County allege personal injury, including autism, developmental delays and/or decreased neurologic function, resulting from farm worker exposure and bystander drift and in utero exposure to chlorpyrifos. The Monterey County cases have been consolidated for discovery purposes, but not for trial. The first trial is set to begin in March 2022. The remaining cases are from the California Central Valley and allege personal injury from occupational, in utero and post-natal exposure to chlorpyrifos oxon, as well as exposure from drinking water contaminated with chlorpyrifos. Additionally, the Central Valley cases include remediation claims due to alleged property contamination from chlorpyrifos. Discovery for the Central Valley cases only recently begun and is expected to continue through 2021. Any losses are not estimable at this time due to various reasons, including, among others, that the litigation remains in its early stages and significant factual issues remain to be resolved.

Litigation related to legacy EID businesses unrelated to Corteva’s current businesses

As discussed below and in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, certain of the environmental proceedings and litigation allocated to Corteva as part of the Separation from DuPont relate to the legacy EID businesses, including their use of PFOA, which, for purposes of this report, means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other

Table of Contents

perfluorinated chemicals and compounds ("PFCs"). Management believes that it is reasonably possible that EID could incur liabilities related to PFOA in excess of amounts accrued. However, any such losses are not estimable at this time due to various reasons, including, among others, that the underlying matters are in their early stages and have significant factual issues to be resolved.

On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against DuPont, EID, and Corteva, seeking, among other things, to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement (the “Delaware Litigation”). On March 30, 2020, the Court of Chancery granted a motion to dismiss. On December 15, 2020, the Delaware Supreme Court affirmed the judgment of the Court of Chancery. Meanwhile, a confidential arbitration process regarding the same and other claims has proceeded (the “Pending Arbitration”). On January 22, 2021, Chemours, DuPont, Corteva and EID entered into a binding memorandum of understanding containing a settlement to resolve legal disputes originating from the Delaware Litigation and Pending Arbitration, and to establish a cost sharing arrangement and escrow account to be used to support and manage potential future legacy per- and polyfluoroalkyl substances (“PFAS”) liabilities arising out of pre-July 1, 2015 conduct (the “MOU”). See Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements for further discussion.

Environmental Proceedings

The company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The matters below involve the potential for $1 million or more in monetary fines and are included per Item ~~103(3)(c)~~103(c)(3)(iii) of Regulation S-K of the Securities Exchange Act of 1934, as amended.

~~Table of~~ ~~Contents~~

Related to Corteva's current businesses

La Porte Plant, La Porte, Texas - Crop Protection - Release Incident Investigations

On November 15, 2014, there was a release of methyl mercaptan at EID's La Porte, Texas, facility. The release occurred at the site’s crop protection unit resulting in four employee fatalities inside the unit. The Chemical Safety Board (“CSB”) issued its final report on June 18, 2019, which included recommendations related to the emergency response program at La Porte. Corteva responded to the CSB on September 30, 2019 outlining the actions it has taken to date to address the recommendations for the site and providing its plan to address the CSB’s remaining recommendations. After the conclusion of the CSB investigation, criminal U.S. Environmental Protection Agency ("EPA") and the Department of Justice ("DOJ") investigations related to the incident continued. On January 8, 2021, EID and the facility's former unit operations leader were indicted by the DOJ on two felony and one misdemeanor charges of violations of the Clean Air Act related to the release. The maximum statutory penalties per charge are $500,000, or twice the gross gain or loss derived from the incident, as well as up to three years of probation and related ongoing reporting obligations. Corteva cooperated fully with the government’s investigation and will vigorously defend against these charges. The trial is currently scheduled for March 2022.

Related to legacy EID businesses unrelated to Corteva’s current businesses

Sabine Plant, Orange, Texas - EPA Multimedia Inspection

In June 2012, EID began discussions with the EPA and the DOJ related to a multimedia inspection that the EPA conducted at the Sabine facility in March 2009 and December 2015. The discussions involve the management of materials in the facility's wastewater treatment system, hazardous waste management, flare and air emissions, including leak detection and repair. These discussions continue. Under the Separation Agreement, Corteva and DuPont will share any future liabilities proportionally on the basis of 29% and 71%, respectively.

Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection

In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC (“Denka”) neoprene manufacturing facility in La Place, Louisiana. EID sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. In the spring of 2017, the EPA, the DOJ, the Louisiana Department of Environmental Quality, EID and Denka began discussions relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. These discussions, which include potential settlement options, continue. Under the Separation Agreement, DuPont is defending and indemnifying the company in this matter.

Table of Contents

New Jersey Directive PFAS

On March 25, 2019, the New Jersey Department of Environmental Protection (“NJDEP”) issued a Statewide PFAS Directive to several companies, including Chemours, DuPont, and EID. The Directive seeks information relating to the use and environmental release of PFAS and PFAS-replacement chemicals at and from two former EID sites in New Jersey, Chambers Works and Parlin, and a funding source for costs related to the NJDEP’s investigation of PFAS issues and PFAS testing and remediation.

New Jersey Directive Pompton Lakes

On March 27, 2019, the NJDEP issued to Chemours and EID a Natural Resource Damages Directive relating to chemical contamination (non-PFAS) at and around EID’s former Pompton Lakes facility in New Jersey. The Directive alleges that this contamination has harmed the natural resources of New Jersey. It seeks $125,000 as reimbursement for the cost of preparing a natural resource damages assessment, which the State will use to determine the extent of such damage and the amount it expects to seek to restore the affected natural resources to their pre-damage state.

Natural Resource Damage Cases

Since May 2017, several municipal water districts and state attorneys general have filed lawsuits against EID, Corteva, Chemours, 3M, and others, claiming contamination of public water systems by PFCs, including but not limited to PFOA. These actions with the municipalities and states seeking economic impact damages for alleged harm to natural resources, punitive damages, present and future costs to cleanup PFOA contamination and the abatement of alleged nuisance with filtration systems. Further information with respect to these proceedings is set forth under "Other PFOA Matters" in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

Netherlands Municipality Cases

In April 2021, four municipalities in the Netherlands filed complaints alleging contamination of land and groundwater resulting from the emission of PFOA and GenX by Corteva, DuPont and Chemours. Further information with respect to these proceedings is set forth under "Other PFOA Matters" in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

Settlement with the State of Delaware

On July 13, 2021, Chemours, DuPont, EID and Corteva entered into a settlement agreement with the State of Delaware reflecting the companies’ and the State’s agreement to settle and fully resolve claims alleged against the companies regarding their historical Delaware operations, manufacturing, use and disposal of all chemical compounds, including PFAS. Further information with respect to this settlement is set forth under "Other PFOA Matters" in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

Table of Contents

Item 1A. RISK FACTORS

~~There have been no material changes~~The significant factors known to us that could materially adversely affect our business, financial condition, or operating results are described in ~~the company's risk factors discussed in Part I, Item 1A, Risk Factors, in the company's~~our most recently filed annual report on Form ~~10-K.~~10-K under Item 1A - Risk Factors, and are supplemented by the following risk factors below.

Risks Related to our Industry

A recent executive order may result in additional regulation of the agricultural industry that could result in the imposition of significant costs and restrictions on the Company’s business operations in the future.

On July 9, 2021, President Biden issued an executive order promoting competition in the American economy. The order encouraged further examination and efforts by U.S. regulatory agencies to avoid market concentrations for agricultural inputs, that could challenge the survival of family farms. The executive order also directs the U.S. Secretary of Agriculture to take action to ensure that the intellectual property system, while still incentivizing innovation, does not also unnecessarily reduce competition in seed and other agricultural input markets beyond what is reasonably contemplated by the U.S. Patent Act and propose strategies for addressing those concerns across intellectual property, antitrust, and other relevant laws. While the ultimate impact of the executive order will depend on the actions ultimately resulting from the U.S. regulatory authorities, actions taken by such authorities may increase the regulation and regulatory costs associated with our industry in the future and restrict the company from pursuing certain growth opportunities, including mergers and acquisitions.

Risks Related to our Operations

The transition in our chief executive officer position will be critical to our success and our business could be negatively impacted if we do not successfully manage this transition.

On June 23, 2021, the company announced that James C. Collins, Jr., chief executive officer ("CEO") will retire from all positions with the company by December 31, 2021. While the company is currently engaged in a search for a new CEO, any failure to timely hire a qualified CEO could hinder the company’s strategic planning, execution and future performance. The departure of key leadership personnel, such as a CEO, can take from the company significant knowledge and experience. While this loss of knowledge and experience can be mitigated through successful hiring and transition, there can be no assurance that we will be successful in such efforts. Further, if the company’s new CEO formulates different or changed views, the future strategy and plans of the company may differ materially from those of the past. While Mr. Collins entered into a letter agreement intended to facilitate a smooth transition, if the company does not successfully manage this transition, it could be viewed negatively by our customers, employees or investors and could have an adverse impact on our business and strategic direction.

5665

Table of Contents

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table summarizes information with respect to the company's purchase of its common stock during the three months ended ~~March 31,~~June 30, 2021:


Month	Month	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of the Company's Publicly Announced Share Buyback Program1	Approximate Value of Shares that May Yet Be Purchased Under the Programs(1) (Dollars in millions)		Month	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of the Company's Publicly Announced Share Buyback Program1	Approximate Value of Shares that May Yet Be Purchased Under the Programs(1) (Dollars in millions)

February 2021		2,530,263	$	44.78	2,530,263	$	587
March 2021		5,116,171	46.27		5,116,171	350
April 2021								April 2021	1,317,265	$	47.60	1,317,265	$	287
May 2021								May 2021	1,411,685	46.75		1,411,685	221
June 2021								June 2021	1,595,384	44.69		1,595,384	150
Total	Total	7,646,434	$	45.77	7,646,434	$	350	Total	4,324,334	$	46.25	4,324,334	$	150

1. On June 26, 2019, Corteva, Inc. announced that its Board of Directors authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

5766

Table of Contents

Item 5. OTHER INFORMATION

None.

5867

Table of Contents

Item 6.EXHIBITS


Exhibit Number						Description

2.1						Separation and Distribution Agreement by and among DuPont Inc., Dow Inc. and Corteva, Inc. (incorporated by reference to Exhibit No. 2.1 to Amendment 3 to Corteva’s Registration Statement on Form 10 (Commission file number 001-38710), filed on April 16, 2019).

3.1						Amended and Restated Certificate of Incorporation of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on June 3, ~~2019.~~2019).

3.2						Amended and Restated Bylaws of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on October 10, ~~2019.~~2019).

3.3						Amended and Restated Certificate of Incorporation of E.I. du Pont de Nemours and Company (incorporated by reference to Exhibit 3.1 to E.I. du Pont de Nemours and Company’s Current Report on Form 8-K (Commission file number 1-815) dated September 1, 2017).

3.4						Amended and Restated Bylaws of E.I. du Pont de Nemours and Company (incorporated by reference to Exhibit 3.2 to E.I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated September 1, 2017).

4						Corteva agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of Corteva and its subsidiaries.

10.1						~~Master Repurchase~~Form of CFO Special RSU Agreement (incorporated by ~~and among Coöperatieve Rabobank, U.A. (New York Branch), MUFG Bank, Ltd. (New York Branch), Standard Chartered Bank (New York Branch), HSBC Bank USA, N.A., and PHI Financial Services, Inc.~~reference from the Form 8-K (Commission file number 001-38710) dated ~~as of February 9, 2021.~~April 6, 2021).

10.2						~~Master Framework~~Letter Agreement bybetween James C. Collins, Jr. and among Coöperatieve Rabobank, U.A. (New York Branch), MUFG Bank, Ltd. (New York Branch), Standard Chartered Bank (New York Branch), HSBC Bank USA, N.A., and PHI Financial Services, Inc. dated as of February 9, 2021.

~~10.3~~						~~Memorandum of Understanding, dated January 22, 2021, by and among The Chemours Company,~~ Corteva, Inc., ~~E. I. du Pont de Nemours and Company and DuPont de Nemours, Inc.~~dated June 21, 2021 (incorporated by reference from the Form 8-K (Commission file number 001-38710) ~~filed January 22,~~dated June 23, 2021).

~~10.4~~						Agreement dated March 18, 2021, among Corteva, Inc., Starboard Value LP and certain of its affiliates (incorporated by reference from the Form 8-K (Commission file number 001-38710) filed March 19, 2021).

31.1						Rule 13a-14(a)/15d-14(a) Certification of the company’s and EID’s Principal Executive Officer.

31.2						Rule 13a-14(a)/15d-14(a) Certification of the company’s and EID’s Principal Financial Officer.

32.1						Section 1350 Certification of the company’s and EID’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.

32.2						Section 1350 Certification of the company’s and EID’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.

101.INS						XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH						Inline XBRL Taxonomy Extension Schema Document

101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document

104						Cover Page Interactive Data File – The Cover Page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101.INS)

5968

Table of Contents

SIGNATURE

Corteva, Inc.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			CORTEVA, INC.
			(Registrant)

			Date:			~~May 5,~~August 6, 2021


			By:			/s/ Brian Titus

						Brian Titus
						Vice President, Controller
						(Principal Accounting Officer)

E. I. du Pont de Nemours and Company

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


			E. I. du Pont de Nemours and Company
			(Registrant)

			Date:			~~May 5,~~August 6, 2021


			By:			/s/ Brian Titus

						Brian Titus
						Vice President, Controller
						(Principal Accounting Officer)

6069

Table of Contents

CONSOLIDATED FINANCIAL STATEMENTS OF E. I. DU PONT DE NEMOURS AND COMPANY

E. I. du Pont de Nemours and Company

Consolidated Statements of Operations (Unaudited)


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions, except per share amounts)	(In millions, except per share amounts)	2021		2020			(In millions, except per share amounts)	2021		2020		2021		2020
Net sales	Net sales	$	4,178	$	3,956		Net sales	$	5,627	$	5,191	$	9,805	$	9,147
Cost of goods sold	Cost of goods sold	2,420		2,269			Cost of goods sold	3,010		2,829		5,430		5,098
Research and development expense	Research and development expense	281		280			Research and development expense	293		273		574		553
Selling, general and administrative expenses	Selling, general and administrative expenses	733		757			Selling, general and administrative expenses	998		965		1,731		1,722
Amortization of intangibles	Amortization of intangibles	183		163			Amortization of intangibles	180		176		363		339
Restructuring and asset related charges - net	Restructuring and asset related charges - net	100		70			Restructuring and asset related charges - net	135		179		235		249
Other income - net	Other income - net	337		1			Other income - net	298		89		635		90
Interest expense	Interest expense	22		42			Interest expense	20		45		42		87
Income from continuing operations before income taxes	Income from continuing operations before income taxes	776		376			Income from continuing operations before income taxes	1,289		813		2,065		1,189
Provision for income taxes on continuing operations	Provision for income taxes on continuing operations	174		119			Provision for income taxes on continuing operations	281		71		455		190
Income from continuing operations after income taxes	Income from continuing operations after income taxes	602		257			Income from continuing operations after income taxes	1,008		742		1,610		999
(Loss) income from discontinued operations after income taxes	(Loss) income from discontinued operations after income taxes	(10)		1			(Loss) income from discontinued operations after income taxes	(45)		0		(55)		1
Net income	Net income	592		258			Net income	963		742		1,555		1,000
Net income attributable to noncontrolling interests	Net income attributable to noncontrolling interests	1		8			Net income attributable to noncontrolling interests	0		3		1		11
Net income attributable to E. I. du Pont de Nemours and Company	Net income attributable to E. I. du Pont de Nemours and Company	$	591	$	250		Net income attributable to E. I. du Pont de Nemours and Company	$	963	$	739	$	1,554	$	989

See Notes to the Interim Consolidated Financial Statements beginning on page ~~66.~~75.

6170

Table of Contents

E. I. du Pont de Nemours and Company

Consolidated Statements of Comprehensive Income ~~(Loss)~~ (Unaudited)


		Three Months Ended March 31,				Three Months Ended June 30,				Six Months Ended June 30,
(In millions)	(In millions)	2021		2020			(In millions)	2021		2020		2021		2020
Net income	Net income	$	592	$	258		Net income	$	963	$	742	$	1,555	$	1,000
Other comprehensive loss - net of tax:
Other comprehensive income (loss) - net of tax:							Other comprehensive income (loss) - net of tax:
Cumulative translation adjustments	Cumulative translation adjustments	(403)		(672)			Cumulative translation adjustments	243		97		(160)		(575)
Adjustments to pension benefit plans	Adjustments to pension benefit plans	8		0			Adjustments to pension benefit plans	8		(6)		16		(6)
Adjustments to other benefit plans	Adjustments to other benefit plans	(157)		3			Adjustments to other benefit plans	(160)		(1)		(317)		2
Unrealized gain on investments	Unrealized gain on investments	10		0			Unrealized gain on investments	0		0		10		0
Derivative instruments	Derivative instruments	65		6			Derivative instruments	31		(2)		96		4
Total other comprehensive loss		(477)		(663)
Comprehensive income (loss)		115		(405)
Total other comprehensive income (loss)							Total other comprehensive income (loss)	122		88		(355)		(575)
Comprehensive income							Comprehensive income	1,085		830		1,200		425
Comprehensive income attributable to noncontrolling interests - net of tax	Comprehensive income attributable to noncontrolling interests - net of tax	1		8			Comprehensive income attributable to noncontrolling interests - net of tax	0		3		1		11
Comprehensive income (loss) attributable to E. I. du Pont de Nemours and Company		$	114	$	(413)
Comprehensive income attributable to E. I. du Pont de Nemours and Company							Comprehensive income attributable to E. I. du Pont de Nemours and Company	$	1,085	$	827	$	1,199	$	414

See Notes to the Interim Consolidated Financial Statements beginning on page ~~66.~~75.

6271

Table of Contents

E. I. du Pont de Nemours and Company

~~Condensed~~ Consolidated Balance Sheets (Unaudited)


(In millions, except share amounts)	(In millions, except share amounts)	March 31, 2021		December 31, 2020		March 31, 2020		(In millions, except share amounts)	June 30, 2021		December 31, 2020		June 30, 2020
Assets	Assets							Assets
Current assets	Current assets							Current assets
Cash and cash equivalents	Cash and cash equivalents	$	2,404	$	3,526	$	1,963	Cash and cash equivalents	$	2,861	$	3,526	$	2,809
Marketable securities	Marketable securities	114		269		10		Marketable securities	39		269		60
Accounts and notes receivable - net	Accounts and notes receivable - net	6,792		4,926		6,775		Accounts and notes receivable - net	6,792		4,926		6,772
Inventories	Inventories	4,321		4,882		4,401		Inventories	3,541		4,882		3,589
Other current assets	Other current assets	1,405		1,165		1,530		Other current assets	1,052		1,165		1,192

Total current assets	Total current assets	15,036		14,768		14,679		Total current assets	14,285		14,768		14,422
Investment in nonconsolidated affiliates	Investment in nonconsolidated affiliates	64		66		64		Investment in nonconsolidated affiliates	68		66		62
Property, plant and equipment - net of accumulated depreciation (March 31, 2021 - $3,874; December 31, 2020 - $3,857; March 31, 2020 - $3,406)		4,299		4,396		4,358
Property, plant and equipment								Property, plant and equipment	8,343		8,253		7,858
Less: Accumulated depreciation								Less: Accumulated depreciation	4,002		3,857		3,565
Net property, plant and equipment								Net property, plant and equipment	4,341		4,396		4,293
Goodwill	Goodwill	10,146		10,269		10,027		Goodwill	10,207		10,269		10,069
Other intangible assets	Other intangible assets	10,584		10,747		11,241		Other intangible assets	10,413		10,747		11,070
Deferred income taxes	Deferred income taxes	433		464		273		Deferred income taxes	442		464		290
Other assets	Other assets	1,987		1,939		2,336		Other assets	1,740		1,939		1,974

Total Assets	Total Assets	$	42,549	$	42,649	$	42,978	Total Assets	$	41,496	$	42,649	$	42,180
Liabilities and Equity	Liabilities and Equity							Liabilities and Equity
Current liabilities	Current liabilities							Current liabilities
Short-term borrowings and finance lease obligations	Short-term borrowings and finance lease obligations	$	1,250	$	3	$	1,996	Short-term borrowings and finance lease obligations	$	677	$	3	$	1,529
Accounts payable	Accounts payable	3,098		3,615		3,021		Accounts payable	3,070		3,615		2,891
Income taxes payable	Income taxes payable	165		123		143		Income taxes payable	234		123		369
Deferred revenue	Deferred revenue	2,247		2,662		1,996		Deferred revenue	748		2,662		431
Accrued and other current liabilities	Accrued and other current liabilities	2,257		2,148		2,083		Accrued and other current liabilities	2,525		2,148		2,312

Total current liabilities	Total current liabilities	9,017		8,551		9,239		Total current liabilities	7,254		8,551		7,532
Long-Term Debt	Long-Term Debt	1,102		1,102		614		Long-Term Debt	1,101		1,102		1,102
Long-Term Debt - Related Party	Long-Term Debt - Related Party	3,012		3,459		3,872		Long-Term Debt - Related Party	2,745		3,459		3,842
Other Noncurrent Liabilities	Other Noncurrent Liabilities							Other Noncurrent Liabilities
Deferred income tax liabilities	Deferred income tax liabilities	902		893		911		Deferred income tax liabilities	935		893		752
Pension and other post employment benefits - noncurrent	Pension and other post employment benefits - noncurrent	4,954		5,176		6,186		Pension and other post employment benefits - noncurrent	4,767		5,176		6,039
Other noncurrent obligations	Other noncurrent obligations	1,814		1,867		1,989		Other noncurrent obligations	1,816		1,867		1,957

Total noncurrent liabilities	Total noncurrent liabilities	11,784		12,497		13,572		Total noncurrent liabilities	11,364		12,497		13,692
Commitments and contingent liabilities	Commitments and contingent liabilities							Commitments and contingent liabilities
Stockholders’ equity	Stockholders’ equity							Stockholders’ equity
Preferred stock, without par value – cumulative; 23,000,000 shares authorized; issued at March 31, 2021, December 31, 2020, and March 31, 2020:
Preferred stock, without par value – cumulative; 23,000,000 shares authorized; issued at June 30, 2021, December 31, 2020, and June 30, 2020:								Preferred stock, without par value – cumulative; 23,000,000 shares authorized; issued at June 30, 2021, December 31, 2020, and June 30, 2020:
$4.50 Series – 1,673,000 shares (callable at $120)	$4.50 Series – 1,673,000 shares (callable at $120)	169		169		169		$4.50 Series – 1,673,000 shares (callable at $120)	169		169		169
$3.50 Series – 700,000 shares (callable at $102)	$3.50 Series – 700,000 shares (callable at $102)	70		70		70		$3.50 Series – 700,000 shares (callable at $102)	70		70		70
Common stock, $0.30 par value; 1,800,000,000 shares authorized; 200 issued at March 31, 2021, December 31, 2020, and March 31, 2020		0		0		0
Common stock, $0.30 par value; 1,800,000,000 shares authorized; 200 issued at June 30, 2021, December 31, 2020, and June 30, 2020								Common stock, $0.30 par value; 1,800,000,000 shares authorized; 200 issued at June 30, 2021, December 31, 2020, and June 30, 2020	0		0		0
Additional paid-in capital	Additional paid-in capital	24,083		24,049		24,004		Additional paid-in capital	24,131		24,049		23,981

Retained earnings / (accumulated deficit)	Retained earnings / (accumulated deficit)	792		203		(158)		Retained earnings / (accumulated deficit)	1,752		203		580
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(3,367)		(2,890)		(3,933)		Accumulated other comprehensive loss	(3,245)		(2,890)		(3,845)
Total E. I. du Pont de Nemours and Company stockholders’ equity	Total E. I. du Pont de Nemours and Company stockholders’ equity	21,747		21,601		20,152		Total E. I. du Pont de Nemours and Company stockholders’ equity	22,877		21,601		20,955
Noncontrolling interests	Noncontrolling interests	1		0		15		Noncontrolling interests	1		0		1
Total equity	Total equity	21,748		21,601		20,167		Total equity	22,878		21,601		20,956
Total Liabilities and Equity	Total Liabilities and Equity	$	42,549	$	42,649	$	42,978	Total Liabilities and Equity	$	41,496	$	42,649	$	42,180

See Notes to the Interim Consolidated Financial Statements beginning on page ~~66.~~75.

6372

Table of Contents

E. I. du Pont de Nemours and Company

Consolidated Statements of Cash Flows (Unaudited)


		Three Months Ended March 31,					Six Months Ended June 30,
(In millions)	(In millions)	2021		2020		(In millions)	2021		2020
Operating activities	Operating activities					Operating activities
Net income	Net income	$	592	$	258	Net income	$	1,555	$	1,000
Adjustments to reconcile net income to cash used for operating activities:	Adjustments to reconcile net income to cash used for operating activities:					Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization	Depreciation and amortization	304		283		Depreciation and amortization	617		583
Provision for deferred income tax		47		26
Provision for (benefit from) deferred income tax						Provision for (benefit from) deferred income tax	124		(136)
Net periodic pension and OPEB benefit, net	Net periodic pension and OPEB benefit, net	(318)		(85)		Net periodic pension and OPEB benefit, net	(641)		(168)
Pension and OPEB contributions	Pension and OPEB contributions	(84)		(95)		Pension and OPEB contributions	(149)		(167)
Net loss on sales of property, businesses, consolidated companies, and investments		0		46
Net (gain) loss on sales of property, businesses, consolidated companies, and investments						Net (gain) loss on sales of property, businesses, consolidated companies, and investments	(1)		30
Restructuring and asset related charges - net	Restructuring and asset related charges - net	100		70		Restructuring and asset related charges - net	235		249
Other net loss	Other net loss	54		138		Other net loss	143		185
Changes in assets and liabilities, net	Changes in assets and liabilities, net					Changes in assets and liabilities, net
Accounts and notes receivable	Accounts and notes receivable	(2,012)		(1,685)		Accounts and notes receivable	(1,957)		(1,712)
Inventories	Inventories	467		398		Inventories	1,334		1,271
Accounts payable	Accounts payable	(448)		(557)		Accounts payable	(525)		(717)
Deferred revenue	Deferred revenue	(401)		(575)		Deferred revenue	(1,931)		(2,147)
Other assets and liabilities	Other assets and liabilities	(247)		(144)		Other assets and liabilities	533		809
Cash used for operating activities	Cash used for operating activities	(1,946)		(1,922)		Cash used for operating activities	(663)		(920)
Investing activities	Investing activities					Investing activities
Capital expenditures	Capital expenditures	(137)		(128)		Capital expenditures	(269)		(202)
Proceeds from sales of property, businesses, and consolidated companies - net of cash divested	Proceeds from sales of property, businesses, and consolidated companies - net of cash divested	20		11		Proceeds from sales of property, businesses, and consolidated companies - net of cash divested	26		18
Investments in and loans to nonconsolidated affiliates						Investments in and loans to nonconsolidated affiliates	(1)		0
Purchases of investments	Purchases of investments	(40)		(67)		Purchases of investments	(56)		(361)
Proceeds from sales and maturities of investments	Proceeds from sales and maturities of investments	194		58		Proceeds from sales and maturities of investments	285		298
Other investing activities - net	Other investing activities - net	(1)		(4)		Other investing activities - net	(2)		(5)
Cash provided by (used for) investing activities		36		(130)
Cash used for investing activities						Cash used for investing activities	(17)		(252)
Financing activities	Financing activities					Financing activities
Net change in borrowings (less than 90 days)	Net change in borrowings (less than 90 days)	828		1,619		Net change in borrowings (less than 90 days)	254		966

Proceeds from related party debt						Proceeds from related party debt	29		67
Payments on related party debt	Payments on related party debt	(447)		(148)		Payments on related party debt	(743)		(246)
Proceeds from debt	Proceeds from debt	419		875		Proceeds from debt	419		2,434
Payments on debt	Payments on debt	0		(1)		Payments on debt	0		(879)
Proceeds from exercise of stock options	Proceeds from exercise of stock options	38		14		Proceeds from exercise of stock options	66		17

Payment for acquisition of subsidiary's interest from the non-controlling interest						Payment for acquisition of subsidiary's interest from the non-controlling interest	0		(60)

Other financing activities	Other financing activities	(21)		(23)		Other financing activities	(32)		(34)
Cash provided by financing activities		817		2,336
Cash (used for) provided by financing activities						Cash (used for) provided by financing activities	(7)		2,265
Effect of exchange rate changes on cash, cash equivalents and restricted cash	Effect of exchange rate changes on cash, cash equivalents and restricted cash	(50)		(117)		Effect of exchange rate changes on cash, cash equivalents and restricted cash	(14)		(95)

(Decrease) / increase in cash, cash equivalents and restricted cash	(Decrease) / increase in cash, cash equivalents and restricted cash	(1,143)		167		(Decrease) / increase in cash, cash equivalents and restricted cash	(701)		998
Cash, cash equivalents and restricted cash at beginning of period	Cash, cash equivalents and restricted cash at beginning of period	3,873		2,173		Cash, cash equivalents and restricted cash at beginning of period	3,873		2,173
Cash, cash equivalents and restricted cash at end of period	Cash, cash equivalents and restricted cash at end of period	$	2,730	$	2,340	Cash, cash equivalents and restricted cash at end of period	$	3,172	$	3,171

See Notes to the Interim Consolidated Financial Statements beginning on page ~~66.~~75.

6473

Table of Contents

E. I. du Pont de Nemours and Company

Consolidated Statements of Equity (Unaudited)


(In millions)	(In millions)	Preferred Stock		Common Stock		Add. Paid-in Capital "APIC"		Retained Earnings (Accumulated deficit)		Accum. Other Comp Loss		Treasury Stock		Non-controlling Interests		Total Equity		(In millions)	Preferred Stock		Common Stock		Additional Paid-in Capital "APIC"		(Accumulated Deficit) Retained Earnings		Accum. Other Comp (Loss) Income		Treasury Stock		Non-controlling Interests		Total Equity
2020	2020																	2020
Balance at January 1, 2020	Balance at January 1, 2020	$	239	$	0	$	23,958	$	(406)	$	(3,270)	$	—	$	7	$	20,528	Balance at January 1, 2020	$	239	$	0	$	23,958	$	(406)	$	(3,270)	$	—	$	7	$	20,528
Net income	Net income							250						8		258		Net income							250						8		258
Other comprehensive loss	Other comprehensive loss									(663)						(663)		Other comprehensive loss									(663)						(663)
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)	Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)					(2)										(2)		Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)					(2)										(2)
Issuance of Corteva stock	Issuance of Corteva stock					14										14		Issuance of Corteva stock					14										14
Share-based compensation	Share-based compensation					2										2		Share-based compensation					2										2
Other - net	Other - net					32		(2)								30		Other - net					32		(2)								30
Balance at March 31, 2020	Balance at March 31, 2020	$	239	$	0	$	24,004	$	(158)	$	(3,933)	$	—	$	15	$	20,167	Balance at March 31, 2020	$	239	$	0	$	24,004	$	(158)	$	(3,933)	$	—	$	15	$	20,167
Net (loss) income																		Net (loss) income							739						3		742
Other comprehensive loss																		Other comprehensive loss									88						88
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)																		Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)							(3)								(3)

Issuance of Corteva stock																		Issuance of Corteva stock					3										3
Share-based compensation																		Share-based compensation					19										19
Acquisition of a noncontrolling interest in consolidated subsidiaries																		Acquisition of a noncontrolling interest in consolidated subsidiaries					(37)								(15)		(52)

Other - net																		Other - net					(8)		2						(2)		(8)
Balance at June 30, 2020																		Balance at June 30, 2020	$	239	$	0	$	23,981	$	580	$	(3,845)	$	—	$	1	$	20,956


(In millions)	(In millions)	Preferred Stock		Common Stock		Add. Paid-in Capital "APIC"		Retained Earnings (Accumulated deficit)		Accum. Other Comp Loss		Treasury Stock		Non-controlling Interests		Total Equity		(In millions)	Preferred Stock		Common Stock		Additional Paid-in Capital "APIC"		Retained Earnings (Accumulated Deficit)		Accum. Other Comp (Loss) Income		Treasury Stock		Non-controlling Interests		Total Equity
2021	2021																	2021
Balance at January 1, 2021	Balance at January 1, 2021	$	239	$	0	$	24,049	$	203	$	(2,890)	$	—	$	0	$	21,601	Balance at January 1, 2021	$	239	$	0	$	24,049	$	203	$	(2,890)	$	—	$	0	$	21,601
Net income	Net income							591						1		592		Net income							591						1		592
Other comprehensive loss	Other comprehensive loss									(477)						(477)		Other comprehensive loss									(477)						(477)
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)	Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)							(2)								(2)		Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)							(2)								(2)

Issuance of Corteva stock	Issuance of Corteva stock					38										38		Issuance of Corteva stock					38										38

Other - net	Other - net					(4)										(4)		Other - net					(4)										(4)
Balance at March 31, 2021	Balance at March 31, 2021	$	239	$	0	$	24,083	$	792	$	(3,367)	$	—	$	1	$	21,748	Balance at March 31, 2021	$	239	$	0	$	24,083	$	792	$	(3,367)	$	—	$	1	$	21,748
Net income																		Net income							963								963
Other comprehensive income																		Other comprehensive income									122						122
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)																		Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)							(3)								(3)

Issuance of Corteva stock																		Issuance of Corteva stock					28										28
Share-based compensation																		Share-based compensation					23		(1)								22

Other - net																		Other - net					(3)		1								(2)
Balance at June 30, 2021																		Balance at June 30, 2021	$	239	$	0	$	24,131	$	1,752	$	(3,245)	$	—	$	1	$	22,878

See Notes to the Interim Consolidated Financial Statements beginning on page ~~66.~~75.

6574

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


			E. I. du Pont de Nemours and Company
			Notes to the Consolidated Financial Statements (Unaudited)

Table of Contents


Note	Note		Page	Note		Page
1	1	Basis of Presentation	67	1	Basis of Presentation	76
2	2	Related Party Transactions	68	2	Related Party Transactions	77
3	3	Segment Information	68	3	Segment Information	77

6675

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION

As a result of the Business Realignment and the Internal Reorganization, Corteva, Inc. owns 100% of the outstanding common stock of EID. EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The primary differences between Corteva, Inc. and EID are outlined below:

•Preferred Stock - EID has preferred stock outstanding to third parties which is accounted for as a non-controlling interest at the Corteva, Inc. level. Each share of EID Preferred Stock - $4.50 Series and EID Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EID and was unaffected by the Corteva Distribution.

•Related Party Loan - EID engaged in a series of debt redemptions during the second quarter of 2019 that were partially funded through an intercompany loan from Corteva, Inc. This was eliminated in consolidation at the Corteva, Inc. level but remains on EID's consolidated financial statements at the standalone level (including the associated interest).

•Capital Structure - At ~~March 31,~~June 30, 2021, Corteva, Inc.'s capital structure consists of ~~738,321,000~~734,421,000 issued shares of common stock, par value $0.01 per share.

The accompanying footnotes relate to EID only, and not to Corteva, Inc., and are presented to show differences between EID and Corteva, Inc.

For the footnotes listed below, refer to the following Corteva, Inc. footnotes:

•Note 1 - Summary of Significant Accounting Policies - refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 2 - Recent Accounting Guidance - refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 3 - Divestitures and Other Transactions - refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 4 - Revenue - refer to page 1011 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 5 - Restructuring and Asset Related Charges - Net - refer to page 1314 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 6 - Supplementary Information - refer to page 1416 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 7 - Income Taxes - refer to page 1618 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 8 - Earnings Per Share of Common Stock - Not applicable for EID

•Note 9 - Accounts and Notes Receivable - Net - refer to page 1820 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 10 - Inventories - refer to page 1921 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 11 - Other Intangible Assets - refer to page 1921 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 12 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities - refer to page 2022 of the Corteva, Inc. interim Consolidated Financial Statements. In addition, EID has a related party loan payable to Corteva, Inc.; refer to EID Note 2 - Related Party Transactions, below

•Note 13 - Commitments and Contingent Liabilities - refer to page 2123 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 14 - Stockholders' Equity - refer to page 2629 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 15 - Pension Plans and Other Post Employment Benefits - refer to page 2932 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 16 - Financial Instruments - refer to page 2932 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 17 - Fair Value Measurements - refer to page 3538 of the Corteva, Inc. interim Consolidated Financial Statements

•Note 18 - Segment Information - Differences exist between Corteva, Inc. and EID; refer to EID Note 3 - Segment Information, below

6776

Table of Contents

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 2 - RELATED PARTY TRANSACTIONS

Transactions with Corteva

In the second quarter of 2019, EID entered into a related party revolving loan from Corteva, Inc., with a maturity date in 2024. As of ~~March 31,~~June 30, 2021, December 31, 2020, and ~~March 31,~~June 30, 2020, the outstanding related party loan balance was ~~$3,012~~$2,745 million, $3,459 million, and ~~$3,872~~$3,842 million respectively (which approximates fair value), with interest rates of 1.52%, 1.62% ~~at March 31, 2021~~, and ~~December 31, 2020,~~1.80%, respectively, ~~and 3.27% at March 31, 2020,~~ and is reflected as long-term debt - related party in EID's interim ~~Condensed~~ Consolidated Balance Sheets. Additionally, EID has incurred tax deductible interest expense of ~~$15~~$13 million and ~~$32~~$28 million for the three and six months ended ~~March 31,~~June 30, 2021, respectively, and $31 million and $63 million for the three and six months ended June 30, 2020, respectively, associated with the related party loan from Corteva, Inc.

As of ~~March 31,~~June 30, 2021, EID had payables to Corteva, Inc., of ~~$55~~$57 million and $91 million included in accrued and other current liabilities and other noncurrent obligations, respectively, $92 million at December 31, 2020 included in both accrued and other current liabilities and other noncurrent obligations, respectively, and ~~$166~~$119 million and $82 million at ~~March 31,~~June 30, 2020, included in accrued and other current liabilities and other noncurrent obligations, respectively, in the interim ~~Condensed~~ Consolidated Balance Sheets related to Corteva's indemnification liabilities to Dow and DuPont per the Separation Agreements (refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements for further details of the Separation Agreements).

NOTE 3 - SEGMENT INFORMATION

There are no differences in reporting structure or segments between Corteva, Inc. and EID. In addition, there are no differences between Corteva, Inc. and EID segment net sales, segment operating EBITDA, segment assets, or significant items by segment; refer to page 3639 of the Corteva, Inc. interim Consolidated Financial Statements for background information on the segments as well as further details regarding segment metrics. The tables below reconcile income from continuing operations after income taxes to segment operating EBITDA, as differences exist between Corteva, Inc. and EID.

Reconciliation to interim Consolidated Financial Statements


Income from continuing operations after income taxes to segment operating EBITDA (In millions)	Income from continuing operations after income taxes to segment operating EBITDA (In millions)	Three Months Ended March 31,				Income from continuing operations after income taxes to segment operating EBITDA (In millions)	Three Months Ended June 30,						Six Months Ended June 30,
		2021		2020			Income from continuing operations after income taxes to segment operating EBITDA (In millions)		2021			2020			2021			2020
Income from continuing operations after income taxes	Income from continuing operations after income taxes	$	602	$	257				$	1,008		$	742		$	1,610		$	999
Provision for income taxes on continuing operations	Provision for income taxes on continuing operations	174		119				Provision for income taxes on continuing operations		281			71			455			190
Income from continuing operations before income taxes	Income from continuing operations before income taxes	776		376				Income from continuing operations before income taxes		1,289			813			2,065			1,189
Depreciation and amortization	Depreciation and amortization	304		283				Depreciation and amortization		313			300			617			583
Interest income	Interest income	(21)		(18)				Interest income		(18)			(9)			(39)			(27)
Interest expense	Interest expense	22		42				Interest expense		20			45			42			87
Exchange losses - net		35		61
Exchange losses (gains) - net								Exchange losses (gains) - net		14			(1)			49			60
Non-operating benefits - net	Non-operating benefits - net	(311)		(73)				Non-operating benefits - net		(315)			(91)			(626)			(164)

Mark-to-market gains on certain foreign currency contracts not designated as hedges1		(1)
Mark-to-market losses on certain foreign currency contracts not designated as hedges1								Mark-to-market losses on certain foreign currency contracts not designated as hedges1		23						22
Significant items	Significant items	100		123				Significant items		135			179			235			302

Corporate expenses	Corporate expenses	34		25				Corporate expenses		32			29			66			54
Segment operating EBITDA	Segment operating EBITDA	$	938	$	819			Segment operating EBITDA		$	1,493		$	1,265		$	2,431		$	2,084

6877


March 31, 2021	12 months or more
(In millions)	Fair value		Gross unrealized losses
U.S. Treasuries	$	65	$	0